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SUMMARY
Morphological changes including fibrosis, vascular degeneration and loss of mesothelium 
occur to the peritoneal membrane during peritoneal dialysis. The loss of mesothelium is 
thought to effect peritoneal homeostasis and host defence, as these cells play a pivotal 
role in these organs response to inflammation. Cancer antigen 125 (CA125), a 
mucilaginous high molecular weight glycoprotein, has been used as a marker of 
peritoneal mesothelial cells mass/turnover and membrane functional integrity in 
peritoneal dialysis patients. The use of new more biocompatible dialysis solutions is 
associated with an increase in CA125 effluent concentration, however it’s precise 
molecular nature, function and regulation is poorly defined. This study investigates the 
transcriptional mechanisms regulating CA125 expression in human peritoneal 
mesothelial cells as well as CA125’s regulation in response to inflammation. 
Additionally, CA125’s function in the process of mesothelial cell repair is examined 
using a novel mesothelial wound healing system.
These investigations have:
• Successfully reconstructed the genomic structure of CA125 and characterised its 
proximal promoter region.
• Demonstrated regulation of CA125 cell surface expression and shedding in 
response to IL-ip and IL-6 trans-signalling.
• Shown the retardation of human peritoneal mesothelial cell CA125 shedding in 
response to high levels of glucose degradation products present within peritoneal 
dialysis fluids.
• Shown the improved wound healing of mesothelial cells in response to elevated 
CA125 levels.
These investigations have clarified existing discrepancies regarding CA125 regulation 
during inflammation by demonstrating its altered expression at the cell surface, in 
response to inflammatory mediators. Additionally, this work has linked clinical 
Observations regarding CA125 effluent levels during peritoneal dialysis to a potential role 
of CA125 in wound healing of the mesothelium.
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Chapter 1 
Introduction
1
1.1 Established Renal Failure
Established renal failure (ERF) occurs as the result of permanent deterioration of the 
renal function (usually expressed as glomerluar filtration rate (GFR)). Normal GFR in 
adults is in the region of 80-130ml/min for males and 70-120 ml/min for females. Thirty 
five percent of newly diagnosed cases of ERF per year occur as a direct result of diabetes. 
Other causes include hypertension, primary and secondary glomerulopathies, cystic and 
interstitial renal diseases and obstructive uropathy [Pastan and Bailey, 1998].
Currently, the preferred treatment for ERF, in most individuals, is kidney transplantation. 
Unfortunately lack of donor kidneys and transplant failure (kidney rejection) limits the 
effectiveness of this treatment [Vale et al, 2005]. Both haemodialysis and peritoneal 
dialysis (PD) can be used to replace the excretory function of the kidney and therefore 
used to treat ERF [Pastan and Bailey, 1998].
The prevalence of ERF is increasing at a rate of approximately 8% per year. In Wales 
alone, 120 new patients are being accepted for long-term dialysis each year. Such 
treatment is associated with a significant impairment in quality of life and therefore poses 
considerable social and economic consequences [Pastan and Bailey, 1998][Vale et al, 
2005].
1.1 Peritoneal Dialysis
1.1.1 Background
Peritoneal dialysis is now an established form of therapy in the management of ERF. First 
attempts to use peritoneal dialysis as a treatment for ERF were made by Wear and co­
workers in 1938 [Wear et al, 1938]. In 1959 a simplified method of intermittent 
irrigation of the peritoneal cavity using a disposable catheter and commercially made PD 
fluids was developed by Maxwell and colleagues [Gokal and Mallick, 1999]. CAPD 
became a viable alternative to haemodialysis 19 years later, in 1978, when Moncrief and
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Popovich showed its adequacy as a treatment for kidney failure in a long-term clinical 
trial [Popovich et al, 1978].
At present more than 35% of the ERF population in the United Kingdom are treated using 
PD [Vale et al, 2005]. Due to its effectiveness as a treatment PD has now outstripped 
haemodialysis worldwide [Prichard, 2005] and is generally accepted as the better form of 
treatment. These potential advantages can be attributed to its slower decrease in residual 
renal function and its adaptability to suit patient requirements [Fenton et al, 1997].
1.1.2 The Technique
The human peritoneal membrane functions as a semi-permeable membrane and hence can 
be used as a dialysis organ [Vale et al, 2005]. Haemodialysis depends on hydrostatic 
pressure to remove waste products from the body, whereas, peritoneal dialysis utilises the 
peritoneum as a semi-permeable membrane across which ureamic waste products and 
water are removed via the physiological processes of diffusion, convective transport and 
osmosis [Gokal and Mallick, 1999].
In practice, PD is performed in a closed system composed of the peritoneal cavity, a long­
term catheter anchored in subcutaneous tissue and a plastic container of peritoneal 
dialysis fluid (PDF) [Gokal and Mallick, 1999]. A typical treatment will consist of 4 
exchanges of 2-2.5 litres of dialysis fluid per day [Pastan and Bailey, 1998]. The 
composition of the dialysis fluid creates an osmotic and chemical gradient between the 
dialysis fluid and the blood capillaries of the peritoneum. During the period of dwell, 
solute transport occurs across the peritoneal membrane. Uremic metabolites move along a 
chemical gradient from the blood into the dialysate in a process known as hydrostatic 
ultrafiltration. Excess water is removed along the osmotic gradient by a process known as 
osmotic ultrafiltration [Chaimovitz, 1994]. The dialysis solution is then drained from the 
peritoneal cavity and the cycle is repeated. Various techniques and regimes have now 
emerged that enhance these transport characteristics [Gokal and Mallick, 1999], although 
the efficiency largely depends on the available vascular surface area [De Vriese, 2002].
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1.1.3 Complications of PD
Due to the bioincompatible nature of conventional peritoneal dialysis fluid, major 
problems occur that limit its effectiveness as a treatment of ERF. These include the loss 
of the peritoneal integrity, and therefore a decrease in its ability to function as a dialysing 
organ [Williams et al, 2003][Davies et al, 1996]. In addition, the presence of an 
indwelling catheter provides a portal for microbial entry and the associated episodes of 
peritonitis (intra-peritoneal inflammation) that occur significantly impact on patient and 
technique survival [Davies et al, 1996][Pastan and Bailey, 1998][Gokal and Mallick, 
1999][Troidle, 2003].
1.1.3.1 PDF biocompatibility
The poor biocompatibility of dialysis fluids has a detrimental effect on the effectiveness 
of peritoneal dialysis as a treatment. During the heat sterilization of the dialysis fluid 
prior to infusion, harmful breakdown products of glucose (glucose degradation products) 
are formed by the breakdown of glucose into low-molecular-weight aldehydes such as 
3DG-acetaldheyde and formaldehyde [Witowski et al, 2001]. During long-term exposure 
GDPs have been shown to be cytotoxic to the peritoneum causing morphological changes 
in the peritoneal membrane and down regulation of the peritoneum’s defence against 
infection [Duwe et al, 1981][Williams et al, 2004]. In vitro studies have also shown that 
GDPs retard the remesothelialization of HPMC, the layer of cells covering the 
peritoneum [Morgan et al, 2003]. Recent advances in the development of new, 
improved, more biocompatible dialysis fluids (containing less GDPs and with improved 
buffer system) have resulted in an improvement in the preservation of the peritoneal cell 
function and are thus promising for the future of long-term peritoneal dialysis [Rippe et 
al, 2001][[Mortier et al, 2004][Williams et al, 2004][Witowski et al, 2004].
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1.2.3.2 Peritonitis
Peritonitis is the most common serious complication of PD and a major reason for 
treatment failure. It presents with abdominal pain, fever and a characteristic cloudy 
peritoneal dialysate (cloudy bag). The condition is diagnosed if the effluent contains 
more than 100 white blood cells/pl of which 50% must be polymorphonucleur cells 
(PMN) [Pastan and Bailey, 1998]. Episodes of peritonitis have been shown to be a risk 
factor in ultrafiltration failure and cause morphological damage to the peritoneum 
[Davies et al, 1996] including thickening of the peritoneal membrane (Figure 1.1) and 
loss of mesothelial cells from the peritoneum.
The main site of infection of the peritoneal cavity is through the lumen of the catheter. 
The main cause of infection is believed to be touch contamination during dialysis 
exchange. Over 70% of episodes are caused by gram-positive skin commensals such as 
Staphylococcus epidermidis. Gram-negative infections e.g. Escherichia coli, may be the 
result of catheter contamination but are more commonly caused by direct infection from 
the gut. Less common but more clinically severe fungal peritonitis accounts for between 
2-10% of all episodes [Greig et al, 2003]. Treatment is usually through self-administered 
intra-peritoneal antibiotics with up to 80% of episodes being treated at home [Pastan and 
Bailey, 1998]. The incidence of peritonitis is now approximately 0.5 episodes per patient 
per year but varies greatly depending on the patient and country. In response to bacterial 
insult a host defence mechanism is activated within the peritoneum, as discussed in 
greater detail in section 1.4.
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Figure 1.1 Thickness of the sub-mesothelial compact zone (microns) in PD 
patients with no previous infections versus patients with one or more previous 
episodes of infection. For each box plot median values are represented by the line 
within the box. The box presents 50% of the values (the 25th and 75th centiles), with 
the bars presenting the highest and lowest values, excluding outliers (®). 
(Unpublished data taken from the Biopsy Registry Study Group).
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1.3 The Peritoneal Cavity
1.3.1 Anatomy
The peritoneum is the largest continuous serous membrane in the body. It forms a closed 
sac in males and an open sac in females (due to the free ends of uterine tubes opening 
directly into the peritoneal cavity). It can be divided into three anatomical regions. The 
parietal portion of the membrane lines the parietes (anterior, lateral and posterior 
abdominal walls, the pelvis and the underside of the diaphragm). The visceral portion of 
the membrane covers the viscera (intra-peritoneal organs and the mesentery). The 
peritoneal membrane also covers a fold in the peritoneal wall known as the greater 
omentum bursa that is situated behind the stomach and adjoining structures [Grey, 1918).
1.3.2 The peritoneal membrane
The original histological description of the peritoneum is credited to von Recklinghausen 
over 100 years ago [Witz et al, 2001 ]. Anatomically the peritoneal membrane consists of 
two distinct layers: 1) a simple epithelial monolayer, know as mesothelium and 2) its 
underlying connective tissue (Fig 1.2). These two layers are separated by an intervening 
discontinuous basement membrane (BM) that supports the mesothelium [Nagy and 
Jackman, 1998]. The basem ent membrane is a thin laminar network composed of 
protoeglycans, type IV collagen, and glycoproteins such as laminin. The mesothelial 
cells (MC) overlaying the basement membrane are thought to play a major role in its 
production and turnover [Nagy and Jackman, 1998 [.
Beneath the mesothelium and the basement membrane lies a layer of connective tissue, or 
sub-mesothelial basal lamina, known as the compact zone. This zone is composed of 
extracellular matrix molecules such as collagen I, collagen III, laminin, fibronectin and 
hyaluronic acid [Witz et al, 20011. The compact zone acts as a selective cellular barrier 
preventing the fibroblasts in the connective tissue from making contact with the 
mesothelial cells. The trafficking of cells and macromolecules across the peritoneal 
membrane is also regulated by the sub-mesothelial compact zone. Proteoglycans within
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the ECM form a gel like substance containing pores of various size and charge density 
and thus functions as a molecular sieve. The peritoneal sub-mesothelial layer also has an 
aqueous layer that facilitates the passage of water, electrolytes, nutrients, hormones and 
waste products between the blood capillaries and the fibroblasts, macrophages and 
dendritic cells that reside within the ECM |Nagy and Jackman, 19981. The movement of 
water is also facilitated by the presence of aquaporin water channels (AQP1 and AQP3) 
that are expressed on mesothelial cells of the peritoneum, endothelium of capillaries and 
on host capillary venules [Marples, 20001|Szeto et al, 2005].
Blood vessels are found throughout the entire peritoneal membrane (Figure 1.2), although 
they are most commonly located at the junction of the compact zone and underlying 
adipose tissue [Williams et al, 2002] and function to supply and remove molecules to and 
from the tissues and organs of the abdominal cavity [Nagy and Jackman, 1998]. A 
lymphatic system is also present within both the visceral and parietal membranes. This 
network of lymphatic vessels functions to maintain the small volume of fluid (normally 
around 50ml) present in the peritoneal cavity and also plays a role in host defence by 
removing foreign bodies that might enter the peritoneal cavity [Nagy and Jackman, 
1998].
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Figure 1.2 Structure of the peritoneal membrane. (A) Cross section of the 
peritoneal membrane shown schematically and (B) Cross section of the peritoneal 
membrane from a normal patient using light microscopy (taken from the peritoneal 
biopsy registry [Williams et al, 2003]).
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1.3.3 The Mesothelium
The mesothelium covers both the parietal and visceral surfaces of the peritoneal 
membrane and is composed of a single resident cell type called mesothelial cells. The 
mesothelium has a cobble-stone like appearance (as seen in Appendix I of Chapter 2) 
with ~ lxl09 mesothelial cells covering ~l-2m2 peritoneal surface [Nagy and Jackman, 
1998] [Mutsaers, 2004]. Typically, mesothelial cells are ~25pm in diameter and contain 
little rough endoplasmic reticulum and a poorly developed golgi apparatus. The luminal 
surface of the cell has a well-developed microvilli border and also displays the occasional 
cilia [Mutsaers, 2004]. Individual mesothelial cells are packed together in epithelial 
sheets by anchoring junctions composed of adherens junctions and desmosomes that 
attach individual cells to their neighbours and mesothelial cells to the basement 
membrane respectively. These junctions have particular importance in development of 
cell polarity and the establishment of a semi-permeable diffusion barrier. Gap junctions 
mediate the passage of chemicals and electrical signals from one cell to another [Nagy 
and Jackman, 1998].
The mesothelium is a slowly renewing tissue with 0.16%-0.5% of mesothelial cells 
undergoing mitosis at any one time although this rate is greatly increased if the 
mesothelium is stimulated with injury. Mesothelial cells are unique from other epithelial 
type cells as re-growth occurs solely at the wound edge as a movement of sheets of cells. 
Like other epithelia mesothelial cells can also be induced to trans-differentiate from an 
epithelial phenotype to a mesenchymal phenotype under certain conditions (e.g. by TGF- 
P or IL-ip) and this process is thought to contribute to the changes in peritoneal 
membrane structure and function during PD [Yanez-Mo et al, 2003]. The major function 
of the mesothelium is to maintain homeostasis within the peritoneal cavity. The important 
functions of the mesothelium can be seen in Table 1.1. Human peritoneal mesothelial 
cells also play a major role regulating the inflammatory response to injury or peritoneal 
infection (discussed in section 1.4).
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Table 1.1 Important functions of the mesothelium
Function Process
Protective barrier and non­
adhesive surface.
-Production of hyaluronic acid (HA) to act as lubricant 
and form pericellular coat [Yung et al, 1996].
Antigen presentation and host 
defence
-HPMC express adhesion molecules such as ICAM-1 
important in leukocyte recruitment [Clayton et al, 
1998]
-HPMC are the major site of cytokine production 
during inflammation [Topley et al, 1993].
Coagulation and fibrinolysis -HPMC have an important role in fibrin deposition and 
removal to prevent peritoneal adhesions.
-HPMC release plasminogen activators (uPA and tPA) 
that participate in the fibrinolytic cascade.
-HPMC release plasminogen activator inhibitors (PAI) 
that aid fibrin deposition.
[Sitter et al, 1995]
Tissue repair and extracellular 
matrix (ECM) remodelling.
-HPMC have the migratory capacity to migrate and 
therefore facilitate wound repair [Leavesley et al, 
1999].
-HPMC synthesise ECM components such as collagen 
types I and III [Harvey et al, 1983].
-HPMC regulate ECM turnover by secreting matrix 
metalloproteinases and tissue inhibitors of 
metalloproteinases [Martin et al, 2000].
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1.3.4 Alterations in the peritoneal membrane
Over the initial 3 to 5 year period of dialysis, PD is generally considered to be an efficient 
therapy for renal failure. This efficiency, however, appears to be limited to this time 
period with a majority of patients switching to haemodialysis in the long term due to the 
failure of PD as a treatment. The main cause of treatment failure is the decline in the 
ability of the peritoneal membrane’s capacity to act as an ultrafiltration membrane. This 
loss of ultrafiltration accounts for the discontinuation in approximately 16% of all 
peritoneal dialysis patients and the transfer to hemodialysis [Krediet, 1999]. Years of 
exposure to bio-incompatible dialysis fluids and repeated episodes of peritonitis 
progressively damage the peritoneal membrane by causing structural changes that 
ultimately result in loss of the membrane’s function as a dialysing organ [Devuyst et al, 
2002][Williams et al, 2003].
Many studies have shown that time on PD is directly related to the extent of the 
morphological changes of the peritoneal membrane and the loss of ultrafiltration [Davies 
et al, 1996][Williams et al, 2002][Williams et al, 2003]. An increased thickening of the 
sub-mesothelial compact zone (Figure 1.3), vascular degeneration and fibrosis can be 
observed in the peritoneal membrane of patients on long term peritoneal dialysis 
[Williams et al, 2003]. Other changes occur such as the loss of mesothelial cells from the 
peritoneal membrane as shown by a decrease in the number of mesothelial cells in 50% 
of PD patients [Unpublished data, Biopsy registry]. This loss may in turn be reflected in 
a decrease in effluent cancer antigen 125 (CA125) levels as seen in other studies [Ho- 
Dac-Pannekeet et al, 1997][Visser et al, 1995]. Cellular changes also occur such as the 
loss of typical HPMC morphology (loss of cuboid shape) and down regulation of 
intercellular adhesion molecules that ultimately leads to fibrosis of the peritoneal 
membrane [Yanez-Mo et al, 2003]. The culmination of these changes are directly linked 
to ultrafiltration failure.
The majority of research over the past 5 years has been focused on the development of 
new more biocompatible PD fluids in order to try and lessen their pathophysiological role
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in loss of membrane function. These studies have identified acidic pH, high 
concentrations of lactate and glucose and the presence of glucose degradation products 
(GDPs) as the main factors in the limited biocompatibility of PD fluids [Witowski et al,
2004]. The development of new sterilization processes in order to reduce GDP formation 
as well as the use of improved buffered PDFs have been shown to significantly increase 
the preservation of the peritoneal membrane during long term PD [Liberek et al,
1993][Witowski et al, 1995][Witowski et al, 2001][Williams et al, 2004].
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Figure 1.3 A comparison of cross sections of peritoneal membrane taken from a 
patient at the start of therapy (A) and a long term PD patient (B) shows a loss of 
mesothelium from the membrane surface, as well as a thickening of the sub- 
mesothelial compact zone, due to increased matrix deposition. (C) Progressive 
thickening of the peritoneal membrane over time during peritoneal dialysis. 
Thickness of sub-mesothelial compact zone shown in microns. (Data taken from the 
Biopsy Registry Study Group [Williams et al, 2003]).
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1.4 Peritoneal inflammation
1.4.1 Control of the peritoneal inflammatory response
The inflammatory response involves a co-ordinated sequence of events in response to 
both physical and chemical insult such as bacterial infection or injury caused by trauma. 
The inflammatory response is divided into two components. These are the humoral 
response and the cellular response (Figure 1.4). Both pathways work to maintain tissue 
homeostasis and to neutralize the insult [Lewis and Holmes, 1993).
A. Humoral Response
Bacterial cell injury
I
Cell Death
I
Inflammatory mediator release
(e.g Complement cascade components 
and kinins)
Capillary Vasodilation
permeability
Fluid and protein release
B. Cellular response
Cell injury
I
Chemotactic factor release 
Migration of leukocy^s to site of injury
W
Neutrophils
I
Monocytes Lymphocytes
I
Immune 
responseInflammatory 
Tissue \  macrophages 
Macrophages \
Phagocytosis
Figure 1.4 The humoral (A) and cellular (B) components of the inflammatory 
response. (Adapted from [Lewis and Holmes, 1993]).
Peritoneal infection is characterized by pain, the appearance of a cloudy dialylsate 
indicative of the massive influx of polymorphonuclear cells (>85%) into the peritoneal 
cavity |Topley, 1995 ] and a time dependant increase in CA125 dialysate levels (Figure 
1.5) [Ho-Dac-Pannekeet et al, 1995]. The inflammatory response is orchestrated by
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resident cell populations of the peritoneum and the cytokine network is able to co­
ordinate the infiltration of leukocytes into the peritoneum [Topley, 1995 f
300 n
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Figure 1.5 CA125 levels during peritonitis. The appearance rate of CA125 in
peritoneal dialysate during peritonitis, shown as percentage of the normal CA125 
control value (Taken from [Ho-Dac-Pannakeet et al, 1995]).
HPMC are the most abundant cell type in the peritoneal cavity and play an integral role in 
the orchestration of the inflammatory response in the peritoneum. After HPMC the most 
abundant cell type in the peritoneal cavity is the peritoneal macrophages (PMO). These 
cells appear to be the first line of defence against invading organisms [De Souza et al, 
1985]. PMO play major roles in the phagocytosis of invading micro-organisms and 
contribute to the production of inflammatory mediators [Topley and Williams, 1994). 
Bacterial activation of resident macrophages results in the initiation of the innate immune 
response and immune cell recruitment [Brauner et al, 1996|.
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1.4.2 The cytokine network of the peritoneum
As seen in Figure 1.6, upon exposure to invading pathogens, PMO are activated which 
causes them to release the pro-inflammatory cytokines IL-ip and TNFa [Douvdevani et 
al, 1994]. These cytokines then direct the resident HPMC monolayer to release high 
levels of IL-8 and express the cell surface adhesion molecule ICAM-1 [Allan et al, 2005]. 
This event results in the recruitment of neutrophils directly from the capillaries of the 
peritoneal membrane. As the number of resident HPMC outweigh the number of PMO 
there is an amplification of the inflammatory response at this step that is fundamental to 
the resolution of inflammation [Topley and Williams, 1994][Hurst et al, 2001].
Regulation of leukocyte trafficking in the peritoneal cavity is dependant on the specific 
release of chemokines by the mesothelium. These chemokines are small (7-10 KDa in 
monomeric form) and are characterized by the arrangement of conserved cysteine motifs 
within the N-terminus of their amino acid structure. Within the CXC sub-family, the 
presence of a glutamine-leucine-arginine (ELR) motif before die first of two conserved 
cysteine residues (separated by another amino acid, X) [Clark-Lewis et al, 1991][Clark- 
Lewis et al, 1993][Clark-Lewis et al, 1995] confers selectivity in recruiting neutrophils 
(whereas non-ELR-CXC chemokines confer selectivity to lymphocytes). In CC 
chemokines the two conserved cysteine residues lay next too each other and are all 
chemotactic for monocyte/macrophages and T Cells [Valente et al, 1988].
In addition to IL-8 production the cytokine IL-6 is also released by HPMC in response to 
IL-ip and TNFa stimulation [Topley et al, 1993]. Circulating IL-6 can then complex 
with the circulating soluble IL-6 receptor (produced by neutrophils) allowing the 
autocrine stimulation of the peritoneum [Jones et al, 2005]. This action results in the 
down regulation of the CXC (IL-8) cytokine gradient and expression of CC (MCP-1) 
chemokines favouring the infiltration of mononuclear cells and activation of pro- 
apoptotic genes in neutrophils. Essentially the IL-6/sIL-6R complex results in a switch of 
the leukocyte population of the peritoneal cavity and the switch from innate to acquired
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immunity (Figure 1.7)[Hurst et al, 2001 ][McLoughlin et al, 2004][McLoughlin et al, 
2005J.
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Figure 1.6 The cytokine network in peritoneal inflammation. Invading mico- 
organisms cause the release inflammatory mediators such as IL -la , TNF-|3 and 
IFN-y fr°m peritoneal macrphages. This results in the release of IL-6 from resident 
HPMC that binds with its soluable receptor (released by recruited 
polymorphonuclear cells) to induce chemokine release by HPMC resulting in the 
recrutiment of leuckocyte cell populations to the site of infection.
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Under normal acute inflammation, IFNy also plays an important role in the trafficking of 
different cell populations to the site of infection, by regulating the release of CXC and 
CC cytokines (Figures 1.6 and 1.7) and by directing apoptosis in infiltrating cell 
populations. For example, IFNy can attenuate IL-1 p induced CXC chemokine release or 
conversely up-regulate IL -lp  induced CC chemokine release, thus regulating both influx 
and removal of immune cell populations [Robson et al, 2001 ].
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Figure 1.7 The sequence of events leading to resolution of peritoneal infection by 
resident and recruited cell populations.
HPMC themselves play an important role in the activation of the inflammatory response. 
As mentioned earlier, HPMC release IL-8 and express cell surface adhesion molecules in 
response to PMO activation. In addition to this, HPMC show an identical action in 
response to direct stimulation with the pathogen itself, as well as the release of
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chemokines such as MCP-1 and RANTES. These events lead to the rapid accumulation 
of neutrophils and mononuclear cells in the first 24 hrs of infection [Topley et al, 1996].
1.4.3 Resolution of peritoneal inflammation
Resolution of inflammation is key to the host’s successful response to peritonitis. The 
recruitment of leukocytes to the peritoneum is obviously beneficial to the host in the 
initial stages of infection, in order to remove the invading pathogen but leukocyte 
persistence in the peritoneal cavity is associated with the local failure of resolution of 
inflammation and can result in the failure of treatment [Hurst et al, 2001] [Robson et al,
2001]. An example of inflammatory dysregulation can be seen during long term CAPD. 
After just nine months of PD, peritoneal defence mechanisms against bacterial infection 
are substantially reduced [McGregor et al, 1989] as neutrophil influx becomes amplified 
and sustained due to alterations in PMO cytokine release and resident macrophages 
become immature [McGregor et al, 1996].
1.5 Interleukin-1 (IL-1) -  role in inflammation and mechanism of action
The IL-1 family of cytokines has an important role in inflammation and host defence and 
is comprised of at least ten members (IL-la, IL-ip, IL-1F5 etc). The two pro- 
inflammatory members of the family are designated IL-la and IL-1 (3 [Allan et al, 2005]. 
In the peritoneal cavity, IL -la  and IL-1 p function to activate HPMC mediated 
chemokine production that can orchestrate the recruitment of immune cells to the site of 
infection/injury.
IL -la  and IL-lp expression is up-regulated in response to various stimuli such as 
endotoxins, produced by invading micro-organisms, lipopolysaccharide (LPS) or TNFa, 
either through transcriptional up-regulation or by mRNA stabilization [Douvdevani et al, 
1994]. Despite being encoded by different sized genes, the two have high sequence 
homology and are both synthesised as large precursor molecules from many cell types of 
the peripheral and central immune system, such as monocytes [Allan et al, 2005],
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epidermal cells, endothelial cells and fibroblasts [Dinarello, 2002]. In the cytosomal 
compartment of these IL-1 producing cells, the IL-la precursor molecule (Pro-IL-la) is 
biologically active and is cleaved by an enzyme called calpain to produce a mature 
protein, whereas, pro-IL-ip is biologically inactive and requires caspase-1 cleavage to 
produce an active 17 KDa protein [Dinarello, 2005]. The mechanism of IL-1 cell release 
has not yet been fully defined. Proposed mechanisms include release by micro-vesicle 
shedding, release through secretary lysosomes and release by cell lysis [Allan et al, 
2005].
Both IL-kx and IL-1|3 exert similar biological effects. IL-la or IL-ip binding to a 
membrane type 1 IL-1 receptor (IL-1R1) allows the association with the IL-1 receptor 
accessory protein (IL-lRacP) and the formation of a complex capable of intracellular 
signalling [Cullinan et al, 1998]. The IL-1 receptors belong to the Toll-like receptor 
family (TLR) that have a major role in immune response. This family of receptors are 
characterized by the presence of a Toll-IL-1 receptor (TIR) domain that trigger a series of 
intricate signalling events, such as MyD88 [O’Neill, 2003], TRAF-2 and IRAK-1 
recruitment and IkB  degradation [Rayet et al, 1999][Celec, 2004] that results in the 
activation of nuclear factor-KB (N F -kB ) [Stylianou et al, 1992] and stress related mitogen 
activated protein kinases (MAPKs) [Allan et al, 2005]. This leads to the transcription of 
many inflammatory responsive genes such as the CXC chemokine IL-8 [Hoffman et al,
2002], cytokines such as IL-6 [Berghe et al, 2000], adhesion molecules like ICAM-1 
[Allan et al, 2005] and the multifunctional acute phase protein called C-reactive protein 
(CRP) [Voleti and Agrawal, 2005].
1.6 Interleukin-6 (IL-6) -  role in inflammation and mechanism of action
IL-6 is a multifunctional cytokine that plays a central role in host defence due to its 
potent ability to induce the acute phase inflammatory response [Berghe et al, 2000]. IL-6 
is commonly described as both a pro- and anti-inflammatory cytokine due to its ability to 
block pro-inflammatory cytokine expression and promote the expression of IL-1 receptor 
anatogonist [Jones et al, 2001][Hurst et al, 2001]. IL-6, therefore, facilitates the switch
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from innate to acquired immunity by orchestrating chemokine-directed attraction and 
apoptotic clearance of leukocytes [McLoughlin et al, 2004]
IL-6 belongs to a family of cytokines whose members act via a receptor complex 
containing the signal transducing protein gpl30. A key feature in the regulation of the 
IL-6 response is the identification of a soluble IL-6 receptor (sIL-6R) that can bind to IL- 
6 to produce a complex capable of stimulating cellular responses, such as proliferation 
arid activation of the inflammatory response [Jones et al, 2001]. sIL-6R itself is present 
in two distinct isoforms. One isoform is produced from the proteolytic cleavage of the 
membrane bound receptor (PC) and the other is produced from differential IL-6R mRNA 
splicing (DS). Both isoforms have been show to elicit common cellular events through 
gpl30 activation [Jones et al, 2001] [McLoughlin et al, 2004].
IL-6 can also activate cells through a membrane bound IL-6 receptor (IL-6R) with the 
central regulation of IL-6 mediated responses occuring through the binding of sIL-6R. 
Cells lacking the cognate IL-6R can still be activated by the IL-6/sIL-6R complex due to 
its ability to interact with the ubiquitously expressed 130 KDa signal-transducing 
glycoprotein (gpl30) in a process termed IL-6 trans-signalling. The first event in IL-6 
signalling involves the homodimerization of the ligand-receptor complex to gpl30 that is 
able to trigger activation of gpl30-associated cytoplasmic tyrosine kinases (JAK1, JAK2 
and TYK2) that subsequently cause the phosphorylation of ST ATI and STAT3. 
Monomeric ST AT subunits can then form homo- and hetro-dimers and translocate to the 
nucleus where they can initiate expression of specific genes [Heinrich et al, 
1998][Heinrich et al, 2003] such as RANTES and MCP-1, in order to promote a 
sustained mononuclear cell population [McLoughlin et al, 2005].
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1.7 Cancer Antigen 125
1.7.1 CA125 in Ovarian Cancer
Ovarian cancer is the 5th most common form of cancer and accounts for 5% of all female 
malignancies. Latest statistics suggest that 1 in 55 women will develop cancer of the 
ovaries at some point during their life. When diagnosed at an early stage the patient has a 
5 year survival of 70%, whereas, those who are diagnosed at a later stage of the disease 
have a 5 year survival rate of 20%, hence underlining the need for an efficient tool for the 
diagnosis of early stage ovarian cancer [Whitehouse and Solomon, 2003].
CA125 was first described in a study carried out on the OVCA433 by Bast and his 
colleagues in 1981 [Bast et al, 1981]. His group developed a murine monoclonal 
antibody, named OC125, that reacted with the OVCA433 cell line from a patient 
suffering with cystadenocarcinoma of the ovaries. The antibody was found to react with 
an antigenic determinant on the surface of the ovarian epithelial tumors. The antigenic 
determinant was named Cancer Antigen 125 (CA125) and was subsequently found to be 
produced by other tumours such as malignant tissue of the lung and breast [Jacobs and 
Bast, 1989],
Serum analysis of CA125 levels in patients suffering with ovarian cancer using a CA125 
immunoradiometric assay showed that 80% had elevated levels (>35 U/ml) when 
compared with normal patients (<35U/ml) thus indicating CA125’s potential as a 
diagnostic tool [Bast et al, 1983]. Elevations in CA125 serum levels are also associated 
with advanced or untreated endometrial cancer [Ziemet et al, 1996]. Since its first 
identification, 26 antibodies have been described that recognize CA125. These 
antibodies can be separated into two groups, either OC125 like- or M il like- antibodies. 
Competition studies showed M il binding is not inhibited by OC125, suggesting they 
bind to different epitopes on the CA125 molecule [Nustad et al, 1996]. This allowed the 
development of a double determinant sandwich assay in which M il acts as the capture 
antibody and OC125 acts as the detection antibody. This assay shows much less 
variation than the original assay and is the current assay used in the diagnosis of ovarian
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cancer. These commercially available kits are now commonly used to monitor the 
disease’s progression and regression as well as the recurrence of the condition 
[Kenemans et al, 1993]. For example, doubling or halving of the CA125 serum levels in 
patients can be indicative of progression or regression of the malignancy. After treatment 
serum levels of less than 35 U/ml indicate successful resolution of the disease whereas 
the disease is still present in 95% of patients with levels above 35U/ml. Recurrence of 
the disease after treatment completion is commonly proceeded by a significant increase in 
CA125 levels sometimes up to a year before the actual recurrence [Kenemans et al,
1993]. Other markers of ovarian carcinoma have been identified such as human kallikrein 
6, osteopontin and claudin 3, but to date CA125 remains the most effective and reliable 
signal for the detection of ovarian cancer [Rosen et al, 2005]. Although, more recent data 
using gene array technology has suggested that the efficiency of malignancy detection 
may be significantly increased if many markers are used in combination [Lu et al, 2004].
1.7.2 CA125 in Peritoneal Dialysis
CA125 was also found to be expressed in normal tissues of the pancreas, kidney, colon, 
the surface of eye and the peritoneum [Loy et al, 1992][Argueso et al, 2003]. Interest in 
CA125 expression in the peritoneal cavity is related to the search for markers that iterate 
the status of the peritoneal membrane. Mesothelial cells were shown to be the major 
CA125 producing cells of the peritoneum [Koomen et a/,1994][Zeillemarker et al,
1994][Epiney et al, 2000] and as a result CA125 has been adopted as a marker of HPMC 
mass and integrity [Visser et al, 1995][Ho-Dac-Pannekeet et al, 1997].
During peritoneal dialysis, CA125 can be found in fluids from the peritoneal cavity. 
Studies in the measurement of CA125 effluent levels of patients undergoing PD, as well 
as in vitro studies, show that it is constitutively produced and secreted by mesothelial 
cells (Figure 1.8(A)) and therefore, it has been suggested that it can be used 
diagnostically as a marker of mesothelial mass and of mesothelial cell integrity [Visser et 
al, 1995]. CA125 levels in the effluent of PD patients show a decrease over treatment
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Figure 1.8 Constitutive expression of CA125. (A) Graph illustrating the positive 
correlation between CA125 concentration and the duration of HMPC cell culture 
(Taken from [Visser et al, 1995]). (B) Graph illustrating the reduction of CA125 
effluent levels during long-term continuous ambulatory peritoneal dialysis (taken 
from [Ho-Dac-Pannekeet et al, 1997]). (C) Graph showing no correlation between 
CA125 concentration and the duration of treatment (taken from [Lai et al, 1997]).
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time (Figure 1.8(B)) suggesting that the loss of mesothelial cell mass correlates to the 
membrane dysfunction in PD patients [Ho-Dac-Pannekeet et al 1997][Sanusi et al, 2001]. 
Further evidence is provided by the positive correlation between the number of HPMC in 
the peritoneal effluent and the CA125 concentration [Koomen et al, 1994][Visser et al,
1995]. Nevertheless these data remain contentious since Lai and his colleagues were 
unable to produce this data in a study of similar size (Figure 1.7(C)) [Lai et al, 1997], 
which may indicate that CA125 is a marker of homeostasis within the peritoneal cavity 
and reflects more than just mesothelial cell mass.
1.7.3 PDF biocompatiblity
The use of CA125 as a marker of peritoneal “health” is reinforced by studies comparing 
dialysis fluid compatibility in medium term clinical trials [Breborowicz et al,
2005][Topley et al, 2005]. In summary, the use of more biocompatible dialysis fluids 
(containing less glucose degradation products and improved buffer systems (i.e. neutral 
pH)) during PD results in elevated CA125 effluent levels after 6 months [Williams et al, 
2004][Rippe et al, 2001][Jones et al, 2001]. The improved biocompatibility of the PDFs 
also result in functional and morphological improvements to the peritoneal membrane 
and mesothelium [Devuyst et al, 2002] and therefore it is still not clear whether an 
increase in CA125 simply reflects a more intact mesothelium or contributes directly to 
function. Studies carried out in a human mesothelial cell model showed that high glucose 
concentrations inhibit mesothelial cell proliferation, suggesting osmotic solutes may 
contribute to the poor biocompatibility of PDFs [Breborowicz et al, 1992]. More 
recently, it has been shown that the GDP content of PD fluid has a significant impact on 
CA125 concentrations found in effluent PD fluid. The lower the GDP content the higher 
the CA125 concentration found in the effluent [Williams et al, 2004].
However, CA125 has not been shown unequivocally to be a predictor or marker of the 
health of the mesothelium. Other studies discredit CA125 as a marker of peritoneal 
health suggesting that the variability between patient samples is too large to gain a 
positive correlation between CA125 concentration and mesothelial mass. This study
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suggested that the observed levels of CA125 produced is a combination of the amount of 
cells present as well as their ability to produce the antigen, which can be effected by 
factors such as patient age and can therefore, not be used as a marker of mesothelial cell 
mass [Breborowicz et al, 2005].
1.7.4 CA125 in peritonitis
As outlined in section 1.4, peritonitis and its associated inflammation are frequent 
complications of peritoneal dialysis. CA125 effluent levels can be seen to be modulated 
during an episode of peritonitis (Figure 1.5) [Ho-Dac-Pannekeet et al, 1995] with some 
studies reporting a 3.5-fold increase in CA125 levels in effluent levels during an episode 
of peritonitis aswell as a 7-fold increase in serum level within 2 months of the 
inflammatory incident, therefore, indicating CA125 as a marker of inflammation [Bastani 
and Chu, 1995]. Other studies suggest the increase in CA125 levels after peritonitis is 
caused by the release of intracellular CA125 as a result of mass mesothelial cell death 
[Visser et al, 1995].
The regulation of CA125 in peritoneal inflammation is poorly understood and there is 
much confusion about its role during inflammation. Some publications have shown that 
pro-inflammatory cytokines such as IL-1|3 have no effect on CA125 expression by 
mesothelial cells [Visser et al, 1995]. In the various ovarian cancer cell lines tested in a 
separate study, IFN-a, IFN-p, IFN-y, TNF-a and TGF-P were found to have little or no 
effect on CA125 expression [Imbert-Marcille et al, 1994], thus providing further 
evidence for the constitutive nature of CA125’s expression and therefore suggest that 
CA125 can be used as a marker of cell mass. Conversely, some other conflicting 
publications have shown that IL-ip can induce [Zeillemarker et al, 1994] or down- 
regulate CA125 cell surface secretion [Zeimet et al, 1996] and therefore, can no longer be 
thought of as a marker of mesothelial cell mass.
In order to understand how CA125 fulfils its potential biological roles it is essential to 
understand how its expression and secretion are regulated under defined conditions. To
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date it is not known if its production is regulated by growth phase, cell damage or 
following direct stimulation of pro-inflammatory cytokines or growth factors known to be 
present in the peritoneal cavity during dialysis.
1.8 The molecular status of CA125
1.8.1 The protein
CA125 is a high molecular weight, highly glycosylated multi-subunit glycoprotein with a 
carbohydrate content of 77% (sialic acid, fucose, manose, galactose, N- 
acetylgalactosamine and N-acetylglucosamine) [Yin and Lloyd, 2001J and is 
predominantly a surface expressed molecule, although it can be found intracellularly (in 
the cytoplasm) and in the extracellular matrix of producing cells [O’Brien et al, 1991]. 
The use of various antibodies has resulted in the detection of varying molecular weights 
ranging from 68Kd to lOOOKd [Yin et al, 2002]. SDS page polyacrylamide gel analysis 
using the antibody OC125 gives rise to a band of approximately 200Kd, thought to 
represent the protein core of the CA125 molecule [Davis et al, 1986]. It has been 
suggested that the form of CA125 found in serum might be a degraded product from a 
larger molecule produced in the peritoneal cavity [Nustad et al, 1998] and may even be 
present as a complex of adhering CA125 molecules [O’Brien et al, 1998].
1.8.2 CA125 is a mucin type glycoprotein
A monoclonal antibody specific for CA125, VK-8, was used to purify the antigen from 
the ovarian cancer cell line OVCAR-3. The purified antigen displayed characteristics 
typical of a mucin type glycoprotein [Lloyd et al, 1997]. These include: 1/ A highly 
glycosylated molecule (77% w/w) dominated by galactose and N-acetylglucosamine, 2/ 
A protein rich moiety rich in serine, threonine and proline molecules, 3/ Predominant 
glycosylation of serine and threonine residues and 4/ Predominantly O-linked glycans 
[Lloyd et al, 1997][Wong et al, 2003]. Further evidence for CA125’s inclusion in to the 
mucin group of glycoproteins stems from similarities in the deduced amino acid sequence
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of MUC16 and the sequence of isolated peptides from CA125, along with the subsequent 
correlation between MUC16 and CA125 mRNA expression [Yin et al, 2001].
1.8.3 CA125 proposed structure
The proposed structure of the antigen can be seen in Figure 1.9. CA125 has a short 
cytoplasmic domain containing a transmembrane domain, a glycoslyated extracellular 
domain and a large amino terminal domain. The extracellular structure contains a 156 
amino acid repeat sequence (upwards of 60 repeats) that displays epitopes for both 
OC125 and M il binding. Each repeat has a conserved methionine residue at position 24, 
thought to be involved in antibody binding, and two conserved cystiene residues, 19 
amino acids apart, indicating the possible presence of a disulphide loop structure 
[O’Brien et al, 2001][Wong et al, 2003]. NMR spectroscopic analysis of the repeat 
structure indicates that each repeat contains a SEA domain composed of two a  helices 
and four p anti-parallel strands [Maeda et al, 2004]. The carboxy-terminal domain has a 
short cytoplasmic tail made of 256 amino acid residues, possibly containing a glycan- 
phosphatidylinositol (GPI) anchor [Nagata et al, 1991].
1.8.4 Molecular Weight
This extraordinarily large moiety appears to be composed of at least 22,152 amino acids 
of which 12,068 constitute the amino terminal domain and approximately 10,000 residues 
representing the 60+ repeat domains. A complete molecule of this magnitude would 
have a molecular weight of approximately 2.5 million daltons and a potential 
glycosyltated molecular weight of more than double that [O’Brien et al, 2002].
1.8.5 Cell surface secretion
CA125 has a proteolytic cleavage site 50 amino acid residues up from its trans-membrane 
domain [O’Brien et al, 2002] but little in known about the specific pathway in which 
CA125 is released from the cell surface. Work carried out on the WISH amnion human
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cell line suggests that the release of CA125 requires both serine or threonine and tyrosine 
phosphorylation which may act as a signal for the proteolytic cleavage of CA125 from 
the cell surface. It has also been suggested that removal of CA125 from the cell may be 
mediated through a pathway involving the plasminogen-plasmin activator, tPA [Fendrick 
et a\, 19971 or the EGF signal transduction pathway JKonishi et al, 1994|[O’Brien et al, 
1998 J.
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Figure 1.9 Proposed structure of the CA125 antigen (Taken from [O’Brien et al, 
2001]).
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1.9 The Gene
1.9.1 Initial characterization
The earliest attempt to characterize the CA125 gene resulted in the identification of 
NBR1 as a CA125 candidate gene. This gene was identified by screening an OVCA432 
lambda ZAP cDNA library with a polyclonal antibody raised to the CA125 antigen and 
was subsequently found to be located on chromosome 17q21.1, the same genomic region 
as the BRCA1 gene [Brown et al, 1996][Whitehouse and Solomon, 2003]. The sequence 
of the gene recovered was found to be void of any transmembrane domain motif 
sequences and when expressed as an epitope-tagged construct appeared to be expressed 
in cytoplasmic and perinuclear locations. It was suggested that NBR1 may code for just 
part of the CA125 complex but it was more likely that the antibody raised to CA125 cross 
reacted with an epitope on NBR1, indicating that NBR1 is not a candidate gene for 
CA125 [Whitehouse and Solomon, 2003].
1.9.2 Cloning of the CA125 gene
Progress in understanding the molecular nature of the CA125 gene was hampered by 
difficulties in cloning the gene. This was until Lloyd and his group screened a lambda 
ZAP cDNA library from OVCAR-3 cells and discovered a 5797bp clone containing a 
stop codon and poly (A) sequence (but no 5’ initiation sequence) [Yin and Lloyd, 2001]. 
This work suggested that CA125 was in fact a mucin gene (MUC16).
Further progress was made, later that same year, when a group from the University of 
Arkansas used controlled CNBr cleavage of the antigen to produce fragments of 
approximately 40Kd, which were subsequently sequenced in an attempt to elucidate 
CA125 gene structure. This study indicated that production of CA125 required a 
transcript of more than 35,000 bases [O’Brien et al, 2001]. Interestingly, this data was 
later proved incomplete by the same group who identified an extension to the N-terminal 
domain that doubled the size of the CA125 antigen lO’Brien et al, 2002]. Therefore, the 
most recent data shows that the CA125 gene occupies over 134,000bp of genomic DNA,
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has a transcript of 67,000 bases and is positioned on chromosome band 19pl3.2, assigned 
to cosmids AC008734 and AC016584 in the genome database [Hovig et al, 2001]. Little 
else is known about the gene with regards to its expression and regulation.
1.10 Function of CA125
1.10.1 Lubricating molecule
The function of CA125 is an area that attracts a great deal of speculation due to the lack 
of understanding of the antigen’s regulation and expression. It’s use as a biological 
marker of the status of the peritoneal mesothelium is well documented, as well as its use 
as a target for the monitoring of ovarian cancer onset and recurrence but these “uses” give 
little clue to its actual biological function.
A major step in the understanding of its function came when it was identified as a mucin 
type molecule [Yin and Lloyd, 2001]. Typically, mucins function as lubricating 
molecules on the surface of epithelial cells and also act as signal transducers allowing the 
binding of a vast array of proteins to their extensive structure [Gum, 1992][Verma et al,
1994]. Given the size of the CA125 antigen it seems likely to be involved in a number of 
functions in parallel. Due to the nature of the molecule and its cell surface expression, 
CA125 is thought to have a role as a lubricating molecule preventing cell-cell adhesions 
of opposing membranes of the peritoneum (although there is no clear evidence for this 
function) [Hardardottir et al, 1990]. Further evidence for this biological function is 
provided by CA125’s apparent lubricating function on the ocular surface epithelium of 
the eye [Hori et al, 2004] and the inhibited adhesion of various cancer cell lines to CA125 
coated plates in vitro [Gaetje et al, 2002].
1.10.2 Mesothelin binding and cellular adhesion
Like CA125, mesothelin is a surface molecule expressed in the mesothelial cell lining of 
body cavities and in many tumour cells [Rump et al, 2004]. An antibody, Mab Kl, was 
first used to identify a 69-kDa precursor that is proteolytically processed into a 40kDa
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membrane-tethered form called mesothelin and a 30kDa secreted form known as 
megakaryocyte potentiating factor (MPF) [Chang and Pastan, 1996][Chowdhury et al, 
1998]. Soluble forms of mesothelin and MPF are detectable in the sera of patients with 
ovarian cancer, indicating its potential use as another marker for the diagnosis of ovarian 
cancer and monitoring its response to therapy [Scholler et al, 1999]. Mesothelins 
biological function remains poorly understood although it is implicated as having a role 
in cellular adhesion [Chang and Pastan, 1996].
Work carried out by Rump and his colleagues in 2004 showed that the polypeptides 
encoding the mesothelin molecule are matched to portions of the CA125. In addition to 
this, they showed a specific affinity for the binding of CA125 to mesothelin, along with 
the co-expression of CA125 and mesothelin in advanced stage ovarian cancer. Binding 
studies monitoring the binding of OVCAR-3 cells to an endothelial cell monolayer 
expressing mesothelin showed that CA125/mesothelin binding mediates the binding of 
the two cell types. Given his findings, Rump speculated that CA125 might contribute to 
the metastasis of ovarian cancer in the mesothelium via mesothelin binding [Rump et al, 
2004].
1.10.3 Galectin binding and export
Galectins are a family of animal lectins that all possess the same carbohydrate binding 
affinity for P-galactosidase and conserved consensus sequence elements in their 
carbohydrate binding sites [Liu et al, 2002]. The biological functions of galectins include 
the regulation of cell adhesion, cell proliferation and cell death [Brewer, 2002]. Recent 
evidence has also implicated galectins to be important regulators of immune cell 
homeostasis. For example, Galectin-1 is widely expressed by cells of the central and 
peripheral immune compartments including macrophages and activated B-cells and has 
many functions including the inhibition of T-cell proliferation as well as the induction of 
cell cycle arrest and apoptosis in these cells [Rabinovich et al, 2002].
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In 2002, Seelenmeyer and her group established that CA125 functions as a counter 
receptor for galectin binding, as both soluble and membrane-associated forms of CA125, 
derived from HeLa cell line lysates, were able to bind to galectins with high efficiency. 
This binding was found to be dependant on |3-galactose-terminated, O-linked 
oligosaccharide chains of CA125 and seemed preferential to galectin-1 [Seelenmeyer et 
al, 2003]. FACS analysis showed that the HeLa cell lines producing endogenous CA125 
had ten times more galectin-1 bound to their cell surface compared to a CHO cell line 
that is CA125 deficient. Interestingly, the cell surface binding capacity for galectin-1 was 
shown to be equal in both the HeLa and CHO cell lines, as was the galectin-1 expression 
levels, suggesting that CA125 maybe involved in the regulation of galectin-1 transport to 
the cell surface and therefore be part of the immune response to inflammation.
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1.11 AIM OF THESIS
1.11.1 Aim
The literature has identified CA125 as a marker of HPMC mass/integrity in the 
peritoneum. During peritoneal dialysis CA125 effluent levels can be seen to change but 
it is unclear whether this is a reflection of the state of the mesothelium or due to 
alterations in the regulation of CA125 expression. The aims of the thesis were to 
examine the regulation of CA125 at the level of transcription by detailed analysis of the 
promoter region.
Peritonitis is a common occurrence in some patients on peritoneal dialysis and is a 
common cause of technique failure in these patients. The role of CA125 during the 
associated inflammatory process may be important in understanding its amplification 
and/or resolution. Therefore, this study was also aimed at identifying the potential 
biological roles for CA125 during the inflammatory state by studying its regulation at the 
level of transcription, surface expression and cell surface secretion in response to classic 
inflammatory mediators. Additionally, this study attempts to further elucidate the 
biological function of CA125 by examining its role in a HPMC wound healing model and 
by using siRNA technology to knock out CA125 expression in these primary cells.
1.11.2 Scope of the thesis
Chapter 3 details the reconstruction of the CA125 gene using a variety of computational 
methods such as use of the Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov) and the internet based Cis-element cluster finder (Cister) 
programme (http://zlab.bu.edu/~mfrith/ cister.shtml). These data were corroborated using 
laboratory based methods such as Polymerase Chain Reaction (PCR) and 5’-Rapid 
Amplification of cDNA Ends (5’-RACE). In addition, the proximal promoter region was 
tested for transcriptional capability using luciferase reporter gene technology.
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Chapter 4 investigates HPMC regulation of CA125 expression during disease conditions 
using an in vitro model of inflammation. Changes in the transcriptional regulation, cell 
surface expression and cell surface secretion of CA125 were analysed using RT-PCR, 
flow cytometry (FACS) and Radioimmunoassay (RIA), respectively, in response to IL-lp 
and IL-6/sIL-6R stimulation.
Chapter 5 examines the biological function of CA125 using a HPMC wound healing 
model. Time-lapse photography was used to analyse the rate of wound closure of 
mechanically scratched HPMC monolayers in response to the addition of exogenous 
CA125 and exogenous OC125 antibody. This chapter also investigates the potential 
relationship between the CA125 levels observed in the effluents of PD patients and the 
level of GDPs present in the dialysis fluids used.
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Chapter2 
Methods and Materials
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2.1 COMPUTATIONAL BASED METHODS
2.1.1 CA125 in silico gene reconstruction
cDNA sequences for CA125 were retrieved from the national centre for biotechnology 
information (NCBI) database at http://www.ncbi.nlm.nih.gov. Using the program BLAST 
(http://www.ncbi.nlm.nih.gov/blast/)[Altschul et al, 1997] genomic clones for CA125 
were  a l so  r e t r i e v e d .  BLAST2  a l i g n m e n t  s o f t w a r e  
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html)[Tatusova et al, 1999] allowed 
direct alignment of the cDNA sequences with the gDNA sequences. These data were 
corroborated using the University of California Santa Cruz (UCSC) genome browser 
(http://genome.cse.ucsc.edu/cgi-biun/hgGateway).
2.1.2 Identification of putative transcription factor binding sites
The CA125 promixal promoter region was screened for the prescence of TFBS’s using 
the internet based Genomatrix suite (http://genomatrix.de/cgi-bin/eldorado/main.pl) and 
the internet based Cis-element cluster finder (Cister) programme 
(http://zlab.bu.edu/~mfrith/ cister.shtml) using standard default parameters. The Estrogen 
Responsive Element  Finder (http://research.i2r.a-star.edu.sg/promoter/ERE- 
V2b/cgi/ere/pl) was used to identify oestrogen responsive elements in proximal promoter 
sequence in accordance with Tang’s method [Tang et al, 2004].
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2.2 CELL CULTURE
2.2.1 Reagents
All chemicals were purchased from Sigma-Aldrich Co, Ltd (Gillingham,UK) unless 
otherwise stated. All chemicals were of analytical grade or higher.
2.2.2 Isolation and culture of human peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC) were isolated from greater omentum tissue 
obtained from consenting patients undergoing elective abdominal surgery using an 
adapted version of Stylianou’s original method [Stylianou et al, 1990]. Briefly, small
pieces of omentum tissue (5cm2) were washed in sterile PBS (Gibco, Invitrogen Ltd,
Paisley, UK) and transferred to 15ml of a trypsin/EDTA (0.1% w/v trypsin and 0.02% 
w/v EDTA) mixture and incubated for 15 mins at 37°C with continuous rotation. HPMC 
were then harvested by centrifugation of the digested tissue at 800g for 6 minutes. 
Pelleted cells were then suspended in growth medium.
2.2.3 HPMC growth conditions
HPMC were grown in Earles salt medium M199 (Gibco) containing 10% fetal calf serum 
(Hyclone, Perbio Science Ltd, Cranlington, Uk) supplemented with lOOpg/ml penicillin, 
lOOpg/ml streptomycin, 2mM glutamine (Gibco), 5pg/ml insulin, 5pg/ml transferrin and 
0.4pg/ml hydrocortisone. Cell monolayers were then grown (incubated at 37°C, 5% 
C02) in T25 Falcon culture flasks (Becton Dickinson, Oxford, UK) until confluent. 
Primary cultures typically attained confluence in 3-5 days. All experiments were 
performed on cells of passage two.
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2.2.4 Characterization of HPMC
2.2.4.1 HPMC Morphology
The morphology of monolayer cultures of HPMC was examined using an inverted light 
microscope (Axiovert 25, Carl Ziess Ltd, Hertfordshire, UK). Confluent HPMC were 
typically polygonal in shape having approximately 5 sides and displaying the classical 
“cobblestone” appearance as seen in Appendix I. Cells adopting this morphology were 
growth arrested (section 2.2.8) and used in various experiments.
2.2.4.2 Immunohistochemistry
HPMC grown to confluence (first passage) on 8-well glass chamber slides (Gibco) were 
washed in PBS before they were fixed and permeabilized by addition of cold (4°C) 
acetone/methanol (1:1 v/v) for 5 minutes at room temperature (RT). The fixative was 
then removed and the cultures allowed to air dry. The cells were subsequently washed in 
0.9% bovine serum albumin (BSA) in PBS (w/v) before the addition of the primary 
antibody (incubated for 45 minutes in a humidified chamber). Following staining with 
the primary antibody the cells were washed a further 3 times in 0.9% BSA/PBS (w/v) 
before incubation with a Fluorscein-conjugate (FITC) secondary antibody for 45 minutes 
in a dark humidified chamber. After a final wash the cells were mounted in PBS/glycerol 
(1.9% v/v) and viewed/photographed under a Leitz Orthoplan fluorescence microscope 
(Leica UK Ltd, Milton Keynes, Uk). The antibodies used are listed below (Table 2.1).
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Table 2.1 Antibodies used for the characterization of HPMC
Antibody Sub-class Optimal
dilution
Supplier
Anti-Human cytokeratin 18 IgGl, kappa 1:800 Dako Cytomation
(clone CY 90) Ltd, Ely, UK.
Anti-swine vimentin IgGl, kappa 1:10-1:25 Dako Cytomation 
Ltd, Ely, UK.
Anti-myosin (smooth and IgG 1:10 Sigma-Aldrich Co
skeletal) Ltd, Gillingham, 
UK.
Anti-human desmin IgGl, kappa 1:50-1:100 Dako Cytomation 
Ltd, Ely, UK.
Anti-human Factort VIII IgGl, kappa 1:25-1:50 Dako Cytomation
(clone F8/F9) Ltd, Ely, UK.
FITC-conjugated rabbit anti­ Immunoglobulins 1:20-1:40 Dako Cytomation
mouse Ltd, Ely, UK.
FITC-conjugated anti-rabbit IgG 1:16-1:32 Sigma-Aldrich Co 
Ltd, Gillingham, 
UK.
2.2.5 Human Kidney (HK) 2 Cells
HK-2 cells are human proximal tubule cells transformed with the human papilloma virus 
16 E6/E7 genes that retain the functional characteristics of fully differentiated proximal 
tubular cells [Ryan et al, 1994]. HK-2 cells were purchased from American Type Culture 
Collection (LGG Promochem, Teddington, UK).
2.2.6 HK-2 Growth conditions
HK-2 cells were grown in a 1:1 mix (v/v) of D-MEM:F-12 medium (Gibco/BRL Life 
Technolodies Ltd) supplemented with 20 mM HEPES (Gibco), 2mM L-glutamine 
(Gibco), 5pg/ml insulin, 5pg/ml transferrin, 5ng/ml sodium selenite, 0.4p,g/ml 
hydrocortisone and 10% fetal calf serum. Cell monolayers were then grown (incubated 
at 37°C, 5% C02) in T25 Falcon culture flasks until confluent.
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2.2.7 Monolayer Sub-culture
On reaching confluence in the primary culture flask, cells were transferred into T75 
culture flasks and then into the required experimental culture vessel (e.g. 6 well plate). 
Firstly the growth media was removed via aspiration and a 1:10 dilution (v/v) of 
trypsin/EDTA in sterile PBS was added in a volume adequate to submerge the cells. Cell 
detachment was then monitored via light microscopy (Axiovert 25). Following 
detachment lOmls of the appropriate growth medium with 10% FCS was added to 
neutralise the trypsin. This was then transferred to a 50ml centrifuge tube (Greiner Bio- 
One Ltd, Stonehouse, UK) and spun at 800g for 6 minutes. The supernatant was then 
removed and the pellet re-suspended in supplemented medium containing 10% FCS 
which was then dispensed into the new culture vessel. Confluent cells were split in a ratio 
of 1:3.
2.2.8 Growth Arrest
Prior to each experiment, the growth phase of the cells was synchronised by growth 
arresting them in serum free supplemented medium M199. Briefly, growth medium was 
removed and the cells were washed twice in serum free M199 to remove residual FCS 
before the addition of fresh serum free medium [Floege et al, 1990]. Under these 
conditions, cells remain viable for up to 96 hours and were typically used after 48 hours 
growth arrest.
2.2.9 Cell Stimulation
HPMC at passage two were grown to confluence in a culture vessel. Following growth 
arrest the spent medium was removed and the cells were washed in serum free medium. 
Stimulation was performed by incubation of the cells with the desired stimulus (i.e. IL- 
1(3, IL-6, retinoic acid, oestrogen) diluted in serum free M199 for varying times and 
concentrations before analysis.
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2.2.10 Oestrogen and Retinoic Acid Stimulation
Cells to be stimulated with oestrogen or all-trans retinoic acid were grown in phenol red 
free Ml99 supplemented with lOOpVml penicillin, lOOp-g/ml streptomycin, 2mM 
glutamine, 5pg/ml insulin, 5pg/ml transferrin, 0.4pg/ml hydrocortisone and 10% 
charcoal/dextran treated FCS (Hyclone). The cells were growth arrested in phenol red 
free M l99 (minus serum) for 48 hours prior to experimentation. This alternative medium 
was used to reduce the amount of oestrogen and retinoic acid in the system.
2.3 RNA ANALYSIS
2.3.1 Chloroform/Isopropanol RNA extraction
One millilitre of tri-reagent was added per well of a 6 well plate and left for 5 minutes 
until all cells were lysed. The lysate was then collected in a 1.5ml microcentrifuge tube to 
which 0.2ml of chloroform was added per 1ml lysate. After mixing by inversion, each 
sample was left to incubate for 5 minutes to allow the separation of two phases. The 
samples were then centrifuged at 12000rpm for 15 minutes (4°C, with no braking). The 
colourless phase was transferred to a clean microfuge tube and the lower phase (and 
interface) discarded. RNA precipitation was achieved by addition of 0.5ml isopropanol 
to each sample before storage over night at -20°C. The RNA was pelleted by 
centrifugation at 12000 rpm for 15 minutes at 4°C. The pellet was then washed by adding 
1.5ml of ice cold ethanol, vortexing briefly and centrifuging at 12000 rpm for 15 minutes 
at 4°C. All traces of ethanol were then removed and the pellet allowed to air dry for 
approximately 1 hour before re-suspension in lOpl of sterile H20.
2.3.2 Determination of DNA and RNA concentration
RNA and DNA concentrations were determined by spectrophotometric analysis using a 
Beckman UV-DU64 spectrophotometer (Beckman Instruments Ltd, High Wycombe, 
UK). In an appropriate cuvette lpg of RNA or DNA was diluted in 54pl of sterile water. 
The absorbance was read at both 260nm and 280nm. A 260/280 ratio of above 1.8 was
43
indicative of a sufficiently pure sample. The concentration was calculated using the 
following formula:
[RNA or DNA] (pg/ml)= Abs260 x Molar extinction coefficient x dilution factor
Molar extinction coefficient for RNA = 40 
Molar extinction coefficient for DNA = 50 
Dilution factor = 55
An Abs260 of between 0.1 -1.0 was required to be in the linear range of the Beer-Lambert 
law. Samples were diluted where necessary and discarded if Abs260 <0.1 .
2.3.3 RNA quantification
RNA integrity was determined by flat bed electrophoresis using a mini gel system 
(Thermo Life Sciences Ltd, Basingstoke, UK) through a 2% agarose gel (composed of lg  
Electrophoresis grade agarose (Ultrapure agarose, GIBCO/BRL), 50ml of 1 X TAE 
buffer (Promega Ltd, Southampton, UK) and 5pl ethidium bromide (5mg/ml). Into a
single well, lp g  of RNA was loaded along with 5pl of loading buffer (15% Ficoll Type
400 (Amersham Biosciences UK Ltd, Chalfont St.Giles, UK) in H20 ,  0.25% Orange G). 
Visualisation of the gel (Figure 2.1) was carried out using ultra violet light in the 
ChemiDoc™ Gel documentation system (Bio-Rad Laboratories Ltd, Hemel Hempstead, 
UK).
28S
Figure 2.1 A RNA agarose gel (2% w/v) showing the 18S and 28S ribosomal 
subunits of total RNA (lpg) extracted from HPMC. The presence of the two distinct 
bands is confirmation of non-degraded RNA that is suitable to be used in further 
experiments.
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2.3.4 Semi-quantitative RT-PCR
Reverse Transcription was performed using the random hexamer method [Topley et al, 
1993]. Briefly, l^ig total RNA in a total volume of 20pl comprising lOOpM random 
hexamers (Amersham Biosciences UK Ltd), 5mM dNTPs (Amersham Biosciences UK 
Ltd), 1 X PCR buffer containing 1.5mM MgCl2 (Applied Biosystems, Warrington, UK) 
and ImM DTT (Invitrogen Ltd) was heated to 95°C for 5 minutes in order to linearise the 
RNA. Following immediate cooling on ice 40U of recombinant RNAsin ribonuclease 
inhibitor (Promega Ltd) and 200U Superscript II Rnase H- reverse 
transcriptase(Invitrogen Ltd) were then added. The RNA was then reverse transcribed by 
heating to 20°C for 10 minutes, 42°C for 60 minutes, 95°C for 5 minutes and finally 4°C 
for 2 minutes. Two microlitres of the resulting cDNA was used in each PCR reaction (see 
section 2.4.1).
2.3.5 5’-Rapid amplification of cDNA ends (5’-RACE)
Firstly, mRNA was isolated from total RNA (75|ig) using Oligo (dT)^ Dynabeads (Dynal 
Biotech, Wirral, UK) in accordance with the manufacturer’s protocol. The isolated 
mRNA was subsequently used in the 5’-RACE reaction using the SMART RACE Kit 
(BD Biosciences, Oxford, UK). Following the manufactures protocol, 3pJ of mRNA was 
reverse transcribed before PCR was used to amplify the resultant cDNA, using the 
Advantage 2 PCR Kit (BD Biosciences). Briefly, 2.5pi of cDNA was amplified using a 
specific primer that binds to the RACE 1 site. See appendix II for 5’-RACE PCR 
conditions. The product generated was then used in a nested PCR reaction (same 
conditions as described above) using a specific primer that binds at the RACE 2 site. The 
products were analysed using a 2% w/v agarose gel, by flat bed electrophoresis. The 
complete RACE mechanism can be seen in Figure 2.2.
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A. Mechanism of cDNA synthesis
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Figure 2.2 5’-RACE Mechanism (adapted from SMART RACE kit protocol (BD 
Biosciences, Oxford, UK)
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2.3.6 RNA Interference
2.3.6.1 Plate layout
HMPC of passage 2 grown in a Falcon T75 growth vessel (Becton Dickinson Ltd) were 
trypsinized as previously described and re-suspended in 10ml supplemented M199 
(+10% FCS) growth medium. In each reaction 1x10s cells were added per well of a 12 
well culture vessel (see below).
2.3.6.2 Total cell Count
The number of resuspended HPMC was determined using a coulter counter (Z2, 
Beckman Coulter UK Ltd, High Wycombe, UK). A 20pl sample of the resuspended 
HPMC was diluted with 20mls of Isoton II balanced electrolyte solution (Beckman 
Coulter UK Ltd) in a counting vial and the counter electrode suspended in the vial. A 
threshold was set on the coulter counter to count HPMC in a sample volume of 0.5mls. 
From this the number of cells in the suspension was determined. The volume of the 
suspension was adjusted to contain lxlO5 cells per 0.9mls.
2.3.6.3 siRNA Transfection
Transient transfection of HPMC with specific siRNA oligonucleotides (CA125 and 
GAPDH) was carried out using siPORT Amine transfection reagent (Ambion (Europe) 
Ltd, Huntington, UK) in accordance with the manufacturer’s protocol. Briefly, 5pl of 
transfection agent was diluted in 45pi Opti-MEM reduced growth medium (Gibco) and 
left to incubate at room temperature for 15 minutes. Meanwhile, the specific siRNA 
oligonucleotides were diluted in Opti-MEM reduced growth medium to give a final 
concentration of lOOnM in a total volume of 50pl. The transfection agent mix and siRNA 
mix were then combined and incubated at room temperature for a further 10 minutes. 
The newly formed transfection complexes (lOOpl) were dispensed into empty wells of a 
12 well culture plate. To each well lxlO5 HPMC (see 2.3.6.2) were then added, so that 
the total volume in each well was 1ml. The plate was then rocked gently back and forth,
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to evenly distribute the complexes, before the cells were incubated at 37°C with 5% C 0 2 
for 48 hours. The mechanism of siRNA can be seen in Figure 2.3.
Introduction of short 
iRNA into cell by - |  
transfection
l l l l l l l l l l
ATP
ADP+P
RISC (RNA-induced 
silencing complex)
RISC activation
AAAAA
Target site 
recognition
A AAAA
Cleavage by endonuclease activity 
followed by further degradation by 
celluar exonucleases.
Silent state of gene expression 
locked by methylation (M)
Figure 2.3 Mechanism of gene knockdown by interference RNA (siRNA).
2.4 DNA ANALYSIS
2.4.1 Polymerase Chain Reaction (PCR)
For each 50pl PCR reaction, 2pl of the cDNA generated from the reverse transcription 
(section 2.3.4) reaction (or 40ng genomic DNA) was used. Each reaction comprised 1 x 
PCR Buffer containing 1.5mM MgCl2 (Applied Biosystems), 5mM dNTPs (Amersham 
Biosciences UK Ltd), 2.5U AmpliTaq Gold (Applied Biosystems Uk Ltd) and ImM 
oligonucleotide primers. The standard PCR protocol can be seen in Appendix II.
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2.4.2 Quantitative Polymerase Chain Reaction
For each 25 pi qPCR reaction, lpl of the cDNA generated from reverse transcription 
(section 2.3.4) was added to a 96-well plate along with equal amounts of the 
commercially available 20x Taqman® PCR Mastermix Reagents (Specific for GAPDH 
and 18S ribosomal RNA (internal endogenous control)) and 2x buffer as per the 
manufacturer’s instructions (Applied Biosystems UK Ltd). Taqman assays were 
performed using an ABI Prism 7000 Sequence Detection System (Applied Biosystems 
Uk Ltd). During the PCR operation, the plate was first held at 50°C for 2 minutes and 
then at 95°C for 10 minutes to denature nucleic acid samples. The amplification process 
was carried out at 95°C for 15 seconds and 60°C for 1 minute. Data were analyzed using 
ABI Prism 7000 SDS software from Applied Biosystems Uk Ltd. Due to the absence of 
the required Equipment at the Institute of Nephrology, the procedure was carried out in 
collaboration with Dr D Fraser at the School of Dentistry, Wales College of Medicine, 
Cardiff University.
2.4.3 Primer design
All primers were designed using internet based Primer 3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgil and purchased from 
Invitrogen Ltd. Primers were designed to have a GC content of 50-60% and a TM 
(annealing temperature) of approximately 60°C. All primers (lypholised upon arrival) 
were reconstituted in sterile H20 to give a stock concentration of 200pM.
2.4.4 Sizing of PCR Products
All PCR products were run on a 2% agarose gel. Each gel comprised 2% w/v agarose, 1 X 
TAE and 5pl ethidium bromide (5mg/ml). 5pl of PCR product was loaded onto the gel 
along with 5pl of loading buffer (15% Ficoll Type 400 in H20 , 0.25% Orange G). 
Typically, the gel was run at 90v for 45-60 minutes. The agarose gels were 
visualised/photographed using a ChemiDoc™ Gel documentation system
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2.4.5 Purification of PCR products
Bands were extracted from an agarose gel using the QIAquick Gel purification kit 
(Qiagen Ltd, Crawley, UK) in accordance to the manufacturers protocol. Briefly, bands 
were made visible on a UV transilluminator (GRI, Braintree, UK) where they were cut 
from the gel and centrifuged at 13000rpm for 5 minutes, through a filter column, in order 
to remove any traces of agarose. The remaining sample was then mixed with equal 
volumes of buffer PB (supplied in kit) and passed through a QIAquick spin column by 
centrifugation (13000rpm for 60 seconds). DNA bound to the column was then washed 
with 0.75ml ethanol by centrifugation (13000rpm for 60 seconds) and eluted in 50pl 
sterile H20.
2.5 CLONING TECHNIQUES
2.5.1 Cloning of 5’-RACE products
Extracted and cleaned DNA fragments were cloned into a pCR®2.1 TOPO sequencing 
vector (see Appendix III) using a TOPO TA cloning® kit (Invitrogen Ltd). A TOPO 
cloning reaction mixture was set up by mixing 2pi fresh PCR product, 0.5pl salt solution, 
0.5pi TOPO vector and 2pi water for a total volume of 5pl. The newly formed vector was 
then used to transform One Shot Escherichia coli (Invitrogen Ltd) as described in section 
2.5.3.
2.5.2 Generation of Luciferase promoter constructs
Purified promoter constructs (generated using PCR) were cloned into a modified version 
of pGL-3 Basic luciferase reporter vector (Promega Ltd) in which the multiple cloning 
site had been altered to include cleavage sites from other common restriction enzymes 
(supplied by Dr. P. Buckland, Department of Psychological Medicine, Wales College of 
Medicine, Cardiff Univeristy). Appendix IV shows the original and modified sequence of 
the pGL-3 multiple cloning site. Using the restriction enzymes Kpnl and SpeI, 5pg of 
modified pGL3 vector was digested for 2 hours at 37°C. The digested vector was then
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analysed by electrophoresis on a 2% agarose gel before being extracted using the 
QIAquick gel extraction kit (see section 2.4.5) in accordance with the manufacturer’s 
protocol. Two micrograms of the digested vector was then treated with 2U shrimp 
alkaline phosphatase (Promega Ltd) in a total volume of 30 pi. Heating to 65°C for 20 
minutes then deactivated the enzyme.
Promoter fragments obtained via PCR were digested using the enzymes outlined in 2.5.5, 
and purified as previously described. The promoter fragments were then cloned into the 
digested and dephosphorylated pGL-3 vector using the following reaction mix. 6pl 
Promoter fragment, 2pl vector, 1 x ligase buffer and 2000U T4 DNA ligase (New 
England Biolabs (UK) Ltd, Hitchin, UK) in a total volume of lOpl. After incubation at 
16°C for 24 hours, One Shot Top 10 Escherichia coli (Invitrogen Ltd) were transformed 
with the recombinant vectors (see section 2.5.3) and grown overnight in a shaking 
incubator. The vectors were then purified and sequenced as previously described.
2.5.3 Transformation
To each sample, 50pl (108 cfu/pg) One Shot Top 10 Escherichia coli cells were added 
and incubated on ice for 30 minutes. The cells were then heat-shocked by incubating at 
42°C for 45 seconds before being placed back on ice for 5 minutes. To the cells, 150pl of 
fresh LB medium (see Appendix V) was added, followed by incubation at 37°C for 
approximately 90 minutes in an orbital shaker (200rpm). These cells were then plated on 
to YT Agar (see Appendix V) containing lOOpg/ml carbenicillin and incubated at 37°C 
overnight.
2.5.4 Purification of recombinant vectors
From each plate 5 colonies were picked and grown in 5ml YT broth (containing 
lOOUg/ml carbenicillin) at 37°C overnight. The cells contained within 1.5ml of each cell 
culture were then pelleted by centrifugation (13,000rpm for 1 min) and the supernatant 
removed by decanting, leaving approximately 50pl residual medium. Pellets were then
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re-suspended by brief vortexing before the addition of 300pl of TENS buffer (50 mM 
Tris [pH 8.0], 20 mM disodium EDTA, 100 mM NaCl, 1% [wt/vol] sodium dodecyl 
sulfate). The solutions were then mixed by inversion and left to incubate at room 
temperature for a maximum of 5 minutes before the addition of 150pl 2M sodium 
acetate. After centrifugation at 13,000rpm for 4 minutes, the supernatants were 
transferred to a second vessel where 900pl pure ethanol was added. Samples were then 
centrifuged for a further 4 minutes at 13,00rpm. The pellet formed was then washed a 
second time as previously described but using 70% ethanol. After the second wash the 
pellet was allowed to dry at room temperature (inverted tube) and re-suspended in 20pl 
sterile water.
2.5.5 Screening for presence of inserts
In order to confirm the presence of the desired insert, 5pi of each resultant sample was 
then digested with the appropriate restriction enzyme, to excise the inserted fragment for 
2 hours (See Table 2.2).
Table 2.2 Restriction enzymes used in plasmid screening
Construct Restriction enzyme
CA125 Promoter -F100 Kpnl and SpeI
-F500 Kpnl and Spe I
-F1000 Kpnl and Spe I
5’-RACE Fragments EcoRl
These products were then separated by electrophoresis on 2% agarose. Any RNA 
contamination in the preparations was removed by adding lpl ribonuclease A (lOmg/ml) 
to the loading buffer. After analysis of the gel, colonies containing the desired promoter 
fragments were re-picked and grown in 5ml YT broth as previously outlined. The 
recombinant vector was then harvested using the QIAspin Mini-prep kit (QIAGEN Ltd) 
in accordance with the manufacturer’s instructions. Samples were eluted in 50pl H20  
instead of TE buffer.
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2.5.6 Sequence analysis
In order to ensure the identity of the target sequence, all promoter and 5’-RACE 
constructs were sent for sequence analysis to The Sequencing Service, The University of 
Dundee, Dundee, UK. 5’-RACE fragments were sequence in a pCR 2.1 TOPO vector 
using M13 forward and reverse primers. Promoter constructs were sequenced in the 
pGL-3 modified vector using RV3 and GL2 primers. The primer sequences can be seen 
in Table 2.3.
Table 2.3 Sequencing oligonucleotide primers
Primer Sequence*
M13 forward GTAAAACGACGCCAG
M13 reverse CAGGAAACAGCTATGAC
RV3 CTAGCAAAATAGGCTGTCCC
GL2 CTTTATGTTTTTGGCGTCTTCC
♦primer sequences are shown in 5’-3’ orientation
2.6 LUCIFERASE ANALYSIS
2.6.1 Plate set up
Confluent 75cm2 flasks of HPMC or HK-2 cells were harvested as described previously. 
After resuspension in the appropriate, supplemented, medium the cells were plated into 6- 
well plates (2ml per well). Cells were grown to a confluence of «70% before transfection.
2.6.2 Transient transfection
Transient transfection of HPMC and HK-2 cells was performed using the lipofection 
agent FuGene 6 (Roche Diagnostics Ltd, Lewes, UK) as this was shown to be the most 
efficient for HPMC transfection [Ohan et al, 2001]. Optimisation experiments on HK-2 
cell transfection [Fraser et al, 2002] and unpublished experiments on HPMC transfection 
have previously determined that a ratio of 3:1 (pi FuGene: pg DNA) was required for 
HPMC transfection in 6-well plates (see Appendix V). When the cells reached the 
required confluence (70%) the growth medium was removed and the cells were washed
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in PBS. The cells were then transfected with lpg of the previously made luciferase 
Firefly promoter constructs (see section 2.5.2) and lpg of Renilla luciferase vector 
(Promega Ltd) in accordance with the FuGene 6 manufacturer’s instructions. The 
transfection was carried out in growth medium without FCS. After 24 hours the 
transfection medium was replaced with fresh medium containing the necessary stimilus 
for the experiment and incubated for a further 24 hours under growth conditions.
2.6.3 Reporter gene analysis in HPMC
The growth medium was removed and the cells were washed with PBS. The cells from 
each well were then scrapped into 1ml PBS and transferred to 1.5ml microcentrifuge 
tubes. The cells were then pelleted using centrifugation at 5000rpm for 2 minutes. The 
supernatant was removed by aspiration and 60pl lysis buffer (supplied in Dual-Glo 
luciferase assay kit (Promega Ltd)) was added to each sample before vortexing for 10 
seconds. The samples were then incubated at room temperature for 15 minutes before 
50pl of each sample was transferred to a white luminometric 96-well plate (Thermo Life 
Sciences). Luciferase activity was then assayed using the Dual-Glo luciferase assay kit as 
outlined in the manufacturer’s protocol. Briefly, lOOpl of Luciferase Assay Reagent II 
(LARII) was added to each sample in the 96-well plate. Immediately after this the 
luminescence of each well was read for 10 seconds using a luminometer (FLUOSTAR 
Optima, BMG Labtechnologies GmbH, Offenburg, Germany). Stop and Glo reagent 
(lOOpl) was then added and Renilla luminescence in each sample was recorded as before.
2.6.4 Reporter gene analysis in HK-2 Cells
The growth medium was removed and the cells were washed in PBS before the addition 
of 500pl of lysis buffer (supplied in Dual-Glo luciferase assay kit) per well. The cells 
were then incubated at room temperature for 15 minutes with gentle agitation. Any 
remaining adhered cells were removed by scrapping and the cell suspension was 
transferred to 1.5ml microcentrifuge tubes where each sample was vortexed for 10 
seconds. Fifty microlitres of each sample was transferred to a white luminometric 96-
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well plate. Luciferase activity was then assayed using the Dual-Glo luciferase assay kit, 
as previously described.
2.7 WESTERN BLOT
2.7.1 Gel preparation
Appropriate percentage SDS-polyacrylamide running gels were used for all Western 
blotting experiments dependant on protein of interest (see figure below for all gel 
compositions). Gels were made using a large vertical apparatus (Bio-Rad Laboratories 
Ltd). Firstly a SDS-polyacrylamide block gel was poured to form a 1cm layer at the 
bottom Of the gel, once polymerised the running gel was added before addition of the 
stacking gel. All gels were left to polymerise over night.
Table 2.4 Western gel compositions
Stacking Gel
3%
Running Gel 
7.5%
10% Block Gel
H20 6.1ml 6.35ml 4.85ml 4ml
Tris 2.5ml 2.5ml 2.5ml 2.5ml (pH8.8)
(pH6.8) (pH8.8) (pH8.8)
SDS (10%) lOOpl lOOpl lOOpl lOOptl
Acrylamide (30%) 1.3ml 1ml 2.5ml 3.34ml
APS 50pl 50pl 50pl 50pl
Temed lOpl 5pl 5\i\ 5 pi
2.7.2 Sample preparation and electrophoresis
Each sample (supernatant (section 2.7.3) or cell lysate (section 2.7.4)) was loaded on to 
the gel in a 2:1 mix (v/v) with sample loading buffer (60mM Tris (pH 6.8), 30% glycerol, 
3mM EDTA, 3% SDS, 0.01% bromophenol blue and 5% p-mercaptoethanol) after 
heating at 95°C for 5 minutes. Samples were then vortexed and centrifuged briefly before 
loading on a gel submerged in 1 x running buffer (30g/L Tris, 144g/L glycine and lOg/L 
SDS made up in H20). The size of the target protein was calibrated by the addition of
55
20pl of high molecular weight protein marker (Amersham Biosciences UK Ltd) to a 
separate well. The gel was then run at 80v (4°C) until the loading buffer reached the end 
of the gel.
2.7.3 Supernatant sample preparation
Supernatants were collected for cell monolayers and spun for 10 minutes at 3000rpm in a 
Vivaspin concentrator centrifuge tube (Vivascience, Epsam, UK) according to the 
manufacturer’s instructions.
2.7.4 Cell lysate sample preparation
Cells lysate samples were collected from HPMC monolayers by the addition of 200pl of 
cell lysis buffer (mix of 0.5% NP-40 in Tris buffered saline (pH 5.5) and 2% protease 
inhibitor cocktail) followed by incubation at RT for 15 minutes. Cell debris was pelleted 
via centrifugation at 13000rpm for 1 minute and the cell lysate removed.
2.7.5 Protein concentration estimation
The protein concentration of each sample was determined using the Bio-Rad protein 
assay (Bio-Rad Laboratories Ltd). Sample protein concentration was determined by direct 
comparison with BSA standards diluted in PBS, ranging from 0-10pg/ml. Appropriately 
diluted standards and samples (lOOpl) were loaded in duplicate in to a flat-bottomed 96 
well plate (Microlite II, Thermo life Sciences) followed by the addition of an equal 
volume of 40% dye binding reagent (Bio-Rad Laboratories Ltd). The absorbance of each 
sample was read (600nm) using the Dynex Revalation 96-multiwell plate reader (Thermo 
Life Sciences Ltd).
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2.7.6 Transblotting
The gel was removed from the vertical slab apparatus and equilibrated in lx Transfer 
buffer (25mM Tris, 192mM glycine, 20% methanol in H20) for 10 minutes with a 
nitrocellulose transblotting membrane (Hybond ECL, Amersham Bioscinces Ltd). Both 
gel and membrane were placed between a layer of filter papers and plastic wool pads and 
assembled into the transblotting apparatus (Bio-Rad Labaratories Ltd). Transblotting was 
performed with cooling (4°C) at 90v for approximately 2 hours.
2.7.7 Blocking and antibodies
Following the transblotting stage the membrane was blocked in 5% w/v non-fat 
powdered milk in PBS Tween 20 (0.2%) for 1 hour. This was followed by 5 washes in 
PBS Tween (0.2%) over 1 hour. The primary antibody was diluted 1:100 in 5% non-fat 
powdered milk/PBS Tween 20 (0.2%) for a total volume of 20ml per membrane. The 
membrane was incubated at 4°C overnight, with gentle rocking. Following five further 
washes in PBS Tween (0.2%), a relevant horseradish peroxidase-conjugated secondary 
antibody (diluted 1 in 1000) in 5% non-fat powdered milk/0.2% PBS Tween was added 
and the membrane incubated at RT for 1 hour, with rocking.
2.7.8 Detection
Following 5 washes in 0.2% PBS Tween 20 over a 2 hour period, the blot was developed 
on high performance autoradiography film (Amersham Biosciences Ltd) using the ECL 
chemiluminescence system (Amersham Bioscineces Ltd) in accordance with the 
manufacturer’s protocol. The exposure time was dependant on each specific experiment.
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2.8 FACS ANALYSIS
2.8.1 CA125 HPMC surface expression
HPMC were removed from the culture flask using 1:10 mix (v/v) of trypsin/EDTA in 
PBS. Medium M199 with 10% FCS was added to neutralise trypsin activity. The cells 
were then centrifuged at 800g for 6 minutes and the supernatant removed by aspiration. 
The mesothelial cell pellet was then resuspended in FACS buffer (PBS containing lOmM 
EDTA, 15mM sodium azide and 1% BSA) and transferred to a 96 well plate (lOOpl per 
well). To each sample lOOpl (0.4p,g/ml) of monoclonal antibody OC125 (Fujirebio 
Diagnostics, Toyama, Japan) was added and incubated at 4°C for 30 minutes. The 
antibody concentration was defined as shown in Figure 4.3 of chapter 4. The cells were 
then washed by centrifugation at 800g for 6 minutes, removing the supernatant and re- 
suspending in 250[il FACS buffer. This was carried out for a maximum of three washes. 
After the third wash the pellet was re-suspended in lOOpl of secondary antibody (1/100 
dilution, rat anti-mouse IgG PE, Becton-Dickinson Ltd), and incubated at 4°C for 30 
minutes. The wash procedure was then repeated. At the end of the last wash the cells 
were re-suspended in 250pl FACS buffer and transferred to FACS tubes. A total of 
10000 cells for each sample were counted on the FACS calibur 4CA cell sorter (Becton 
Dickinson Ltd) using the FL2-PE detector. HPMC void of antibody staining and HPMC 
stained with only secondary antibody were used as controls to ensure that no non-specific 
binding was present. Data was analysed using Cell Quest-pro software (see Figure 2.4).
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A. Fluorescence Intensity Histogram
Counts
Counts
FL2-H
FL2-H
M l: Fluroescence intensity gate. Defines the % surface expression of specific cell 
surface antigen (Boxed values-Histogram Statistics).
Negative staining population
Positive Control Staining population (no cell stimulation, 48 hours)
Positive staining population (cell stimulation, 48 hours)
B. Histogram Statistics
File: 25.2.3.009 Acquisition Date: 25-Feb-03
Gate: No Gate Gated Events: 10000
Total Events: 10000
Marker Events % Gated % Total
All 10000 100.00 100.00
48 hour control-no stimulation M1 10000 81.92 81.92 6.56%
change in
48 hour- stimulated M1 10000 88.48 88.48 Expression
Figure 2.4 Calculation of percentage shift in positively stained cells.
A(i) Histogram demonstrating the shift of positively stained cells into M l compared 
to the negatively stained cells. A(ii) Histogram showing the shift in expression of a 
surface expressed antigen between stimulated and unstimulated cells. B. Histogram 
statistics provide a value for the % change in staining/expression for a specific 
antigen.
59
2.9 RADIOIMMUNOASSAY (RIA)
2.9.1 Determination of CA125 supernantant concentration
Supernatants were assayed for CA125 concentration using the CA125 (II) 
Radioimmunoassay kit (Fuji-Rebio Diagnostics). All procedures were carried out in 
compliance with the manufacturers protocol. Briefly, to lOOpl of each sample a single 
capture antibody (Mil)  coated bead was added followed by the addition of lOOp-1 of 
tracer antibody (125I OC125, mouse, monoclonal) and was subsequently incubated at 
room temperature for 20±2 hours. Each bead was then washed in a minimum of 15ml 
distilled H20  (by continuous addition and aspiration) and measured for its radioactivity 
(CPM) in a gamma counter (Gambyt CS10/20 gamma counter). In order to determine 
unknown CA125 concentrations, a standard curve was constructed by plotting average 
CPM versus CA125 concentration of the standards supplied by the manufacture (Figure 
2.5).
3.5
3.0
2.5
S  2.0 y = 0.6664x+1.4318 
R2 = 0.9857SP 1.5
1.0
0.5
1.5 20 0.5 1 2.5 3
Log Concentration (U/ml)
Figure 2.5 Calibration curve showing Log of CPM versus Log of CA125 
Concentration.
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2.10 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
2.10.1 MCP-1 ELISA
Supernatant samples were assayed for MCP-1 concentration in accordance with the BD 
OptEIA™ Human MCP-1 ELISA set protocol. Briefly, each well of a 96 well micro-titre 
plate (Immulon 4HBX, Thermo Life Sciences Ltd) was coated by the addition of lOO^ il 
anti-human MCP-1 monoclonal capture antibody and incubated overnight. The plate was 
then washed 3 times with the provided wash buffer on a wellwash 4 automatic plate 
washer (Thermo Life Sciences Ltd) before blocking via a 2 hour incubation with 
200pl/well assay diluent. After a further 3 washes with wash buffer lOOpl of each 
standard sample and control was added into an appropriate well and left for 2 hours at 
room temperature (1:20 dilution of the working samples was used). Each well was then 
washed 5 times in wash buffer before lOOpl working detection solution (biotinylated anti­
human MCP-1 monoclonal antibody and avidin-horseradish peroxidase conjugate) was 
added to each well and left for 1 hour at RT. This was then followed by a further series 
of washes. lOOpl of substrate solution was then added to each well and incubated in the 
dark for a maximum of 30 minutes (without sealing the plate). To stop the reaction 50^1 
of stop solution (2M H2S04) was swiftly added to each well. The absorbance of each 
sample was read (450nm) using the Dynex Revalation 96-multiwell plate reader. MCP-1 
concentrations were deduced using the logarithmic relationship between the standards 
(pg/ml) and their absorbances (450nm).
2.10.2 IL-8 ELISA
Supernatant samples were assayed for IL-8 concentration in accordance with the BD 
OptEIA™ Human IL-8 ELISA set protocol. Briefly, each well of a 96 well micro-titre 
plate was coated by the addition of lOOpl anti-human IL-8 monoclonal capture antibody 
and incubated overnight. The plate was then washed 3 times with the provided wash 
buffer on a Wellwash 4 automatic plate washer before blocking via a 2 hour incubation 
with 200pl/well assay diluent. After a further 3 washes with wash buffer, lOOpl of each 
standard, sample and control was added into an appropriate well and left for 2 hours at
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Jroom temperature (1:30 dilution of the working samples was used). Each well was then 
washed 5 times in wash buffer before lOOpl working detection solution (biotinylated anti­
human IL-8 monoclonal antibody and avidin-horseradish peroxidase conjugate) was 
added to each well and left for 1 hour at RT. This was then followed by a further series 
of washes. lOOpl of substrate solution was then added to each well and incubated in the 
dark for a maximum of 30 minutes (without sealing the plate). To stop the reaction, 50pl 
of stop solution (2M H2S04) was swiftly added to each well. The absorbance of each 
sample was read (450nm) using the Dynex Revalation 96-multiwell plate reader. IL-8 
concentrations were deduced using the logarithmic relationship between the standards 
(pg/ml) and their absorbances (450nm).
2.11 TIME LAPSE PHOTOGRAPHY
2.11.1 Scratch wounding of HPMC monolayer
HPMC were grown to confluence and growth arrested as described in section 2.2.8. The 
monolayer was then wounded with a single scratch using a sterile 1ml pipette tip (tarstedt 
Ltd, Leicester, UK), without damaging the plastic base. This resulted in a linear wound 
approximately 0.5 -  0.6 mm in width (removing approximately 4% of the HPMC 
monolayer). The wounded monolayers were then washed with M l99 medium, to remove 
any detached cells and cellular debris. Cells were then incubated with test or control 
solution for defined time periods. For experimental procedures, solutions were prepared 
with M199 containing 2mmol/L N-2-hydroxyethylpiperazine-N’-2ethanesulfonic acid 
(HEPES)(Gibco) to ensure a pH of 7.4 was maintained throughout the experiment.
2.11.2 Assessment of wound closure by time-lapse photography
The nude area in each well was identified microscopically and the co-ordinates recorded 
for subsequent data capture. Wound closure or HPMC migration was monitored using an 
Axiovert 100M inverted microscope fitted with a XY automated scanning stage and 
incubator (Carl Zeiss Ltd, Welwyn Garden City, UK). The incubator was maintained at 
37°C with 5% C02 using a heated insert and vertical airflow. At 1 hour intervals images
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were captured from a defined position in each well using a 2.5x Objective on an Orca 
C5985 digital video camera (Hamamatsu Photonics Uk Ltd, Welwyn Garden City, UK). 
Images were analysed using Openlab version 3.0.8 on a Macintosh G4 computer 
(Improvision Ltd, Coventry, UK). The rate of wound closure was calculated by 
measuring the reduction in denuded area (in pixels) at 60 minutes intervals until the 
wound was completely closed. Rate of HPMC wound closure (pixels/hour) was 
determined by measuring the area of the wound at each time point.
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APPENDIX I
Characterization of HPMC
Confluent m onolayer of HPM C showing typical polygonal shape and “classic” 
cobblestone appearance.
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B. APPENDIX II
1. 5’-RACE PCR protocol
-94°C for 3 minutes (Denaturation step)
-94°C for 1 minute -N
-64°C for 1 minute* ^ 15 cycles
-72°C for 3 minutes * Decreases by 2°C every 5 cycles
-94°C for 1 minute -N
Uo00ini for 1 minute ^ 10 cycles
-72°C for 3 minutes
-72°C for 10 minutes (Final extension step)
2. Standard PCR protocol
-94°C for 2 minutes
-94 °C for 0.5 minutes
-55 °C for 1 minute
l ON 00 o n for 1 minute
-68 °C for 15 minutes
;
26 -36 cycles (dependant 
on primers used)
All PCR reactions were carried out in a GeneAmp PCR System 9700 Thermo-cycler 
(Applied Biosystems Ltd).
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APPENDIX III
1. pCR®2.1 -TOPO® sequencing vector Map
Multiple 
cloning site
P1ar lacZa
fl on
pUC on pCR®2.1 -TOPO( 
3.9Kb
2. pCR®2.1 -TOPO® Multiple cloning site
CAGGAAACAGCTATGAC CCAAGC TACCGA GCTCG-GAT CCACTA 
M13 Reverse primer Hindlll Kpnl Sacl BamWl Spe I
GTGCTG 
BstX I
CGCTC G GCATCT CATCTA GCCCAA
Xhol Nsil Xbal Apal
CCTATAGTGAGTCGTATTA CTGGCCGTCGTTTTAC 
T7 promoter M13 Forward (-20) primer
GGCGGC
Noil
TGGAAT
EcoRl
TGGAAT GATATC ACACTG 
EcoRl EcoRV BstX I
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APPENDIX IV
1. pGL3 basic (Modified) Vector Map
on
SV40 Late poly(A) signal 
(for luc+ reporter)
pGL3-Basic Vector 
(Modified)
Synthetic poly(A) 
signal/transcriptional 
pause site (for 
ackground reduction)
K pnl 
Sac I 
Aos III 
Not I 
Xba I 
Spe I 
Bam HI 
Xma l/Sma I 
Ain I 
Eco RI 
Eco RV 
Bin dill
2. pGL3 basic (Modified) Multiple cloning Sites
• pGL-3 Basic
GGTACC GAGCTC TT ACGCGT GCTAGC—CCGGG CTCGAG—ATCT
Kpnl Sacl Mlul Nhe I Smal Xhol Bglll
GCGATCTAAGT AAGCTT
Hindlll
• pGL-3 Basic (Modified)
GGTACC GAGCTC CA CCGCGG TG GCGGCC GC TCTAGA ACTAGT
Kpnl Sad Aoslll Notl Xbal Spel
GGATCC CCCGGG CTGCAG GAATTC GATIATC AAGCTT
BamHl Smal Pstl EcoRl EcoRV Hindlll
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APPENDIX V 
1. LB Medium
lOg Bacto-tryptone 
5g Bacto-yeast extract 
5g NaCl
1L Deionised H20  
pH 7.5
2. LB Agar Plates
lg Bacto-tryptone 
0.5g Bacto-yeast extract 
0.5g NaCl 
0.8g Bacto-agar 
0.1L Deionised H20
Autoclaved agar was allowed to cool before the addition of carbenicillin (lOOpl/ml). 
Molten agar was then poured into 90mm petri-dishes.
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APPENDIX V
Optimisation of HPMC transfection conditions
HPMC were transfected with lp g  Renilla  vector using varying ratios of pi FuGene: pg 
DNA described in 2.6.2. Transfected HPMC were then analysed for luciferase activity as 
described in 2.6.3. The experiment was carried out on mesothelial cells demonstrating 
approximately 70% or 100% confluence.
^  12000i 
■*—»
‘8 t10000-
I
!  8000- 
<
£  6000- 
8 4000-U
cS
|  2000- 
oJ o J— '
Untransfected
Optimisation of HPMC transfection conditions and confluency using FuGene 6 
transfection reagent. Red bars = 70 % confluent HPMC, Blue bars = 100% 
confluent HPMC.
These data indicate that HPMC should be transfected with pi FuGeneipg DNA of 3:1 at 
70% confluency.
6:1 Ratio3:1 Ratio
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Chapter 3
Elucidation of the genomic structure and 
anlaysis of the putative promoter region 
of the human CA125 gene
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3.1 INTRODUCTION
Numerous studies have identified and used CA125 as a diagnostic tool to detect the onset 
and recurrence of ovarian cancer [Bast et al, 1983] and have suggested a possible role for 
the molecule as a marker of mesothelial cell mass in the dialyzed peritoneum 
[Zeillemarker et al, 1994][Visser et al, 1995][Ho-Dac-Pannekeet et al, 1995]. However, 
studies concerning the regulation of CA125 by mesothelial cells, under homeostasis, have 
produced contradictory results [Imbert-Marcille et al, 1994] [Zeillemarker et al, 1994] 
[Visser et al, 1995][Zeimet et al, 1996] and the control of expression of CA125 by 
HPMC remains poorly understood.
CA125 expression is not confined to the mesothelial cells of the peritoneal cavity; organs 
such as the pancreas, kidney, colon and the eye also express the antigen [Loy et al, 
1991][Argueso et al, 2003]. Studies examining CA125 regulation in these other cell types 
may, therefore, provide data relevant to the control of its expression in the peritoneum. A 
recent study examining the ocular surface of the eye showed that CA125 expression may 
be regulated by retinoic acid (RA) at the level of transcription and translation [Hori et al,. 
2004]. In addition, a role for RA in the regulation of CA125 in various cervical and 
ovarian adenocarcinoma cells lines has been suggested [Nakai et al, 1993][Langdon et al, 
1998][Xu et al, 2005], while analysis serum levels has shown that CA125 expression in 
females can be modulated by oestrogen [Nonogaki et al, 1991][Karabacak et al, 2002].
The fundamental processes controlling gene expression are conventionally simplified by 
considering the transcription of a single gene in a specific cell type and at a specified 
time, although clearly these events do not occur in isolation [Smale and Kadonaga, 2003]. 
Approximately 30,000 genes are encoded by the human genome and their regulation will 
depend on the specific cellular context under consideration. To date, very little is known 
of the mechanisms controlling the transcription of the CA125 gene in any cell type.
Transcriptional regulation of gene expression is mediated by the promoter region which 
typically extends 250bp upstream and 50bp downstream of the transcription initiation
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start site (TIS) as seen in Figure 3.1 [Strachan and Read, 1999]. Within this region, the 
core promoter encompasses the TIS and extends approximately 45bp upstream and 40bp 
downstream from  this site [Strachan and Reed, 1999]. A variety of DNA control 
elements may be present in this core region, where they serve to bind the RNA 
polymerase II basal transcription complex, prior to the initiation of gene transcription. 
These include the “TA TA ” box, which binds the Transcription Factor IID (TFIID) 
complex, the BRE element that binds TFIIB, the transcription initiation site (TIS) and the 
down stream promoter element (DPE) [Smale and Kadonaga, 2003].
In addition to the core promoter region, the upstream proximal promoter region may also 
contribute to the control of gene expression and does so most frequently via recognition 
sequences known as transcription factor binding sites (TFBSs). Transcription factors are 
typically small proteins that can bind to these specific DNA motifs in order to modulate 
transcription via the core prom oter and to act as transcriptional mediators. Common 
examples of these sequences are CCA AT boxes for nuclear factor-1 (NF-1) binding and 
GC boxes which bind specificity protein (Sp)l and Sp3 [Lewin, 2000].
T r a n s c r i p i o n  
F a c t o r  
b i n d i n g  
( i . e .  S p l )
- 7 5
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Figure 3.1 Schematic representation of an eukaryotic promoter region.
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To understand the mechanisms involved in the regulation of CA125 expression, 
knowledge of the genomic structure of the CA125 gene including the TIS and upstream 
promoter sequences was essential. At the start of this project, as discussed in section 
1.9.1, previous attempts to clone the entire CA125 cDNA had been unsuccessful [Brown 
et al, 1996][Whitehouse and Solomon, 2003]. However, over the duration of this project 
further progress was reported and it is now known that the CA125 gene maps to 19pl3.2, 
spans over 134 kb of genomic DNA and encodes a full length transcript of approximately 
67 kb [Yin and Lloyd, 2001][0’Brien et al, 2001][0’Brien et al, 2002].
At the beginning of this study, the CA125 genomic sequence was accessible via cosmid 
sequences AC008734 and AC016584. In order to better understand the function and 
transcriptional regulation of the CA125 gene, the genomic structure was reconstructed in 
silico. The 5’ end of the coding region was then examined in greater detail, in order to 
identify the CA125 TIS, the upstream proximal promoter region and the regulatory 
sequences within this region. Cloned proximal promoter luciferase reporter constructs 
were then tested for their ability to drive transcription of the reporter gene under 
endogenous and defined conditions.
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3.2 METHODS
3.2.1 In silico reconstruction of the human C A125 gene
The genomic structure of the human CA125 gene was reconstructed by combining a 
variety of in silico methods discussed in sections 2.1.1.
3.2.2 In silico analysis of the proximal promoter region for transcription factor 
binding sites
The sequence upstream of the CA125 coding region was analysed for putative TFBSs 
using internet-based software as described in 2.1.2.
3.2.3 Amplification of transcribed products from CA125 exon 1 and 2 from total 
RNA
On the basis of these in silico data, RT-PCR was carried out using specific primers (Table 
3.1) to amplifiy expressed products from CA125 exons 1 and 2. Firstly, HPMC total 
RNA was extracted and reverse transcribed as described in section 2.3. PCR was then 
carried out as described in section 2.4.1. The products of the amplification were 
visualized and sized by flat bed agarose gel electrophoresis as outlined in 2.4.4.
Table 3.1 CA125 exon 1 and 2 oligonucleotide primers
Primer pair Sense-strand sequence Anti-sense strand sequence Product size
RT-PCR-5' CACCCTGAGAAATTTTGGAGTT CACGATTGCACCTGTAGATGTC 256bp
RT-Exon2 CTGTCTCTTCTCCCACAGAACC GGAACAGTTGTTTCTGGAGTC 334bp
All primers are in 5’- 3’ orientation
The position of all primers specific to the 5’ end of the CA125 gene used in this chapter 
can be seen in Figure 3.2 (page 76). Genomic in silico data were used to design these 
primers using internet based software as described in 2.4.3.
74
3.2.4 Analysis of CA125 terminal expressed sequences from purified mRNA
mRNA was purified from HPMC total RNA using Oligo (dT)^ Dynabeads as described 
in section 2.3.5. RT-PCR was then used to analyse the expression of CA125 mRNA 
termini using the primers shown in Table 3.2 and Figure 3.2.
Table 3.2 CA125 mRNA termini oligonucleotide primers
Primer pair Sense-strand sequence Anti-sense strand sequence Product
size
RT-PCR- 3' 
CA125 R 
RT-PCR-5'
ACTGGCTCGGAGAGTAGACAGA
GGAGAGGGTTCTGCAGGGTC
CACCCTGAGAAATTTTGGAGTT
CACTGTTGCTGGACGTTGTATT
GTGAATGGTATCAGGAGAGG
CACGATTGCACCTGTAGATGTC
288bp
400bp
256bp
All primers are in 5’- 3’ orientation
The gene specific primers shown in Table 3.3 and Figure 3.2 were designed for use in 5’- 
rapid amplification of cDNA ends (5’-RACE) analysis to identify upstream expressed 
CA125 sequence, as shown in 2.3.5.
Table 3.3 5’-RACE oligonucleotide primers
-
Primer pair Inner primer Outer primer
5’-RACE TCCATGCTGAAACCCTCAGGCCT GGTCATCTTCTCCCACCCGCTCCT
All primers are in 5’- 3’ orientation
The 5’-RACE products were cloned into PCR 2.1 TOPO sequencing vector (Appendix 
III-chapter 2) as described in 2.5.1 and sequenced (section 2.5.6). RT-PCR from cDNA 
and PCR from gDNA with additional primers (Table 3.4 and Figure 3.2) were used in
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+ 1081 GTGTCTTCTCTGACCTCCACTTCTCAATTCAAGAGCCTTAGTATCTGCCAGTATCACACACTGAGCATTAGCTCCATCTCATGGGGGTGTAGGTAGGGGCTCTATCTGCATCTTTCTTTC
+ 9 6 1 TTTTTTTCTTTCTTTCCCTTCCTCCCTTCCTCACTCCCTCGGTCCTCTCTTTCTTTCCTTTTCTTTCTTCCTTCCTCCCTTCCTCCCTCCCTCCCTCTCTCTTTCTCTCTTTCTTTCTTT
+ 8 4 1 CCTTCTTTCTTTCTTTCTCTCTTCCTTCCCTCCCTCCCTCCTTCCTTCCTTTCTCTTTCTTTCTCTTTCTTTCTTTTTTTCCTTCCTTCCTTCCTTCTTTCTCTTTCTCTCCCTCCCTTC
+ 7 2 1
+ 6 0 1
CTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTT
F 5 ( X )
CTTTTCTTTCTTTCTCTTTCTTTTTGAGACAGAGCTCTTATTACCCATGCTGGAGTGCAGTGGTGTGACCTTGGCTTACTGCAACATCTGCCTCCTAGGGTCAAGTGATTCTCCTGCCTC
+ 4 8 1
+ 3 6 1
+ 2 4 1
O
ON +121
- 1 2 1
AGCCTCCTAAGTAGCTGGGATTACAGACACATGCCACCACACCCAATATTTATTTTTATTAAAATTTTTTTTAAAATTATTTTTAAAAAATTAAAAATAATTTTGTATTTTTAGTAGAGA
P 3  — ►
CGGGGTTTCTCCATGTTGGTCAGGCTGATCTCAAACTCCCAACCTCAGGTGATCCTCCCACCTCACCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCCAGCCTGGTTCCTG
F I O O  — ►  P 2 ----- J
GTTTCTAAGACATCACACACACACACACACACACACACACACACTCACACACTCAGAGAGAGAGAGAGAGAGAGGATCATTAAGACATGATACACTAAGAAATTCTATTCTGCAGACACT
PI P 0
- 2 4 1
GAGAATCCGTTAAAAAGTTTGAAGGGAAGAATTGAGATCATCAGGTGTTTATTTGAGGAAATTGTCTGTGGTTGAACTATCCTTTCCTTTCTCTCCCTt^AGATTTGbTCTTCTCAATTAd
4 —  F R  R T - P C R  5 ’ — ►
AAGCGTTGCACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGGTTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCA
4 —  P R  4 — 5 ’ - R A C E  I n n e r  4 — 5 ’ - R A C E  O u t e r
GGGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGGCAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCTGGGTCATCTTCTCCCA
4 —  R T - P C R - 5 ’
CCCGCTCCTTGATGACAGGGAGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCACCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATA
= RT-PCR-5’ ■ ■  = 5’-RACE ■ ■  = P0, PI, P2 and P3 primers = Promoter (F) construct primers Underlined = Reverse(R) primers
Figure 3.2 Oligonucleotide primer sites for the analysis of the 5’-end of the CA125 gene. The 5’-39 orientation of each 
oligonucleotide primer is indicated by an arrow.
further analysis of upstream expressed CA125 sequences. Amplification products were 
sized and visualised as described in 2.4.4.
Table 3.4 CA125 upstream analysis oligonucleotide primers
Primer pair Sense-strand sequence Anti-sense strand sequence (PR) Product size
PI TCCTTTCTCTCCCTGAGATTTG TTCTT AGACCT CC ATCCAG AGG 223bp
P2 TGCAGACACTGAGAATCCGTTA TTCTTAGACCTCCATCCAGAGG 317bp
P3 GATCTCAAACTCCCAACCTC TTCTTAGACCTCCATCCAGAGG 521bp
PO TGAGATTTGGTCTTCTCAATTA TTCTTAGACCTCCATCCAGAGG 210bp
All primers are in 5’- 3’ orientation
Expressed sequence tag (EST) sequences upstream of the CA125 locus were identified 
using the UCSC Genome Bioinformatics internet site (http://genome.cse.ucsc.edu/). 
Specific primers were designed (Table 3.5) spanning the 5’ terminus of CA125 exon 1 
and the most proximal upstream EST (AA633929, for EST sequence see appendix I). RT- 
Exon2 primers (Table 3.1) specific to CA125 mRNA were used as a positive control.
Table 3.5 EST analysis oligonucleotide primers
Primer pair Sense-strand sequence (EST F) Anti-sense strand sequence Product
size
RT-EST1 AGCACATTTCCCCTGTGATAAG TGTGTCTAGAAGAGCTGCCGTA 163bp
RT-EST2 AGCACATTTCCCCTGTGATAAG TTCTTAGACCTCCATCCAGAGG 296bp
All primers are in 5’- 3’ orientation
3.2.5 Amplification and analysis of the putative CA125 proximal promoter 
transcriptional activity in vitro
Three nested fragments spanning the putative proximal promoter region were then 
amplified (Table 3.6 and Figure 3.2) from gDNA (section 2.4.1), sized (section 2.4.4) and 
purified from an agarose gel (section 2.4.5).
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Table 3.6 Nested CA125 promoter construct oligonucleotide primers
Construct Sense-strand sequence Anti-sense strand sequence (FR)
F100 
F500 
FI 000
CCGGTACCGAGAGAGAGGATCATTAAGACATGA
CCGGTACCGCTCTTATTACCCATGCTGGAG
CCGGTACCCACACTGAGCATTAGCTCCATC
CCACTAGTGACCTGGGAAAACCTGTGTCrA 
CCACT AGTGACCTGGGAAAACCT GTGT CT A  
CCACTAGTGACCTGGGAAAACCTGTGTCTA
All primers are in 5’- 3’ orientation 
Red=Kpnl restriction site, Blue = Spe 1 restriction site
These nested promoter fragments were then cloned into a pGL3-modified vector 
(Appendix IV-chapter 2) as described in section 2.5, and the clones were screened for the 
presence of the desired fragments using enzymatic digestion (section 2.5.5) followed by 
sequencing (section 2.5.6). Luciferase assays were carried out as described in section 
2.6.
3.2.6 Analysis of CA125 promoter activity in response to retinoic acid and 
oestrogen stimulation
HPMC expression of the oestrogen receptor (ER) was verified by Western blot (as 
described in section 2.7) using a rabbit anti-oestrogen receptor antibody (Zymed Labs 
Inc;Invitrogen Ltd). HPMC were transfected with the putative promoter constructs as 
described in section 2.6.2. Each construct was then assayed for transcriptional activity in 
HPMC stimulated for 24 hours with either 10 nmoles of all-trans retinoic acid or 100 
nmoles of 17|3-Oestradiol using the luciferase assay described in 2.6. For each promoter 
construct the luciferase activity was normalised to the negative control promoterless 
pGL-3 vector. To ensure the system was responsive to RA and oestrogen stimulation, 
MCP-1 (section 2.10.1) and IL-8 (section 2.10.2) assays were carried out on the 
supernatants from the luciferase experiments.
78
3.2.7 Statistical analysis of luciferase assays
All data are presented as mean [±standard error of the mean (SEM)] on the assigned 
number of independent experiments (n) performed on averaged duplicate samples for 
each experiment. Statistical significance was determined using the two-way ANOVA in 
SPSS v ll.5  for Windows. Where appropriate, analysis was undertaken using a non- 
parametric statistical test (Friedman Test using SPSS vll.5  for Windows). Differences 
were considered significant when p<0.05.
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3.3 RESULTS
3.3.1 In sttico reconstruction of the human CA125 gene
While computational prediction of gene structures has improved significantly over the 
last few years, accurate identification of promoter regions has yet to be optimised. 
Therefore, a combination of in silico and in vitro methodologies were used to reconstruct 
the CA125 genomic structure. The CA125 reference cDNA sequence was compared with 
high-throughput genomic sequences available via the NCBI database 
(http://www.ncbi.nlm.nih.gov). From these findings the CA125 genomic structure was 
reconstructed and the upstream putative proximal promoter sequence identified. Table 3.7 
shows the predicted sizes of each component of the CA125 genomic structure and Figure
3.3 shows a schematic representation of the CA125 genomic and cDNA structure.
Several cDNA sequences for CA125 were retrieved (date: Jan 2002) from the NCBI 
database (www.ncbi.nih.gov/):
- AF361486 Homo sapiens mucin 16 (MUC16) mRNA, partial cds (5797bp).
- AF414442.1 Homo sapiens ovarian cancer related tumour marker CA125 mRNA, 
complete cds (35350bp).
- AF414442.2 Homo sapiens ovarian cancer related tumour marker CA125 mRNA, 
complete cds (66765bp).
The most complete mRNA sequence currently available for CA125 throughout this study 
was AF414442.2 which comprised of a very large mRNA of 66.765Kb that encoded a 
theoretical CA125 protein of 22152 amino acids. BLAST (www.ncbi.nlm.nih.gov/blast/) 
analysis using this sequence retrieved genomic clones AC016584 and AC008734. 
BLAST2 alignment software (www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html) was used to 
align the AF414442.2 mRNA sequence with these genomic clones. In December 2005, 
after this study had been completed, the database curators merged the exonic sequences 
to form a composite CA125 reference mRNA sequence, NM_024690. A comparison of 
the structure of these CA125 mRNAs is shown in Figure 3.3B.
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Table 3.7 Predicted sizes of the introns and exons of the CA125 genomic 
structure using data gathered from the UCSC genome browser database.
exon size (bp) intron size (bp) exon size (bp) intron size (bp)
1 9479 1 1784 43 66 43 720
2 105 2 2585 44 125 44 230
3 21696 3 1824 45 68 45 612
4 114 4 3991 46 173 46 629
5 4680 5 2102 47 36 47 259
6 36 6 5010 48 66 48 1178
7 36 7 243 49 122 49 205
8 60 8 4339 50 68 50 619
9 128 9 311 51 173 51 312
10 68 10 4834 52 36 52 256
11 153 11 648 53 66 53 1264
12 36 12 258 54 125 54 227
13 65 13 900 55 68 55 582
14 126 14 532 56 173 56 331
15 68 15 592 57 36 57 261
16 163 16 329 58 66 58 1161
17 36 17 261 59 124 59 226
18 66 18 2949 60 68 60 624
19 131 19 221 61 173 61 331
20 68 20 607 62 36 62 253
21 173 21 349 63 66 63 1096
22 36 22 259 64 122 64 207
23 66 23 713 65 68 65 596
24 125 24 236 66 173 66 330
25 68 25 614 67 36 67 5672
26 173 26 329 68 125 68 97
27 36 27 258 69 68 69 4715
28 61 28 914 70 173 70 2904
29 127 29 235 71 36 71 1526
30 70 30 600 72 51 72 779
31 184 31 327 73 122 73 90
32 36 32 258 74 68 74 148
33 66 33 946 75 173 75 2157
34 125 34 237 76 131 76 355
35 68 35 973 77 68 77 1724
36 173 36 315 78 149 78 2248
37 36 37 257 79 152 79 328
38 66 38 935 80 68 80 2063
39 125 39 253 81 167 81 4255
40 68 40 921 82 42 82 322
41 183 41 328 83 80 83 783
42 36 42 256 84 187
81
A. Genomic DNA structure of CA125
0 Kb
5’
10 Kb 20 Kb
9 10
11 12 13 14 15 16 1718
H— hi— I I I I I
19 20 21 22 23 24 25 26 27 28 29 30
- H — H — I I I H I------ H-
31 32 33 3435 3637 38 39 40 4142 43 44 45 46 47 48 49 50 5152 53 54 55 56 57 58 59 60 6162 63
I 1 I  I I  1 1 1  I I  I I I  I I  ■  I I  I I  I I I  I I  I I I - - - - - H — 1 4 4 -
64 65 66 67
-H —n -
68 69
- H -
70 71
+
72 73 7475 
-1 -1 1 +
76 77 
+ +
78
+
79 80
-4+
81
+
82 83 84
- 4 4 -+ 3’
B. Comparison of the NM_024690 and AF41442.2 sequence mRNA structures
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Figure 3.3 CA125 genomic structure. (A) Schematic representation of the
genomic structure of the CA125 gene. Exons are represented as black rectangles 
and introns are represented as thin black lines. (B) Comparisons of the reference 
sequences NM_024690 and AF414442.2 mRNA structures. The disordered region 
(*) comprised repetitive sequence that could not be ordered in the mRNA structure 
due to sequencing ambiguities from AF414442.2.
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As can be seen in Figure 3.3A, the in silico reconstruction of the CA125 gene resulted in 
the unequivocal alignm ent of the entire NM _024690 sequence. However only 62.5% 
alignment of the AF414442.2 message was achieved and the internal repeat region of 
23997bp was composed of repetitive transcription of scrambled combinations of exonic 
sequence. These data agreed closely with subsequent analysis at the UCSC genome 
browser (http://genome.cse.ucsc.edu/cgi-bin/hgGateway: Date:May 2004). Importantly, 
the unambiguous and identical alignment of the 5 ’ end of CA125 exon 1 permitted the 
identification of the putative transcription start site and sequence data for analysis of the 
proximal promoter region. It should be noted that, due to the identical 5 ’ and 3 ’ terminal 
sequences of N M _024690 and AF414442.2, reference is made to the AF414442.2 
sequence in the remainder of this chapter.
3.3.2 In silico analysis of the proximal promoter region for transcription factor 
binding sites
Using available internet based software (as described in 2.1.2) the lkb  of sequence 
directly upstream of the TIS of AF414442.2 was analysed for transcription factor binding 
sites (TFBSs). As shown in Figure 3.4 input of the sequence data in to the “Cis-element 
cluster finder” (http://zlab.bu.edu/~mfrith/ cister.shtml) showed a grouping of TFBSs in 
the putative proximal promoter region (Figure 3.1) and further upstream.
600 800 1400200
±
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0-6
0-4
0.2
O
0 .2
0 .6
0.8
1
  c1water probability
cls-elements: T8T8 Spl CPE ERE NF-1 E2F Myf CC8RT 8P-1
Figure 3.4 Analysis of the lkb upstream of reference CA125 mRNA sequence 
AF414442.2 (3’ to 5’) for TFBS’s using “Cister” internet based software.
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Figure 3.4 shows a cluster of transcription factor binding sites in the putative CA125 
prom oter region sequence providing indirect confirm atory evidence of promoter 
identification. Interestingly, considering the involvement of CA125 in ovarian cancer, 
this analysis identified the presence of three EREs (oestrogen responsive elements) 
having probability/m atches of 0.99, 0.46 and 0.28. The ERE showing the highest 
probability/match of the identified consensus sequences is highlighted with * in Figure 
3.4. Of the three EREs, only the presence, sequence and position of the ERE showing the 
highest probability/m atch (0.99) was corroborated using other internet based TFBS 
identification programs such as the Genomatrix Matinspector (http://genomatrix.de/cgi- 
bin/eldorado/main.pl) I Quandt et al, 19951 and the Oestrogen Responsive Element Finder 
(Figure 3.5) (http://research.i2r.a-star.edu.sg/promoter/ERE-V2b/cgi/ere/pl) as outlined in 
Tang’s method for the identification of oestrogen responsive genes |Tang et al, 2004]. 
The CA125 sequence identified showed 83% identity with the consensus sequence.
B.
ERE core motif
A. 1st ERE 
half site
SPACER 2nd ERE 
half site
2n GGTCA 3n TGACC 2n
5’ CTCCATGTTGGTCAGGCTGATCTCAAACTCC 3’
Figure 3.5 Identification of an ERE in the proximal promoter region of the 
CA125 gene (A) Illustration of ERE consensus sequence (taken from [Tang et al, 
2004]). (B) Alignment of CA125 sequence with the ERE consensus sequence. This 
sequence was identified using the Oestrogen Responsive Element Finder [Tang et al, 
2004].
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As described in section 3.1, previous studies have indicated that human peritoneal 
mesothelial cells are RA responsive [Kim et al, 1987]. Analysis of the CA125 proximal 
promoter sequence using the internet based TFBS identification program [Quandt et al, 
1995| identified a RAR binding site. This sequence (5’ TGGTCA) corresponded closely 
to the steroid receptor core m otif 5 ’-PuGG(T/A)CA |M ader et al, 1993] suggesting that 
the CA125 response to RA may be mediated via this site. The position of the ERE and 
RAR can be seen in Figure 3.7(page 87).
3.3.3 Amplification of the CA125 5’ region
After in silico reconstruction of the CA125 gene, pairs of oligonucleotide primers were 
designed for analysis of the 5 ’ end of the gene and of CA125 exon two. The specificity 
of each primer pair is described in Table 3.8.
Table 3.8 CA125 (5’ end) oligonucleotide primer specificity
Primer Name Specificity
RT-PCR-5’ Specific to the exon 1 sequence of A F414442.2 sequence (see Figure
3.2).
RT-Exon2 Designed to produce a fragment spanning exon 2 of our in silico CA125
structure as shown in the schematic below.
Forward
1 — ►  2 3
^  CA125 5’ genomic structure
Reverse
In order to detect the 5 ’ end of the reference CA125 cDNA sequence and to verify our in 
silico data, as well as testing for gDNA contamination, RT-PCR was carried out using the 
primers described in Table 3.8.
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Figure 3.6 Amplification of products from CA125 exons 1 and 2 by RT-PCR. -RT 
= negative control for reverse transcription, -PCR = negative control for PCR. 
Double stranded DNA markers are given (lkb+) with their sizes in bp.
As shown in Figure 3.6, an RT-PCR product of predicted size (256bp) was obtained for 
the RT PCR-5’ primers. This confirmed the expression of CA125 exon 1 in HPMC and 
suggested that the very large AF414442.2 mRNA sequence was complete at its 5 ’ end 
although amplification from  total RNA produced a weak exon 1 specifc band. An RT- 
PCR product of correct size was also obtained for the RT Exon 2 primers (334bp) which 
corroborated our existing in silico  CA125 5 ’ gene structure and no evidence of 
amplification of larger products from contaminating gDNA was observed. The in silico 
genomic and protein sequence can be seen in Figure 3.7.
86
+ 1 0 8 1  GTGTCTTCTCTGACCTCCACTTCTCAATTCAAGAGCCTTAGTATCTGCCAGTATCACACACTGAGCATTAGCTCCATCTCATGGGGGTGTAGGTAGGGGCTCTATCTGCATCTTTCTTTC
X
+ 9 6 1  TTTTTTTCTTTCTTTCCCTTCCTCCCTTCCTCACTCCCTCGGTCCTCTCTTTCTTTCCTTTTCTTTCTTCCTTCCTCCCTTCCTCCCTCCCTCCCTCTCTCTTTCTCTCTTTCTTTCTTT
+ 8 4 1  CCTTCTTTCTTTCTTTCTCTCTTCCTTCCCTCCCTCCCTCCTTCCTTCCTTTCTCTTTCTTTCTCTTTCTTTCTTTTTTTCCTTCCTTCCTTCCTTCTTTCTCTTTCTCTCCCTCCCTTC
+ 7 2 1  CTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTT
+ 6 0 1  CTTTTCTTTCTTTCTCTTTCTTTTTGAGACAGAGCTCTTATTACCCATGCTGGAGTGCAGTGGTGTGACCTTGGCTTACTGCAACATCTGCCTCCTAGGGTCAAGTGATTCTCCTGCCTC
+ 4 8 1  AGCCTCCTAAGTAGCTGGGATTACAGACACATGCCACCACACCCAATATTTATTTTTATTAAAATTTTTTTTAAAATTATTTTTAAAAAATTAAAAATAATTTTGTATTTTTAGTAGAGA
X X
+ 3 6 1  CGGGGTTTCTCCATGTTGGTCAGGCTGATCTCAAACTCCCAACCTCAGGTGATCCTCCCACCTCACCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCCAGCCTGGTTCCTG
M
+ 2 4 1  GTTTCTAAGACATCACACACACACACACACACACACACACACACTCACACACTCAGAGAGAGAGAGAGAGAGAGGATCATTAAGACATGATACACTAAGAAATTCTATTCTGCAGACACT
X
+ 1 2 1  GAGAATCCGTTAAAAAGTTTGAAGGGAAGAATTGAGATCATCAGGTGTTTATTTGAGGAAATTGTCTGTGGTTGAACTATCCTTTCCTTTCTCTCCCTGAGATTTGGTCTTCTCAATT§|
X X
1 ^  a a g c g t t g c a c a a t t c c c c c a a c c t c c a t a c a t a c g g c a g c t c t t c t a g a c a c a g g t t t t c c c a g g t c a a a t g c g g g g a c c c c a g c c a t a t c t c c c a c c c t g a g a a a t t t t g g a g t t t c a
T I S  k r c t i p p t s i h t a a l l d t g f p r s n a g t p a i s p t l r n f g v s
- 1 2 1  GGGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGGCAAATGTTGACCTGTCC ATGCTGAAACCCTCAGGCCTGGGTCATCTTCTCCCA
G S S E A L Q R P P S L R G F F L D L H P E A N V D L S M - L K P S G L P G S S S  
- 2 4 1  CCCGCTCCTTGATGACAGGGAGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCACCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATA
P T R S L M T G S R S T K A T P E M D S G L T G A T L S P K T S T G A I V V T E
Figure 3.7 Genomic and protein sequence of the CA125 S’-UTR derived from the NCBI database. Blue = Translation 
start site from AF414442.2, Purple = Stop codon, Bold = ERE, Underlined = RARE, Highlight (grey) = Consensus 
Intron-Exon boundary motif, Highlight (yellow)= Sequence showing high identity with the consensus TIS motif.
Further inspection of the putative CA125 5 ’-UTR sequence revealed that the 5 ’end of the 
A F 414442.2 mRNA sequence was in-fram e with respect encoding amino acids, as 
illustrated in Figure 3.7. Furtherm ore, the 5 ’ end of AF414442.2 and the adjacent 
upstream nucleotides resembled a consensus intron/exon boundary sequence (5’-AG-3’) 
[Zhang, 1998] as highlighted in grey in Figure 3.7. The possibility therefore remained 
that AF414442.2 com prised only protein coding sequence, and that the transcription 
initiation start site (TIS) lay further upstream. Nevertheless, a sequence was identified 15 
bp further upstream  which showed identity with the TIS consensus sequence motif 
(YYANWYY where Y =Pryrim idine, W=A or T) [Smale, 1997][Smale and Kadonaga, 
2003| as shown in Figure 3.10 (page 90).
3.3.4 Analysis of the 5’ terminal expressed sequence
mRNA isolated from HPMC total RNA was used as a template for RT-PCR with primers 
specific to the 3’ and 5 ’ termini of the CA125 gene (RT-PCR-3’ and RT-PCR-5’ primers, 
Table 3.2) as well as prim ers specific for the repeat region of the gene (CA125 R 
primers, Table 3.2). These analyses were performed to confirm that a complete CA125 
mRNA (Figure 3.8) was recovered from  a purified mRNA template. Once again, 
however, the exon-1 specific fragment amplified weakly.
1 K H +  R T P C R - 3 ’ R T P C R - 5 ’ C A 1 2 5  R  - R T  - P C R
200 -mm ***
Figure 3.8 Amplification of the 5’ and 3’ terminals of the CA125 gene. -RT = 
negative control for reverse transcription, -PCR = negative control for PCR. Double 
stranded DNA markers are given (lkb+) with their sizes in bp.
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RT-PCR products of predicted size were obtained for all the primers suggesting that the 
CA125 message synthesised by HPM C’s was complete with respect to AF414442.2. 5 ’- 
RACE was then carried out on the same mRNA sample in order to identify additional 
expressed sequence at the 5 ’ end of the gene (Figure 3.9).
R lkb+
Figure3.9 CA125 specific 5’-RACE reaction. R=Products of the 5’-RACE 
reaction. Double stranded DNA markers are given (lkb+) with their sizes in bp.
The 5 ’-RACE reaction am plified four major products, labelled A, B, C and D (Figure 
3.9), that consistently appeared in replicate 5 ’-RACE reactions. After cloning into the 
PCR 2.1 TOPO vector and sequence analysis, band A was found to be the product of 
non-specific am plification and was not related to CA125. A BLAST search showed 
strong sequence identity with the Human Rabl (Ras like GTPase) receptor. Band D was 
truncated and contained no additional 5 ’ sequence. Bands B and C contained a 9 base 
extension to the 5 ’-UTR as shown in Figure 3.10. 5 ’-RACE sequence data can be seen in 
Appendix I.
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+ 1 0 8 1  GTGTCTTCTCTGACCTCCACTTCTCAATTCAAGAGCCTTAGTATCTGCCAGTATCACACACTGAGCATTAGCTCCATCTCATGGGGGTGTAGGTAGGGGCTCTATCTGCATCTTTCTTTC
X
+ 9 6 1  TTTTTTTCTTTCTTTCCCTTCCTCCCTTCCTCACTCCCTCGGTCCTCTCTTTCTTTCCTTTTCTTTCTTCCTTCCTCCCTTCCTCCCTCCCTCCCTCTCTCTTTCTCTCTTTCTTTCTTT
+ 8 4 1  CCTTCTTTCTTTCTTTCTCTCTTCCTTCCCTCCCTCCCTCCTTCCTTCCTTTCTCTTTCTTTCTCTTTCTTTCTTTTTTTCCTTCCTTCCTTCCTTCTTTCTCTTTCTCTCCCTCCCTTC
+ 7 2 1  CTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTT
+ 6 0 1  CTTTTCTTTCTTTCTCTTTCTTTTTGAGACAGAGCTCTTATTACCCATGCTGGAGTGCAGTGGTGTGACCTTGGCTTACTGCAACATCTGCCTCCTAGGGTCAAGTGATTCTCCTGCCTC
+ 4 8 1  AGCCTCCTAAGTAGCTGGGATTACAGACACATGCCACCACACCCAATATTTATTTTTATTAAAATTTTTTTTAAAATTATTTTTAAAAAATTAAAAATAATTTTGTATTTTTAGTAGAGA
X X
+ 3 6 1  CGGGGTTTCTCCATGTTGGTCAGGCTGATCTCAAACTCCCAACCTCAGGTGATCCTCCCACCTCACCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCCAGCCTGGTTCCTG
M
+ 2 4 1  GTTTCTAAGACATCACACACACACACACACACACACACACACACTCACACACTCAGAGAGAGAGAGAGAGAGAGGATCATTAAGACATGATACACTAAGAAATTCTATTCTGCAGACACT
X
+ 1 2 1  GAGAATCCGTTAAAAAGTTTGAAGGGAAGAATTGAGATCATCAGGTGTTTATTTGAGGAAATTGTCTGTGGTTGAACTATCCTTTCCTTTCTCTCCCTGAGATTTGGTCTTCTCAATTAG
X X
1 ^  AAGCGTTGCACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGGTTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCA
T I S  K R C T I P P T S I H T A A L  L D T G F P R S N A G T P A I S P T L R N F G V S  
- 1 2 1  GGGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGGCAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCTGGGTCATCTTCTCCCA
G S S E A L Q R P P S  L R G F F L D L H P E A N V D L S M l K P S G I a P G S S S  
- 2 4 1  CCCGCTCCTTGATGACAGGGAGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCACCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATA
P T R S L M T G S R S T K A T P E M D S G L T G A T L S P K T S T G A I V V T E
Figure 3.10 Genomic and protein sequence of the CA125 5’-UTR derived from the NCBI database. Blue 
=Translation start site from AF414442.2, Purple = Stop codon, Bold = ERE, Underlined = RARE, Red = Additional 
expressed sequence (5’-RACE), Highlight (grey) = Consensus Intron-Exon boundary motif, Highlight (yellow) = 
S e q u e n c e  s h o w i n g  h i g h  i d e n t i t y  w i t h  t he  c o n s e n s u s  TI S  mo t i f .
+ 1 0 8 1  GTGTCTTCTCTGACCTCCACTTCTCAATTCAAGAGCCTTAGTATCTGCCAGTATCACACACTGAGCATTAGCTCCATCTCATGGGGGTGTAGGTAGGGGCTCTATCTGCATCTTTCTTTC
X
+ 9 6 1  t t t t t t t c t t t c t t t c c c t t c c t c c c t t c c t c a c t c c c t c g g t c c t c t c t t t c t t t c c t t t t c t t t c t t c c t t c c t c c c t t c c t c c c t c c c t c c c t c t c t c t t t c t c t c t t t c t t t c t t t
+ 8 4 1  CCTTCTTTCTTTCTTTCTCTCTTCCTTCCCTCCCTCCCTCCTTCCTTCCTTTCTCTTTCTTTCTCTTTCTTTCTTTTTTTCCTTCCTTCCTTCCTTCTTTCTCTTTCTCTCCCTCCCTTC
+ 7 2 1  CTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTT
+ 6 0 1  CTTTTCTTTCTTTCTCTTTCTTTTTGAGACAGAGCTCTTATTACCCATGCTGGAGTGCAGTGGTGTGACCTTGGCTTACTGCAACATCTGCCTCCTAGGGTCAAGTGATTCTCCTGCCTC
+ 4 8 1  AGCCTCCTAAGTAGCTGGGATTACAGACACATGCCACCACACCCAATATTTATTTTTATTAAAATTTTTTTTAAAATTATTTTTAAAAAATTAAAAATAATTTTGTATTTTTAGTAGAGA
X X
+ 3 6 1  CGGGGTTTCTCCATGTTGGTCAGGCTGATCTCAAACTCCCAACCTCAGGTGATCCTCCCACCTCACCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCCAGCCTGGTTCCTG
M
+ 2 4 1  GTTTCTAAGACATCACACACACACACACACACACACACACACACTCACACACTCAGAGAGAGAGAGAGAGAGAGGATCATTAAGACATGATACACTAAGAAATTCTATTCTGCAGACACT
X
+ 1 2 1  GAGAATCCGTTAAAAAGTTTGAAGGGAAGAATTGAGATCATCAGGTGTTTATTTGAGGAAATTGTCTGTGGTTGAACTATCCTTTCCTTTCTCTCCCTGAGATTTGGTCTTCTCAATTAG
X X
1 ^  AAGCGTTGCACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGGTTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCA
T I S  K R C T I P P T S I H T A A L ' L D T G F P R S N A G T P A I S P T L R N F G V S  
- 1 2 1  GGGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGGCAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCTGGGTCATCTTCTCCCA
G S  S  E A L Q R P P S  L R G F F L D L H P E A N V D L S K h K P  S G L P G S  S S 
- 2 4 1  CCCGCTCCTTGATGACAGGGAGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCACCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATA
P T R S L M T G S R S T K A T P E M D S G L T G A T L S P K T S T G A I V V T E
Figure 3.10 Genomic and protein sequence of the CA125 5’-UTR derived from the NCBI database. Blue 
=Translation start site from AF414442.2, Purple = Stop codon, Bold = ERE, Underlined = RARE, Red = Additional 
expressed sequence (5’-RACE), Highlight (grey) = Consensus Intron-Exon boundary motif, Highlight (yellow) = 
S e q u e n c e  s h o w i n g  h i g h  i d e n t i t y  w i t h  t he  c o n s e n s u s  TI S  mo t i f .
The additional 5 ’-UTR sequence retrieved through the 5 ’-RACE reaction contained an in­
frame stop codon (TAG). This represented a block to the translation of any sequence 
further upstream. Together with the identification of a nearby consensus TIS motif, these 
combined data suggested that the CA125 proximal promoter region lay immediately 
upstream of the A F414442.2 sequence, as shown in Figure 3.10. RT-PCR was carried 
out (Figure 3.12(i)) using nested primers spanning the region upstream of the 5 ’-UTR 
extension (Figure 3.11) to identify any further upstream expressed sequences. Using 
identical reaction conditions, a control amplification from gDNA was carried out to 
ensure reaction condition and primers were functional (Figure 3.12(H)).
P3 \  P2 \  PI \  P0 \
5’ --------------------------------- I '' / 3’
^  PR
-----------------------------------  210bp
--------------------------------------------------------  223bp
-------------------------------------------------------------------------------- 317bp
  521bp
Figure 3.11 Schematic representation of sequential upstream primer positions 
and fragment sizes (bp). The red block represents the extended RACE sequence.
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Figure 3.12 PCR amplification of the sequence upstream of the 5’-UTR extension, 
(i) PCR amplification from HPMC cDNA. |3-A = Positive (3-Actin control for PCR. 
RT-Exon2 = Positive control for the CA125 message. -RT = Negative control for 
reverse transcription. -PCR = Negative control for PCR (ii) PCR amplification 
from HPMC gDNA. Double stranded DNA markers are given (lkb+) with their 
sizes in bp.
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No bands were seen in the RT-PCR reaction for any of the primer pairs used. Both 
positive control amplifications produced bands of predicted size, suggesting the reaction 
conditions were appropriate and that CA125 message was present in the sample. Four 
bands of the correct size were amplified from gDNA as seen in Figure 3.12(ii), 
suggesting that the primers and reaction conditions were efficient and that no additional 
upstream expressed sequence was present. These data provided further indirect evidence 
to the location of the CA125 putative promoter region.
To further support the identification of the 5’ end of the CA125 gene, RT-PCR was 
performed using anti-sense strand primers specific for the 5’-terminus of the CA125 
coding region and a sense strand primer specific for the coding sequence of the nearest 
upstream EST AA633929 (Figure 3.13A), as found using the UCSC Genome 
Bioinformatics Site (http://genome.cse.ucsc.edu/). RT-Exon2 primers were used as a 
positive control in the experiment (Figure 3.13B).
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EST F
= AF414442.2 (5 ’ end) ^  = EST AA633839 / \ / \  = Genomic Sequence
B. + lkb RT-EST1 -RT-PCR RT-EST2 -RT -PCR RT-Exon2 -RT-PCR
500 * *  
400 mtm
300 M M  
100
Figure 3.13 Upstream EST analysis. (A) Locations of oligonucleotide primers 
used in amplification of CA125 the 5’ end (AF414442) and the EST (AA633839) 
immediately upstream of AF414442.2. (B) RT-PCR Amplification spanning CA125 
5’ coding region and EST (AA633839). -RT = negative control for reverse 
transcription, -PCR = negative control for PCR. Double stranded DNA markers are 
given (lkb+) with their sizes in bp.
Figure 3.13B suggests that the EST AA633839 is not expressed as part of the CA125 
message as no bands were produced using the RT-EST1 and RT-EST2 primers. Bands of 
the correct size were am plified using the RT-Exon2 primers indicating the CA125 
message was transcribed in the reverse transcription process. In order to substantiate 
these data the same experiment, as shown in 3.13, was carried out using lower annealing 
temperatures and varying cycle numbers (Figure 3.14).
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Figure 3.14 RT-PCR amplification spanning CA125 5’ coding region and EST 
AA633839 at varying annealing temperatures (T J  of 45°C and 50°C and a range of 
amplification cycles. -RT = negative control for reverse transcription, -PCR = 
negative control for PCR. Double stranded DNA markers are given (lkb+) with 
their sizes in bp.
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As seen in Figure 3.14, the RT-EST1 primers produced a discrete single product of 
approximately 550bp in the 35, 40, and 45 cycle reactions at an annealing temperature of 
45°C, and an identically sized product was produced in the 40 and 45 cycle reactions at 
an annealing temperature of 50°C. Bands of predicted size were amplified using the RT- 
Exon2 primers (except in the 30 cycle reactions) indicating the CA125 message was 
transcribed in the reverse transcription process. Sequencing and alignment of the RT- 
PCR band produced in these reactions indicated no significant match between the 5 ’- 
CA125 sequence (AF414442.2) or the nearest upstream EST sequence (AA633929). 
BLAST alignment indicated strong sequence identity (98.17%) between the RT-PCR 
product and the Hom o-sapien zinc finger protein 587 (NM_032828.1) confirming the 
non-specific nature of the amplification. Sequence data are provided in Appendix II.
3.3.5 Amplification and analysis of putative CA125 proximal promoter 
transcriptional activity in vitro
Inserts for nested prom oter constructs (Figure 3.15) were generated by the PCR 
amplification of the putative promoter region from gDNA as shown in Figure 3.16. The 
primer binding sites and promoter construct sequences can be seen in Figure 3.17.
—► TIS
■ CA125 Exon 1
— ~7 — 7  — 7
 | ^ ---------
Sense strand Common anti-sense
primers strand primer (FR)
Amplify
F100 (243) 
F500 (635)
F I000 (1092)
Figure 3.15 Upstream putative promoter constructs. (A) Schematic for the 
generation of nested PCR fragments for the CA125 core promoter region. Three 
nested fragments were generated; F100, F500 and F1000. Actual nested fragment 
sizes are shown in bp.
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The anti-sense prim er was tailed with a SpeI (ACTAGT) restriction site and the sense 
strand primers were tailed with Kpnl (GGTACC) restriction sites to aid cloning into the 
pGL-3 luciferase vector. In each case, am plification of discrete single products of 
predicted size suggests that amplification was successful.
lkb+ -PCR FI 000 -PCR F5000 -PCR F100
1000
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400
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200
100
Figure 3.16 PCR amplification of nested promoter fragments from genomic DNA. 
Expected sizes for each fragment: P100 (258bp), P500 (645bp), F1000 (1194bp). 
-PCR = negative control for PCR. Double stranded DNA markers are given (lkb+) 
with their sizes in bp.
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The anti-sense prim er was tailed with a Spe I (ACTAGT) restriction site and the sense 
strand primers were tailed with Kpnl (GGTACC) restriction sites to aid cloning into the 
pGL-3 luciferase vector. In each case, am plification of discrete single products of 
predicted size suggests that amplification was successful.
lkb+ -PCR F1000 -PCR F5000 -PCR F100
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Figure 3.16 PCR amplification of nested promoter fragments from genomic DNA. 
Expected sizes for each fragment: P100 (258bp), P500 (645bp), F1000 (1194bp). 
-PCR = negative control for PCR. Double stranded DNA markers are given (lkb+) 
with their sizes in bp.
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+ 1 0 8 1
F 1 0 0 0 — ►
GTGTCTTCTCTGACCTCCACTTCTCAATTCAAGAGCCTTAGTATCTGCCAGTATCACACACTGAGCATTAGCTCCATCTCATGGGGGTGTAGGTAGGGGCTCTATCTGCATCTTTCTTTC
+ 9 6 1 TTTTTTTCTTTCTTTCCCTTCCTCCCTTCCTCACTCCCTCGGTCCTCTCTTTCTTTCCTTTTCTTTCTTCCTTCCTCCCTTCCTCCCTCCCTCCCTCTCTCTTTCTCTCTTTCTTTCTTT
+ 8 4 1  CCTTCTTTCTTTCTTTCTCTCTTCCTTCCCTCCCTCCCTCCTTCCTTCCTTTCTCTTTCTTTCTCTTTCTTTCTTTTTTTCCTTCCTTCCTTCCTTCTTTCTCTTTCTCTCCCTCCCTTC
+ 7 2 1  CTTCCTTCCTTCCTTCCTTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTT
F 5 0 0  ^
+ 6 0 1  CTTTTCTTTCTTTCTCTTTCTTTTTGAGACAGAGCTCTTATTACCCATGCTGGAGTGCAGTGGTGTGACCTTGGCTTACTGCAACATCTGCCTCCTAGGGTCAAGTGATTCTCCTGCCTC
+ 4 8 1  AGCCTCCTAAGTAGCTGGGATTACAGACACATGCCACCACACCCAATATTTATTTTTATTAAAATTTTTTTTAAAATTATTTTTAAAAAATTAAAAATAATTTTGTATTTTTAGTAGAGA
X X
+ 3 6 1  CGGGGTTTCTCCATGTTGGTCAGGCTGATCTCAAACTCCCAACCTCAGGTGATCCTCCCACCTCACCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCCAGCCTGGTTCCTG
M F 1 0 0  ►
+ 2 4 1  GTTTCTAAGACATCACACACACACACACACACACACACACACACTCACACACTCAGAGAGAGAGAGAGAGAGAGGATCATTAAGACATGATACACTAAGAAATTCTATTCTGCAGACACT
00
+ 1 2 1  GAGAATCCGTTAAAAAGTTTGAAGGGAAGAATTGAGATCATCAGGTGTTTATTTGAGGAAATTGTCTGTGGTTGAACTATCCTTTCCTTTCTCTCCCTGAGATTTGGTCTTCTCAATTAG
<<—  F R  X X
1 ^  AAGCGTTGCACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGGTTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCA
T I S  K R C T  I  P P T S  I  H T A A L L D T G F P R S N A G T P A I S P T L R N F G V  S  
- 1 2 1  GGGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGGCAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCTGGGTCATCTTCTCCCA
G S S E A L Q R P P S L R G F F L D L H P E A N V D L S M I . K P S G L P G S S S  
- 2 4 1  CCCGCTCCTTGATGACAGGGAGCAGGAGCACTAAAGCCACACCAGAAATGGATTCAGGACTGACAGGAGCCACCTTGTCACCTAAGACATCTACAGGTGCAATCGTGGTGACAGAACATA
P T R S L M T G S R S T K A T P E M D S G L T G A T L S P K T S T G A I V V T E
Figure 3.17 Genomic and protein sequence of the CA125 5’-UTR derived from the NCBI database. Blue = 
Translation start site from AF414442.2, Purple = Stop codon, Green = Promoter construct primer sites, Bold = ERE, 
Underlined = RARE, Red = Additional expressed sequence (5’-RACE), Highlight (grey) = Consensus Intron-Exon 
boundary motif, Highlight (yellow) = Sequence showing high identity with the consensus TIS motif.
Each construct was then assayed for endogenous transcriptional activity using the 
luciferase assay described in 2.6. This was carried out in primary human mesothelial 
cells (HPMC) and a human kidney cell line (HK-2). For each promoter construct the 
luciferase activity was normalised to the negative control promoterless pGL-3 vector as 
shown in Figure 3.18.
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Figure 3.18 Endogenous luciferase activity of the CA125 proximal promoter 
constructs and pGL-3 control construct in (A) primary HPMC and (B) HK-2 cells. 
Luciferase activity is expressed as the magnitude of normalized luciferase activity 
relative to the promoterless negative control (pGL-3). ‘n ’ refers to the number of 
independent experiments.
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As seen in Figure 18A, there was no significant change in luciferase activity between the 
F100, F500 and FIOOO HPMC transfected constructs. Interestingly, the F1000 promoter 
construct showed a trend towards an increase (p=0.097) in promoter activity when 
compared with the promoterless control vector in HPMC as seen by an approximate 2- 
fold increase in activity when compared to the promoterless control construct. This same 
trend was not observed in the HK-2 cell transfections (Figure 3.18B). Of the two cell 
types, HK-2 cells had a 10-fold higher transfection efficiency than HPMC. This reflected 
the well documented difficulties often encountered when transfecting primary cell 
cultures compared to transformed cell lines.
3.3.6 Analysis of CA125 promoter activity in response to oestrogen and retinoic 
acid stimulation
As discussed in section 3.1, oestrogen has been reported to induce CA125 expression 
[Nonogaki et al, 1991][Karabacak et al, 2002]. Due to the subsequent identification of an 
ERE in the proximal CA125 promoter region (Figure 3.5) and the known anatomical 
location of CA125 (covering the ovaries) it seemed plausible that CA125 expression was 
regulated by oestrogen. The action of oestrogen is mediated by receptors known as 
oestrogen receptor-a (ER-a) and oestrogen receptor-P (ER-|3); ligand-dependent 
transcription factors that bind to 17|3-Estradiol in the cytoplasmic compartment of the cell 
and translocate to the nucleus, where they interact with specific DNA sequences, known 
as oestrogen responsive elements (ERE), to drive gene expression [Enmark and 
Gustafsson, 1999] [Tang et al, 2004]. In order to determine whether HPMC expressed 
these oestrogen receptors, a Western blot was performed using a rabbit anti-oestrogen 
receptor antibody (Zymed Labs. Inc; Invitrogen Ltd) at a concentration of lug/ml on 
HPMC cell lysates (Figure 3.19).
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Figure 3.19 Identification of the oestrogen receptor subunits ERa and ERp in 
HPMC by Western blot. 20pg of total protein extracted from HPMC was run in 
lanes 1 and 2. Lanes 1 and 2 represent HPMC cultured from different patients. 
Molecular weight markers are given in kDa.
Western blot analysis identified two distinct bands. These bands corresponded to the 
alpha and beta subunits of the oestrogen receptor [Enmark and Gustafsson, 1999], having 
molecular weights o f 67kDa and 55kDa respectively, and suggested that HPMC were 
oestrogen responsive cells.
In addition, as outlined in section 3.1, CA125 expression may also be regulated by 
retinoic acid (RA) [Nakai et al, 1993][Langdon et al, 1998][Hori et al, 2004][Xu et al,
2005]. RA acts through retinoic acid receptors (RARs) that undergo a conformational 
change when bound to the RA ligand. This complex then orchestrates the transcription of 
specific genes via DNA responsive elem ent binding (RARE) [Bastein et al, 2004]. 
Therefore, using our previously described luciferase assay system, primary HPMC were 
tested for their ability to drive the transcription of the luciferase reporter gene in the 
presence of optimal concentrations of all-trans retinoic acid (100nmoles)[Hori et al, 
2004| or 17|3-oestradiol (100 nmoles)[Garmy-Susini et al, 20041.
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Figure 3.20 Luciferase activity of the CA125 proximal promoter constructs and 
pGL-3 control vector in response to retinoic acid and 17p-oestradiol stimulation. 
(A) Blue = retinoic Acid stimulation (10 nmoles), Red = Control. (C) Blue = 17(3- 
oestradiol (100 nmoles), Red = Control. Luciferase activity is expressed as the 
magnitude of normalized luciferase activity relative to the promoterless negative 
control (pGL-3). (B) IL-8 concentrations of supernatant samples acquired from RA 
stimulation. (D) MCP-1 concentrations of supernatant samples acquired from 17|3- 
oestradiol stimulation, ‘n’ refers to the number of independent experiments.
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No statistically significant change was seen in any of the promoter constructs in response 
to all-trans retinoic acid (Figure 3.20A) or 17(3-oestradiol stimulation (Figure 3.20C) 
when compared to the control (unstimulated) transfections or the promoterless pGL-3 
control. The high variances seen in these experiments may be attributed to tissue specific 
variability, as seen in primary mesothelial cell cultures. There was also no significant 
change in luciferase activity between F100, F500 and F1000 constructs.
Mesothelial cell production of the inflammatory cytokine IL-8 can be seen to increase, 
approximately 3-fold, in response to RA stimulation (Figure 3.20B) while 17(3-estradiol 
stimulation reduces MCP-1 production by over 50% (Figure 3.20D). The fidelity of 
HPMC activation is shown in figures 3.20B and 3.20D as they illustrate the activation 
and responsiveness of cultured HPMC to 17(3-oestradiol [Kanda and Watanabe, 2003] 
and retinoic acid [Dai et al, 2004] as previously described in human keratinocytes.
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3.4 DISCUSSION
The genomic structure of the CA125 gene has been elucidated for the first time. A 
combination of in silico and in vitro methodologies were used, as previously described 
during the characterisation of the N-methyl-D-aspartate glutamate receptor [Williams et 
al, 2002]. Thus the >65kb mRNA sequence, AF414442.2, that was available at the 
beginning of this project, was used to identify clones containing intact gDNA sequence 
by BLAST analysis. Alignment of these mRNA and gDNA sequences using BLAST2 
was then used to deduce the genomic structure of the CA125 gene. The genomic 
sequence upstream of CA125 exon 1 thus represented the putative promoter region. 
Luciferase analysis of nested PCR amplified fragments from this region was subsequently 
performed to investigate the transcriptional regulation of this large surface expressed 
mucin. Promoter analysis of several other members of the mucin gene family has been 
described previously [Gum et al, 1997][Van Seuningen et al, 2000][Chen et al, 
2001][Perrais et al, 2001][Gum et al, 2003][Shekels et al, 2003].
The reconstructed genomic structure of the CA125 gene indicated the presence of 84 
exons within the genomic structure that occupied approximately 134 kb of the genome 
and produced a transcript of 66.765 kb. Due to a large tandem repeat region in the central 
region of the message, unambiguous sequence alignment was restricted to the 5’ and 3’ 
ends of mRNA sequence AF414442.2. The recently released composite reference CA125 
mRNA sequence NM_024690 is not internally repetitive and is aligned completely and 
unambiguously with gDNA from chromosome 19pl3.2. The existence of this ambiguous 
large repeat region did not allow accurate reconstruction of the repeat domain but may 
partly explain the high variability in the reported molecular size of CA125 RNA 
transcripts [O’Brien et al, 2001] and protein molecules [Fendrick et al, 1997][Nustad et 
al, 1997]. These findings are consistent with gene structure studies on other mucin genes, 
such as MUC1 and MUC5AC, that also identified tandem repeat domains within their 
structures that permit the synthesis of variably sized molecules by tandem repeat 
polymorphisms [Spicer et al, 1991][Escande et al, 2001].
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After closer inspection of the 5’ end of the in silico CA125 genomic sequence, it became 
apparent that the 5’untranslated region (UTR) was in-frame with respect to amino acid 
encoding, suggesting that the TIS (transcription initiation start site) was further upstream. 
The 5’ terminal sequence of exon 1 also resembled an intron-exon boundary [Zhang, 
1998], providing further evidence that there may be more expressed sequence upstream. 
Bearing in mind that many 5’ truncated mRNA sequences have been deposited on public 
access databases [Coleman et al, 2002][Casadei et al, 2003] and in order to identify the 
CA125 TIS, 5’-RACE was used to identify any further upstream expressed sequence. 5’- 
RACE analysis identified 9bp of additional, previously unidentified, expressed sequence 
(with regard to AF414442.2) at the 5’-end of the CA125 gene as seen in Figures 3.9 and 
3.10. The additional sequence included an in-frame stop codon (TAG) and thus 
represented a barrier to translation of any upstream sequences. Critically, since the first 
methionine codon encoded by mRNA AF414442.2 coincided with the predicted 
translation start site of CA125, this provided strong evidence that the sequence upstream 
of this site was non-coding.
As seen in Appendix I, identical sequences were recovered for bands B and C. This result 
was unpredicted since the size of these bands appears to be different in Figure 3.9 (Band 
B~300bp, Band C»260bp). This discrepancy was attributed to the accidental repeated 
cloning of the same band. Since the predicted size of the larger band B was consistent 
with the observed size of the DNA fragment cloned and sequenced it was apparent that 
the larger of the two fragments had been cloned. This is consistent with 5’-RACE 
sequence data from the analysis of the human HAS gene family that show smaller 5’- 
RACE bands may represent truncated forms of full-length mRNAs [Monslow et al, 
2004]. It was therefore assumed that band C was either a 5’-truncated CA125 specific 
sequence or a product of non-specific amplification.
Further analysis of the 5’ sequence located a motif (5’-TGAGATTT-3’) with high 
identity to the TIS consensus motif, YYANWYY (Y=Pryrimidine, W=A or T) [Smale, 
1997], positioned 6bp upstream from the additional RACE sequence (Figure 3.10). This 
provided strong evidence that the TIS and the promoter region of the CA125 gene had
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been identified. The absence of a downstream promoter element (DPE) or TATA box 
core promoter consensus motifs [Smale and Kadonaga, 2003] in the surrounding 
sequence does not detract from the possibility that this is promoter sequence as many 
other genes [Smale, 1997] including MUC3A [Gum et al> 2003] and CD80 [George et al,
2006] do not have DPEs or TATA box motifs in their promoter regions. In addition, the 
absence of RT-PCR products amplified between AF414442.2 and EST AA633830 
(Figures 3.13 and 3.14), the absence of RT-PCR products using any of the nested 
upstream fragments tested in Figure 3.12 and the cluster of TFBS present in the sequence 
(Figure 3.4) suggested that the CA125 TIS and proximal promoter had been identified 
and that the 5’-upstream flanking region constitutes the CA125 promoter region.
The sequence directly upstream of the CA125 TIS was amplified and analysed for 
transcriptional activity using a dual-luciferase assay system. Initially, the endogenous 
promoter activity of each promoter construct in HK-2 cells and primary HPMC was 
examined by testing their ability to drive the transcription of the luciferase gene. In HK-2 
cells none of the constructs produced a significant increase in luciferase output when 
compared to the promoterless control. HK-2 cells were originally selected for use in this 
system due to their ease of transfection, as shown previously [Monslow et al, 2004]. 
Subsequent analysis showed that HK-2 cells do not express CA125 (see appendix III), 
rendering them unsuitable for this system in any capacity other than acting as a negative 
control for the HPMC analysis.
When the CA125 promoter constructs were transfected into primary HPMC cells, a trend 
towards an increase in luciferase output was observed using the F1000 promoter construct 
that was not observed in the HK-2 cell transfections. This vector displayed an 
approximate 2-fold increase in activity compared to that of the other constructs, 
demonstrating its endogenous promoter activity. As seen in Figure 3.2, the difference 
between the FI000 and F500 promoter construct sequence is the existence of an extensive 
polypyrimidine tract region approximately 385bp in length. Although considerably larger 
than other simpler repeat regions described in the literature, some studies have shown the 
regulation of genes such as VEGF [Sun et al, 2005] and human c-ets-2 [Mavrothalassitis
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et al, 1990] by polypyrimidine/purine repeat regions in their promoter regions thus 
indicating a possible mechanism by which the CA125 promoter regulates gene 
expression. This represents, along with the cloning of larger promoter constructs, a target 
for future work in order to further understand the mechanisms involved in the regulation 
of CA125 transcription.
As mentioned previously, the F1000 construct displayed a 2-fold increase in promoter 
activity when compared to the promoterless control vector. This activity is substantially 
less than that reported for promoter constructs from mucin gene MUC6 which displayed 
an 80-fold increase in activity compared to control vectors [Sakai et al, 2005]. However, 
analysis at a different mucin locus demonstrated that the transcriptional regulation of 
these genes varies. Thus, the promoter of the highly expressed cell surface MU Cl 
showed only a 5-fold increase over control values [Thathiah et al, 2004]. The CA125 
data described above suggest that the low-level endogenous promoter activity of the 
F1000 fragment is sufficient for the constitutive expression of this very large protein.
As seen in Figure 3.20, though not statistically significant, stimulation of transfected 
HPMC with RA resulted in an approximate 2-fold increase in the luciferase activity of the 
FI000 construct, while stimulation with 17p-oestradiol resulted in approximate 3- and 2- 
fold inhibitions of the F500 and F1000 constructs luciferase activity, respectively. These 
data suggest that CA125 transcription may be up regulated through the RARE motif, 
possibly via a mechanism involving the polypryrimidine repeat region due to the specific 
induction of the F1000 construct. It is also possible that CA125 mRNA synthesis might 
be down regulated through the ERE motif, in a mechanism similar to that described in 
other studies examining the complement-3 (C3) promoter [Harrington et al, 2003] and the 
CRH-BP promoter [Van De Stolpe et al, 2004], as indicated by the reduced activity of 
both F500 and FI000 constructs. The above findings are consistent with previous studies 
on the regulation of CA125 by retinoic acid [Nakai et al, 1993][Hori et al, 2004] but 
disagree with previous reports regarding the effects of oestrogen [Nonogaki et al, 
1991][Karabacak et al, 2002]. Additionally, the profile of luciferase activity observed for 
control transfections in these experiments, appears to be inconsistent with the endogenous
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activity displayed in Figure 3.18A, possibly due to an altered response of HPMC to the 
phenol red free M l99 medium and charcoal/dextran treated FCS in which they were 
grown [Garmy-Susini et al, 2004]. Statistical significance was not achieved in these 
experiments, possibly due to the highly variable and notoriously difficult process of 
transfecting primary HPMC demonstrated by a maximal primary HPMC transfection 
efficiency of 1% reported elsewhere [Ohan et al, 2001]. Additional replicate experiments 
would possibly allow improved definition of the observed changes, nevertheless, the level 
of modulation displayed by the CA125 promoter region matches the observed magnitude 
of induction seen in CA125 expression shown in our chapter 4 studies (<45% increase) 
and in other in vitro [Zeillemarker et al, 1994][Zeimet et al, 1997] and in vivo [Jones et 
al, 2001] [Williams et al, 2004] CA125 studies.
Chromatin architecture may have a profound impact on transcription including ERE and 
RAR dependent gene activation. As previously described, ligand binding induces a 
conformational change in the receptor complex (dimer) that allows translocation into the 
nucleus and association with specific response element motifs (section 3.3.2) in the target 
DNA sequence thus promoting transcription via specific interactions with the core 
polymerase apparatus [Klinge, 2001][Bastein et al, 2004]. Additionally, upon stimulation, 
conformational changes to the receptor allow the recruitment of a protein complex that 
has the ability to modify DNA-histone interactions, possibly via acetylation of specific 
histone lysine residues, rendering the DNA more accessible to the transcriptional 
machinery [Sanchez et al, 2002][Clayton et al, 2006]. Mindful of the influence of 
chromatin modification on the transcriptional process from genomic DNA, it is worthy of 
note that these factors were absent from our in vitro system. Therefore the results 
obtained using pGL-3 luciferase reporter constructs containing CA125 promoter inserts 
may not accurately represent the native regulation of CA125 mRNA synthesis in vivo.
In conclusion, having successfully reconstructed and characterised the CA125 5’ flanking 
sequence, we demonstrated that the CA125 promoter has low-level endogenous activity. 
This is consistent with the regulation of this large, highly expressed, gene whose 
production has previously been shown to have a low magnitude of modulation
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[Zeillemarker et al, 1994][Zeimet et al, 1997][Jones et al, 2001][Williams a/, 2004]. 
Data has been provided suggesting that the regulation of CA125 transcription may occur 
through the polypyrimidine repeat region, as well as through retinoic acid receptors and 
oestrogen receptors present in the proximal promoter region. The low levels of 
modulation of CA125 expression shown in this work is further highlighted in chapter 4 of 
this thesis where IL-ip and IL-6 trans-signalling can be seen to induce CA125 expression 
levels consistent with our present findings. The regulation of CA125 at the level of 
transcription remains far from clear. This works serves to highlight the need for the 
repeated examination of the CA125 promoter region in response to RA and Oestrogen, 
and ultimately, the need for the generation of functional murine knockout models in order 
to progress our understanding of the regulation and function of CA125.
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APPENDIX I
5’-Race Sequence data (5’-3’)
Band A Non-specific to CA125
CAAATTTAGGGGGGGCGAAATTGGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGG
ATATCTGCAGAATTCGCCCTTAGGAGCGGGTGGGAGAAGATGACCACCAGGGTGGCTCCCAGCAC
CCAGAAGACGGCCGAGCCCGCACCAGCCAGCCAGAAGAAGGGGAAGGAGATGCCTCCAGCCAGAG
CATACTGATGCGCTGGGCTCACCTCTCGGCCAAAGAGCACAAGCTTGGACTCCAAGGTGCGCAGA
TAGAGAATGTAACAGGCGCCGAAAAAGACAGCCAGAGCCACCAGCAACATAGGGGACGTCACCAC
ACAGTACAGGATGAGGCCCAGGAACACGAACACATAGTTGCTCTGGTAGTACTCCACGTTGCGTA
CGAGGCGCTGGCACAGCTCTCCCAGGTTGCGGGGCCGTGAGAAGCGCTGCTGGTCCACGAAGGTG
CTCCAGGGCCGGATGGCCGCGCGGCGCCGCTCCAGCCACTCCCGGCCTGCACCGGAGGGAATCAG
CTTCGGCAGCAGGGTCGTGCCGCTCAGCCCTTCCGCCTCGGCATCTTTCTGCTGGTCCTTCTGCG
CTGCCATGTCTGCGTCGTGAGGGGGGAGCTGCTGTCCCCGCGTACTCTGCGTTGATACCACTGCT
TGCCCTATAGTGAGTCGTATTAGAAGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCC
GAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGC
TCACAATTCCACACAACATACGAGCGAGCATAAAGTGTAAAGCCTGGGGTGCCTATGAGTGACTA
CTCACATAGTGCGTGCGCTCACTGCCGCTTTCAGTCGGAAACTGTCTTGCACTGCATTATGATCG
CCACGCCGGGGAAAGGCGTTGCGATTGGGGCCTTCCGCTTCCCGCTCATGATCGTGGCCTGAGTT
CGTGCGGGGAGGGTTACGCTTCTCAGCGGTAACCGTTCGAATCGTACAGAACTTGCAAGGCCGAG
GCACTACGGCCTTCGTTCAGGTCCCCTGGATCAATCGCCT
BandB (233 bp) 9 bp Extension
CTCAATTAGAAGCGTTGTACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGG
TTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCAG
GGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTCTTAGACCTCCATCCAGAGG
CAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCT
BandC (233 bp) 9 bp Extension
CTCAATTAGAAGCGTTGTACAATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGG
TTTTCCCAGGTCAAATGCGGGGACCCCAGCCATATCTCCCACCCTGAGAAATTTTGGAGTTTCAG
GGAGCTCAGAAGCTCTGCAGAGGCCACCCTCTCTGAGGGGATTCTCTTAGACCTCCATCCAGAGG
CAAATGTTGACCTGTCCATGCTGAAACCCTCAGGCCT
110
Band D (85 bp) Truncated
A G A G G C C A C C C T C T C T G A G G G G A T T C T T C T T A G A C C T C C A T C A G A G G C A A A T G T T G A C C G T T C C A
T G C T G A A A C C C T C A G G C C T
= Additional 5 'RACE sequence 
= 5 'RACE Gene specific primer
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APPENDIX II
A. Predicted composite sequence (5’-3’) of CA125 (AF414442.2) and EST 
(AA633929)
EST F — ►
AGCACATTTCCCCTGTGATAAGTACCTTCTCATCTCTCAGGGCCCTCCTTAAATATTACCTCCTA
T G A G A A G T C T T C C C T G A T G A C T C T A T G G A A A A T T A T G C T T C T C T C T C A A T T A G A A G C G T T G C A C A
RT-EST 1
ATTCCCCCAACCTCCATACATACGGCAGCTCTTCTAGACACAGGTTTTCCCAGGTCAAATGCGGG
G A C C C C A G C C A T A T C T C C C A C C C T G A G A A A T T T T G G A G T T T C A G G G A G C T C A G A A G C T C T G C A G A
RT-EST 2
GGCCACCCTCTCTGAGGGGATTCTTCTTAGACCTCCATCCAGAGG
■ H  = Upstream EST sequence (AA633929) ■ ■ ■ =  CA125 5’-end sequence (AF414442.2)
B. Nucleotide sequence (5’-3’) of RT-PCR band produced using the RT-EST1 
primers
C C C C C C T T C C T G T T G G A A C C T T T G G C C T G A T G T T T G A A T G A G G T T A C C C T T T T G A C C A A A A G A T T
T C C C A C A T T C T C T A C A C T C A T A A G G C C C T T C T C C A G T G T G A A C A C G C T G A T G G C T A A T A A G G C T G
C C C T T C T G A C T A A A A G A T T T C C C G C A C T C C T C A C A G G G A T A A G C T G T C T G T C C A G T G T G G A C T C G
C T G A T G T T G A A T A A G G C T G C T C T T T C G A C T A T A A G A T T T C C C A C A C T C T C C A C A A T C A T A A G G T C
C T T T T G C A G T G T G A T C T C G C T G A T G A T T A C T G A A G C T G A C A T A T C T G C T A A A G G A T T T T C C A C A A
T C A C T G C A C A C A T A A C A T C C A T C T C T A G T G A A A A G T T T C T G G T G T G G A A T A A C T G A G T G T T T G G T
G G A G A G G G C T T A T G A G C G T A G A G A A T A C G G G T A A T T A C T T A G G T C A A T C C C G G A A A G A T A
1 1 2
APPENDIX III
CA125 expression by HK-2 cells versus HPMC
RT-PCR was carried out on RNA extracted from HK-2 cells (as in sections 2.3, 2.4.1 and
2.4.4) using primers specific for the repeat region of the CA125 gene (CA125 R, Table
3.2) and P-actin. The same am plification was carried out on RNA extracted from HPMC 
as a positive control.
HK-2 HPMC 
+kb 1 1 1 1 ' 1 -RT -PCR
1000
850 'm~
650 ««■»
son
400 “  “  * C A 1 2 5 R
300 AMl ___
200 *** *■“* mmm <  p-actin
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Specific amplification of the CA125 repeat region by RT-PCR in HK-2 cells and 
HPMC. -RT = negative control for reverse transcriptase, -PCR = negative control 
for PCR. Double stranded DNA markers are given (lkb+) with their sizes in bp.
Bands of predicted size were am plified from HPMC total RNA suggesting the reaction 
conditions were optimal for CA125 specific amplification. No bands were amplified for 
HK-2 cell RNA suggesting HK-2 cells do not express CA125.
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Chapter
The regulation of CA125 expression 
during inflammation
114
4.1 INTRODUCTION
The introductory chapter of this thesis has described the inflammatory cascade that takes 
place, locally, in the peritoneal cavity in response to dialysis fluid driven injury or to 
invasion by micro-organisms (Sections 1.4, 1.5 and 1.6). Presently it is not known how 
CA125 expression is regulated during the inflammatory response or how the antigen may 
itself contribute to this process. Previous studies have provided sharply contrasting 
results relating to the control of CA125 expression during inflammation. CA125 effluent 
levels have been shown to increase during and after episodes of peritonitis [Ho-Dac- 
Pannakeet et al, 1995][Bastani and Chu, 1995] but it is not known whether this is a result 
of alterations to the mesothelium or a direct result of the modulation of HMPC CA125 
production by inflam m atory m ediators. In 1995, V isser et a l reported that CA125 
expression by HPMC did not appear to be controlled by the inflammatory cytokines (i.e. 
IL -ip ) and thereby postulated that CA125 was only expressed in a constitutive manner 
[Visser et al, 1995]. This data was in conflict with other studies that showed the 
modulation of CA125 expression by IL -113 and other pro-inflam m atory cytokines 
[Zeillemarker et al, 1994][Zeimet et al, 1996]. However, to add further confusion to the 
situation, Zeillemarkers study indicated an increase in CA125 secretion while Zeim et’s 
study docum ented a decrease in CA125 shedding in response to the same pro- 
inflammatory cytokines.
Currently, we know very little about the mechanisms involved in the control of CA125 
expression under norm al conditions. To date, no studies have investigated the 
mechanisms involved in the transcriptional control of the gene (as we have attempted in 
chapter 3). Present evidence indicates that CA125 is predominantly a surface expressed 
antigen that can be shed although it’s exact biological function remains unkown. The 
structure of the protein core suggests that the molecule has a proteolytic cleavage site 
allowing its release from the cell surface [O’Brien et al, 2002] and SEA domains that 
allow the subsequent cleavage of the released molecule [Maeda et al, 2004][Palm ai- 
Pallag et al, 2005] but little is understood about the specific pathways involved in this
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process. In order to investigate these unknown mechanisms we must first understand 
how CA125 is regulated under defined conditions.
As previously described, HPM C play a key role in the coordination and control of the 
inflamm ation [Topley, 19951. W ork carried out at this Institute has shown that in 
response to IL-1[3 stim ulation, HPMC release IL-6. This in turn binds to its soluble 
receptor (sIL-6R) and induces the release of chemokines from resident HPMC for the 
subsequent recruitm ent of leukocyte populations [Topley et al, 1993][Topley et al, 
1996[[McLoughlin et al, 2004). Using an in vitro HPMC model we have demonstrated 
that the addition of IL-1[3 drives the early phase of the inflammatory response [Topley et 
al, 2003 J and that IL-6/sIL-6R will trigger the later resolution phase of the response 
[McLoughlin et al, 2004] in primary human mesothelial cells. In this chapter we use this 
in vitro model of inflammation to re-evaluate how CA125 expression is regulated during 
inflammation by exam ining CA 125’s control at the level of transcription, cell surface 
expression and the subsequent release from the cell surface in response to IL -lp  and IL- 
6/sIL-6R stimulation.
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4.2 METHODS
All HPMC for the subsequent experiments were harvested from consenting patients 
undergoing elective abdominal surgery and grown into confluent monolayers as discussed 
in sections 2.2. All cells were growth arrested for 48 hours in serum free M199 prior to 
stimulation. In this chapter, the n number given for each experiment refers to the number 
of individual omental isolations (from separate donors) on which experiments were 
performed.
All data are presented as mean [±standard error of the mean (SEM)] of the assigned 
number of independent experiments (n) performed on averaged duplicate samples for 
each experiment. Data were analysed using two-way ANOVA on SPSS v ll.5  for 
Windows. For Figure 4.13 significance was determined using the Student T-test (Excel 
for Mac®). Differences were considered significant when p<0.05.
4.2.1 Analysis of CA125 production by HPMC
HPMC cell lysate and supernatant samples were prepared as described in section 2.7.3 
and 2.7.4 respectively. A Western blot was then performed as outlined in section 2.7. 
Primary antibody; Anti-CA125 OC125 (purchased from Fuji-Rebio Diagnostics Inc), 
Secondary antibody; Anti-mouse HRP (Santa-Cruz Biotechnologies; Antigen Bioclear 
Uk Ltd, Caine, UK).
4.2.2 Analysis of CA125 regulation in response to IL-lp stimulation
4.2.2.1 Analysis of CA125 transcription
Cells were stimulated with recombinant human IL-lp (R&D Systems Europe Ltd, 
Abingdon, UK). At 0, 3, 6,12, 24 and 48 hours the cells were harvested and the RNA 
extracted as described in section 2.3.1. The total amount of RNA was quantified (section
2.3.2) before it was reverse transcribed (section 2.3.4). The resultant cDNA was then 
used in a PCR reaction using CA125 specific primers (Table 4.1) as described in section
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2.4.1. The PCR products were visualized using ethidium bromide staining following gel 
electrophoresis (section 2.4.4). Densiometric analysis was carried out using Chemidoc® 
computer software.
Table 4.1 Oligonucleotide primers used in RT-PCR experiments
Primer pair Sense-strand sequence Anti-sense strand sequence Cycle No
P-Actin GGAGCAATGATCTTGATCTT CCTTCCTGGGCATGGAGTCCT 30
CA125 Repeat GGAGAGGGTTCTGCAGGGTC GTGAATGGTATCAGGAGAGG 30
HLGP AACCTCCTTCCCAGAATCCAGG CCTCTGTGTGCTGCTTCATTGGG 30
All primers are in 5’ - 3’ orientation
4.2.2.2 Analysis of CA125 cell surface expression
Cells were stimulated with recombinant human IL-1 (3. At defined time points the cells 
were harvested, stained and analysed as described in section 2.8.
4.2.2.3 Analysis of CA125 cell surface secretion
Cells were stimulated with recombinant human IL-ip. At defined time points the 
supernatant samples were collected and centrifuged at 5000g for 3.5 minutes in order to 
remove any detached cells and cell debris. The supernatants were then assayed for CA125 
concentration as described in section 2.9.
4.2.2.4 Analysis of CA125 promoter activity
HPMC were transfected with the putative promoter constructs (section 2.6.2) and 
stimulated with IL-lp as described in section 2.2.9. Luciferase assays were then carried 
out using HPMC as discussed in section 2.6.
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4.2.3 Analysis of CA125 regulation in response to IL-6/sIL-6R stimulation
4.2.3.1 Analysis of CA125 transcription
Cells were stimulated with recombinant human IL-6 (R&D Systems Europe Ltd) and 
recombinant human sIL-6R (R&D Systems Europe Ltd). At 0, 3, 6,12, 24 and 48 hours 
the cells were harvested and the RNA extracted, as described in section 2.3.1. The total 
amount of RNA was quantified (section 2.3.2) before it was reverse transcribed (section
2.3.4). The resultant cDNA was then used in a PCR reaction using CA125 specific 
primers (for primer sequence see Table 4.1) as described in section 2.4.1. The PCR 
products were visualized using ethidium bromide staining following gel electrophoresis 
(section 2.4.4). Densiometric analysis was carried out using Chemidoc® computer 
software.
4.2.3.2 Analysis of CA125 cell surface expression
Cells were stimulated with recombinant human IL-6 and recombinant human sIL-6R. At 
defined time points, the cells were harvested, stained and analysed as described in section 
2 .8.
4.2.3.3 Analysis of CA125 cell surface secretion
Cells were stimulated with recombinant human IL-6 plus recombinant human sIL-6R. At 
defined time points, the supernatant samples were collected and centrifuged at 5000g for
3.5 minutes in order to remove any detached cells and cell debris. The supernatants were 
then assayed for CA125 concentration as described in section 2.9.
4.2.3.4 Analysis of CA125 promoter activity
HPMC were transfected with the putative promoter constructs (section 2.6.2) and 
stimulated with IL-6/sIL-6R as described in section 2.2.9. Luciferase assays were then 
performed using HPMC as discussed in section 2.6.
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4.2.4 Analysis of MCP-1 concentration in response to IL-lp and IL-6/sIL-6R 
stimulation
Growth arrested HPMC were stimulated with IL-1(3 and IL-6/sIL-6R (R&D systems). 
After 24 hours the supernatants were collected and centrifuged at 5000g for 3.5 minutes. 
The supernatants were then assayed for MCP-1 concentration as described in section 
2.10.1.
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4.3 RESULTS
4.3.1 Analysis of CA125 production by HPMC
In order to determ ine the nature and molecular weight of the CA125 antigen being 
produced by HPMC a W estern blot was performed using pooled supernatant (SNT) 
samples (obtained after 48 hours growth arrest) and cell lysate samples extracted from 
growth arrested HPM C. The com m ercially produced CA125 antigen was used as a 
positive control.
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Figure 4.1 Western Blot analysis of CA125 production by HPMC. 20pg Total 
protein was run in each lane. Molecular weights are given in kDa.
As demonstrated in Figure 4.1, CA125 was detected in the HPMC lysates but not in the 
supernatant samples. A lthough CA125 is known to be shed from the cell surface of 
HPMC, these data may simply reflect the large difference seen between the amount of 
CA125 present within the cell and the am ount released from the cell. Figure 4.1 also 
illustrates that CA125 molecules of varying molecular weights are produced as shown by 
the diffuse band seen for the reference antigen (between ~ 200 and lxlO 6 kDa) and for the 
HPMC lysate sample (between »  1000 and lx lO 6 kDa (arrows)).
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4.3.2 Analysis of CA125 regulation in response to IL-lp stimulation
4.3.2.1 Analysis of CA125 transcription
In order to determ ine the effect that pro-inflam m atory cytokines have has on the 
transcription of the CA125 gene, confluent monolayers of growth arrested HPMC were 
incubated in the presence or absence of IL-lj3. IL -ip  was used at lOOpg/ml, as previous 
work has shown this to induce sub-maximal activation in HPMC (Topley et al, 1993]. 
As shown in Figure 4.2, at 0, 3, 6, 12, 24 and 48 hours, the cells were analysed for gene 
expression using H LGP prim ers (specific for the 5 ’ terminus of the CA125 coding 
region), CA125 R primers (specific for the repeat region of the CA125 message) and |3- 
actin primers (specific for the |3-actin housekeeping gene).
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6 ‘ 12 24 48 -RT -PCR
HLGP 
C A 125 R 
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Figure 4.2 HPMC expression of CA125 in response to IL-lp. Representative 
agarose gel showing expression levels of the CA125 gene (CA125 R and HLGP) and 
p-actin in control (un-stimulated) and stimulated (IL-ip (100pg/ml)) at defined time 
points. -RT=Negative control for reverse transcription, -PCR=Negative control for 
PCR.
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Semi-quantitative analysis of CA125 transcription was achieved using a ratio of each 
product compared to the P-actin housekeeping gene, via densiometric analysis (Figure 
4.3).
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Figure 4.3 Densiometric analysis of CA125 gene expression in response to IL-ip 
(lOOpg/ml) stimulation. (A) Analysis of the CA125 R primer specific expression as a 
ratio of p-actin. Blue bars = Control, Red bars = IL-ip (lOOpg/ml) stimulation. (B) 
Analysis of the HLGP primer specific expression as a ratio of p-actin. Blue bars = 
Control, Red bars = IL-lp (lOOpg/ml) stimulation, ‘n ’ refers to the number of 
independant experiments.
As can be seen in Figure 4.3, analysis of CA125 gene expression in response to IL -lp , 
using either of the CA125 specific primers, shows no statistically significant change in 
expression over the 48 hour period when compared to the control expression.
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4.3.2.2 Analysis of CA125 cell surface expression
Prior to analysis of CA125 cell surface expression, the optimal concentration of the 
OC125 mouse anti-human antibody was evaluated in preliminary FACS experiments as 
seen in Figure 4.4.
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Figure 4.4 Optimization of the OC125 antibody concentration for mesothelial cell 
CA125 staining.
Figure 4.4 shows that a 1/1000 dilution of the OC125 stock (0.4mg/ml) is the optimal 
dilution for CA125 staining. Therefore, OC125 was used at 0.4pg/ml for all subsequent 
FACS experim ents. The secondary antibody: Rat anti-mouse IgG-PE was used at 
62.5ng/ml as defined in previous experiments.
To determine the effect that IL-1(3 has on cell surface expression of CA125, confluent 
growth arrested HPMC were treated with IL -lp  (lOOpg/ml) or control serum free M l99 
and the surface expression of CA125 was analysed at defined time points using FACS 
analysis (Figure 4.5).
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Figure 4.5 Control of mesothelial cell CA125 cell surface expression in response 
to IL-ip (lOOpg/ml) stimulation. Each bar represents the CA125 surface expression 
of IL-lp stimulated HPMC normalized to the un-stimulated control. Change in 
CA125 cell surface expression is shown as change in % expression, ‘n ’ refers to the 
number of independent experiments.
As shown in Figure 4.5, the amount o f CA125 expressed on the HPMC cell surface is 
increased by IL -ip  stimulation in a time dependant manner. When compared to the 
control cell surface expression, stimulation with IL-1(3 can be seen to induce a significant 
change 50% increase) in CA125 surface expression after 24 and 48 hours stimulation.
4.3.2.3 Analysis of CA125 cell surface secretion
In order to determine whether a change in surface expression of CA125 was associated 
with the amount released from the cell surface, HPMC were stimulated with IL -1 (3 for 
defined times. At defined time points the supernatant samples for both control (serum 
free M 199) and IL -lp  stim ulated ce lls  were collected and analysed for CA125  
concentration (Figure 4.6).
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Figure 4.6 Cell surface secretion of CA125 from HPMC in response to IL-ip 
stimulation. HPMC were treated with serum free medium (grey) or stimulated with 
lOOpg/ml IL-ip (pink) and analysed for CA125 concentration at defined time points. 
Changes in CA125 concentration are shown as a change in concentration compared 
to the zero hour time point, ‘n’ refers to the number of independent experiments.
Although not statistically significant, these data indicate a trend in the amount of CA125 
released from the surface as observed by an increase in CA125 shedding from the cell 
surface in response to IL - ip  stim ulation after 48 hours when compared to the un­
stimulated control cells.
4.3.2.4 Analysis of CA125 promoter activity
HPMC were transfected w ith the putative prom oter constructs (see chapter 3) as 
described in section 2.6.2. Each construct was then assayed for transcriptional activity in 
HPMC, stimulated for 24 hours in the presence or absense IL -ip  (lOOpg/ml), using the 
luciferase assay described in 2.6. For each promoter construct the luciferase activity was 
normalized to the promoterless control vector, pGL-3.
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Figure 4.7 Luciferase activity of the CA125 proximal promoter constructs and 
pGL-3 control construct in response to IL-lf$ (lOOpg/ml) stimulation. Luciferase 
activity is expressed as the magnitude of normalized luciferase activity relative to 
the promoterless negative control (pGL-3). Blue bars = Control, Green bars = IL-ip 
(lOOpg/ml) stimulated, ‘n’ refers to the number of independent experiments.
No significant change was seen in any of the promoter constructs in response to IL -1 (3 
when compared to the pGL-3 control. There was also no significant change in luciferase 
activity between stimulated F I00, F500 and F1000 constructs and the control constructs, 
although an upward trend was observed for the larger promoter fragments, as seen in our 
previous prom oter experim ents in chapter 3. The high variances seen in these 
experiments may be attributed to tissue specific variability as seen in primary mesothelial 
cells cultures.
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4.3.3 Analysis of CA125 regulation in response to IL-6/sIL-6R stimulation
4.3.3.1 Analysis of CA125 transcription
Previous work has identified a key role of IL-6/sIL-6R signalling in regulating the 
response of HPMC during inflammation [Jones et al, 2005][Hurst et al, 2001J. In order 
to determine the effect this signaling cascade has on the transcription of the CA125 gene, 
confluent monolayers of HPMC were incubated in the presence or absence of IL-6/sIL- 
6R. Both IL-6 and sIL-6R were used at lOng/ml, which has been previously described to 
be the optimal concentration to induce chemokine production in HPMC [Hurst et al, 
20021. As shown in Figure 4.8, at 0, 3, 6, 12, 24 and 48 hours the cells were analysed for 
gene expression using HLGP primers (specific for the 5 ’ terminus of the CA125 coding 
region), CA125 R primers (specific for the repeat region of the CA125 coding region) 
and |3-actin primers (specific for the |3-actin housekeeping gene).
HLGP 
CA125 R 
(3-ACTIN
CONTROL
y i t t r■ ■■ —: 48 -RT -PCR
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Figure 4.8 HPMC expression of CA125 in response to IL-6/sIL-6R stimulation. 
Representative agarose gel showing expression levels of the CA125 gene (CA125 R 
and HLGP) and p-actin in control (un-stimulated) and stimulated IL-6/sIL-6R 
(lOng/ml each) at defined time points. -RT=Negative control for reverse 
transcription, -PCR=Negative control for PCR.
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Semi-quantitative analysis o f CA125 transcription was carried out by determining the 
ratio of each product com pared to the P-actin housekeeping gene via densiom etric 
analysis (Figure 4.9).
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Figure 4.9 Densiometric analysis of CA125 gene expression in response to IL- 
6/sIL-6R (lOng/ml each) stimulation. (A) Analysis of the CA125 R primer specific 
expression as a ratio of p-actin. Blue bars = Control, Red bars = IL-6/sIL-6R 
stimulation. (B) Analysis of the HLGP primer specific expression as a ratio of p- 
actin. Blue bars = Control, Red bars = IL-6/sIL-6R (lOng/ml) each stimulation, 
‘n’refers to the number of independent experiments.
As can be seen in Figure 4.9, analysis of CA125 gene expression using the CA125 repeat 
primers and HGLP primers shows no significant change in CA125 expression over the 48 
hour period in response to IL-6/sIL-6R stimulation.
Time (hours)
Time (hours)
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4.3.3.2 Analysis of CA125 cell surface expression
To determine the effect of IL-6/slL-6R signalling on cell surface expression of CA125 
confluent mesothelial cell monolayers were treated with varying concentrations of IL-6 
plus slL-6R (lO ng/m l) or w ith serum free M l99 alone (control) and the surface 
expression of CA125 was analysed at defined time points using FACS analysis (Figure 
4.10).
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Figure 4.10 Control of mesothelial cell CA125 cell surface expression in response 
to IL-6 and sIL-6R (lOng/ml) stimulation. Each bar represents the CA125 surface 
expression of IL-6/sIL-6R stimulated HPMC as normalized to its un-stimulated 
(Ong/ml) control. Yellow bars = 24 hours stimulation. Green bars = 48 hour 
stimulation. Changes in CA125 cell surface expression is shown as changes in % 
expression. ‘n’ refers to the number of independent experiments.
As seen in the Figure 4.10 after 48 hours stimulation with IL-6 (lOOng/ml) and sIL-6R 
(lOng/ml) there is a trend towards a decrease in expression (p=0.073) compared to the
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control cells as well as a trend towards a decrease in expression compared to the 24 hour 
stimulation. This is indicative of a reduction of CA125 expression at the cell surface in 
response to IL-6/sIL-6R stimulation.
4.3.3.3 Analysis of CA125 cell surface secretion
In order to determ ine if this IL-6 trans-signalling mediated reduction in surface 
expression of CA125 was associated with increased shedding from the cell surface, 
HPMC were stimulated with various IL-6 concentrations together with sIL-6R (lOng/ml) 
for defined times. At these time points the supernatant samples for both serum free 
medium (control) and IL-6/sIL-6R stim ulated cells were collected and analysed for 
CA125 concentration (Figure 4.11).
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Figure 4.11 Change in HPMC CA125 cell surface secretion in response to IL-6 
and sIL-6R [lOng/ml] stimulation. Grey bars = 24 hours, Pink bars = 48 hours, ‘n ’ 
refers to the number of independent experiments.
Stimulation with IL-6/sIL-6R can be seen to induce a trend towards a dose dependant 
increase (at 48 hours, 100 ng/ml IL-6, p=0.073) in CA125 released from the cell surface 
when compared to the un-stimulated controls. IL-6/sIL-6R can also been seen to induce a
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trend towards a time dependant increase (lOOng IL-6, 24 hour vs 48 hour, p=0.164) in 
CA125 cleavage from the cell surface as shown by the change in the amount of CA125 
released from cells stim ulated for 24 hours O  maximal 1.5-fold increase) and cells 
stimulated for 48 hours (= maximal 3-fold increase).
4.3.3.4 Analysis of CA125 promoter activity
HPMC were transfected with the putative promoter constructs (chapter 3) as described in 
section 2.6.2. Each construct was then assayed for transcriptional activity in HPMC 
stimulated for 24 hours with IL-6 (lOng/ml) and sIL-6R (lOng/ml), using the luciferase 
assay described in section 2.6. For each promoter construct the luciferase activity was 
normalised to the negative control promoter less pGL-3.
pGL3 F100 F500 FI 000
Construct n=3
Figure 4.12 Luciferase activity of the CA125 proximal promoter constructs and 
PGL-3 control construct in response to IL-6 (10ng/ml)/sIL-6R (lOng/ml) stimulation. 
Luciferase activity is expressed as the magnitude of normalized luciferase activity 
relative to the promoterless negative control (pGL-3). Blue bars = Control, Green 
bars = IL-6 (10ng/ml)/sIL-6R (lOng/ml) stimulated, ‘n’ refers to the number of 
independent experiments.
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No significant change was seen in any of the promoter constructs in response to IL-6/sIL- 
6R when compared to the pGL-3 control. There was also no significant change in 
luciferase activity between stimulated FI00, F500 and FI000 constructs and the control 
constructs though the observed trend (i.e. increased activity of larger constructs) remains 
consistent with our previous luciferase data from chapter 3. The high variances seen in 
these experiments may be attributed to tissue specific variability as seen in primary 
mesothelial cells cultures.
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4.3.4 Analysis of MCP-1 concentration in response to IL-ip and IL-6/sIL-6R 
stimulation
To ensure that the HPMC model, exam ined in this chapter, was activated under the 
defined conditions used, MCP-1 assays were performed on supernatants gathered from 
the experiments. Previous to this work, other studies indicate that MCP-1 production by 
HMPC in vitro is increased in response to IL -lp  and IL-6/sIL-6R stimulation [Li et al, 
1998].
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Figure 4.13 MCP-1 production by HPMC in response to IL-ip (lOOpg/ml) and IL- 
6/sIL-6R (lOng/ml each) stimulation after 24 hours incubation. *p<0.05. ‘n’ refers to 
the number of independant experiments.
As seen in Figure 4.13 both IL-1|3 and IL-6/sIL-6R induced a significant increase in 
mesothelial cell MCP-1 production after 24 hours, consistent with other studies 
examining the effect of these inflammatory mediators on MCP-1 production [Li et al, 
1998|[Hurst et al, 2002]. This ensured the fidelity of the stimulatory conditions used and 
illustrates the activation and response of HPMC to the specific stimulations used in the 
experiments within this chapter.
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4.4 DISCUSSION
As documented in many previous studies, CA125 is predominantly a surface expressed 
antigen that is shed from the surface of the cell by an unknown mechanism [Fendrick et 
al, 1997][0’Brien et al, 1998][0’Brien et al, 2002]. The current debate regarding CA125 
regulation stems from differing opinions as to whether the antigen is constitutively 
expressed or whether it is specifically secreted and regulated in response to inflammatory 
mediators and cytokines. As discussed in the introduction to this thesis, both IL-ip and 
IL-6 trans-signalling are major mediators in the onset and progression of inflammation in 
the peritoneal cavity [Topley et al, 1993][Jones et al, 2005]. Although no previous 
studies have examined the effect of IL-6 trans-signalling on CA125 expression, many 
studies have examined the effect of IL-lp on CA125 expression, with differing results. 
This chapter aims to clarify these discrepancies and further understand how CA125 might 
be regulated in the inflamed peritoneum.
The transcriptional regulation of CA125 in response to inflammatory mediators in HPMC 
has not been previously reported in the literature and therefore remains unclear. In an 
attempt to clarify the situation, CA125’s transcriptional control in response to 
inflammatory mediators was examined. As seen in Figures 4.3 and 4.9, the expression of 
the CA125 gene is not significantly altered by IL-1(3 or IL-6/sIL-6R stimulation over a 
period of 48 hours suggesting that CA125 gene is not regulated at the level of 
transcription in response to these stimuli. The luciferase reporter gene assay developed in 
chapter 3 allowed further investigation of CA125’s transcriptional regulation by IL-lp 
and IL-6/sIL-6R. Using this system, CA125 putative promoter luciferase constructs were 
transfected into primary HPMC and tested for their transcriptional activity in the presence 
or absence of IL-ip and IL-6/sIL-6R. Consistent with our previously described data, 
under control conditions the CA125 promoter showed low level expression (see chapter 3 
discussion). As seen in Figure 4.7 and Figure 4.12, the promoter constructs displayed no 
significant change in transcriptional activity when stimulated with IL-1 (3 and a small but 
not significant increase in response to IL-6/sIL-6R stimulation. Nevertheless, these data, 
in conjunction with our RT-PCR findings, suggest that CA125 expression in probably not
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regulated at the level of transcription. Therefore, the changes seen in CA125 production, 
by inflammatory cytokines, described in the literature [Zeillemarker et al, 1994][Ziemet 
et al, 1996] and this chapter, suggest that changes in CA125 expression may result from 
an alternative level of regulation, i.e. regulation of its surface expression and cleavage 
from the cell surface potentially by an as yet unknown cleavage enzyme. Such control 
has previously been observed in the regulation of MUC1 that is potentially regulated by 
the ADAM family of proteases [Brayman et al, 2004]. Additionally, regulation by 
mRNA stabilization, as seen in the control of MUC5AC expression [Fischer et al, 2002], 
cannot be excluded as a mode of CA125 regulation although the low rate of turnover 
demonstrated for CA125 (Chapter 3-Figure 3.18A), the variation in molecular weight and 
the negligible amount of CA125 released from the cell (compared with the amount 
sequestered in and on the cell surface), observed from Western blot analysis (Figure 4.1), 
suggest that CA125 is probably regulated by post transcriptional mechanisms, possibly 
activated on the surface of HPMC.
Due to the apparent lack of transcriptional regulation of CA125 in response to 
inflammatory mediators and the suggestion that CA125 expression may be controlled on 
the cell surface, FACS analysis was utilized as this allowed the examination of the effect 
IL-ip and IL-6 signalling on the surface expression of CA125. As seen in Figure 4.5, IL- 
lp significantly increased the surface expression of CA125 after 24 and 48 hour (40-50% 
increase) when compared to the control levels. In contrast to the effect IL-1(3 has on 
CA125 surface expression, IL-6/sIL-6R (Figure 4.10) was observed to cause a reduction 
in the amount of CA125 expressed on the cell surface after 48 hours (24% decrease). 
These data suggest that CA125 surface expression can be regulated at both the level of 
surface expression and a subsequent coordinated increase or decrease in cell surface 
shedding in response to inflammation. These data further corroborate the theory that 
CA125 expression can be regulated in response to inflammatory mediators and that this 
control occurs post-transcriptionally, by a mechanism controlling changes in surface 
expression.
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To further investigate the effect of inflammatory mediators on CA125 regulation, their 
effect on the amount of antigen released/shed from the cell surface was examined by 
measuring the CA125 supernatant levels of IL-ip and IL-6/sIL-6R stimulated growth 
arrested HPMC monolayers. As seen in Figure 4.6, IL-ip induced only a small increase 
in the amount of CA125 shed from the cell surface after 48 hours. Together with the 
increased expression of CA125 at the cell surface (Figure 4.5), these data suggest that IL- 
lp  might increase the turnover of CA125 at the cell surface by increasing CA125 
expression on the cell surface and subsequently increasing the amount of CA125 that is 
released by the cell. Furthermore, the secretion of other members of the mucin gene 
family, such as MUC5AC [Gray et al, 2004] and MUC2 [Kim et al, 2002] have also been 
shown to be regulated by this pro-inflammatory cytokine thus suggesting a common 
control mechanism of mucin expression.
Similar to the effect of IL-1 (3, combined stimulation with IL-6 and sIL-6R resulted in a 
trend towards an increase in the amount of CA125 released from the surface of HPMC 
(approximate 2 fold increase after 48 hours (Figure 4.11)). Additionally, Figure 4.10 is 
suggestive of a trend towards a IL-6/sIL-6R induced decrease in CA125 surface 
expression under identical conditions thus suggesting a possible coordinated reduction in 
cell surface CA125 levels via increased cell surface shedding. These are the first studies 
to have examined the effect of IL-6 trans-signalling on CA125 expression and highlight 
the dependency for further analysis into the mechanisms by which IL-6/sIL-6R may 
possibly regulate CA125 expression. Interestingly, despite the lack of statistical 
significance in these data, the observed trends seen in our system are consistent with the 
ability of IL-6 to induce the expression of other mucins, such as MUC5B and MUC5AC, 
in the inflamed trachea [Chen et al, 2003]. The induction of these mucins is mediated by 
similar cellular signalling pathways as seen in the inflamed peritoneum such as the JAK 
and ERK pathways [Jones et al, 2005]. Together, these data suggest that the co­
coordinated increase in CA125 cell surface expression in response to IL-ip and an 
increased CA125 shedding from the cell surface in response to IL-6 signalling may be a 
primary mechanism in the regulation of CA125 release. It should be noted that due to the 
high variability in the observed levels of CA125 measured within this chapter statistical
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significance was not acheived. Further definition of the observed effects may be achieved 
through the repeated analysis of IL-ip and IL-6 stimulated CA125 expression in 
additional donor samples.
Although the mechanism by which CA125 is shed from the cell surface is far from 
understood, it has been suggested that proteolytic cleavage sites present on the CA125 
molecule may facilitate its release by cleavage enzymes [Fendrick et al, 1997][O’Brien et 
al, 2001]. It therefore seems plausible that the regulation of “enzyme” activity may be 
responsible for the regulation of CA125 cell surface biology. Mesothelial cells produce a 
vast number of proteases including metalloproteinase enzymes (MMPs), such as 
stromelysin [Marshall et al, 1993], that may potentially be responsible for the processing 
of CA125 at the cell surface. MMPs have previously been shown to be active during 
peritoneal inflammation [Martin et al, 2000] and in other organs such as the bowel [Naito 
et al, 2005]. More specifically, expression of many members of the MMP family have 
been shown to be regulated by IL-ip and IL-6 during inflammation of the skin [Dasu et 
al, 2003], joints [Fuchs et al, 2004] and the peritoneum [Martin et al, 2000]. The 
production and activation of proteolytic enzymes therefore presents a possible mechanism 
by which CA125 cell surface release may be regulated during inflammation.
No previous studies have examined transcription, cell surface expression or the effect of 
IL-6 trans-signalling on the regulation of CA125 in a similar manner to this study. The 
regulation of CA125 production by inflammatory cytokines demonstrated here both 
corroborates [Zeillemarker et al, 1994] and disagrees with other studies [Visser et al, 
1995][Ziemet et al, 1996] regarding the cell surface release of CA125 in vitro and may 
therefore be seen to add further confusion to an already unclear situation. One major 
issue that differentiates this study from previously published work is the use of an HPMC 
in vitro model that employs a growth arrest period (incubation in FCS free culture 
medium) in order to not only synchronize the growth phase of the cells prior to 
stimulation [Floege et al, 1990] but to exclude any exogenous stimulatory agents present 
in FCS, such as cytokines [Parkash, 2001] and growth factors [Nitz et al, 2003] that may 
modulate cell function. Evidence of the importance of the growth arrest period has been
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demonstrated in Chapter 3 where both oestrogen and retinoic acid both induce small 
changes in luciferase activity of our CA125 promoter constructs (Chapter 3, Figure 3.20) 
in a growth arrested system void of these stimuli [Garmy-Susini et al, 2004]. Since both 
oestrogen and retinoic acid are present in FCS, and considering CA125’s apparent 
modulation by them, it would seem that the use of a non-growth arrested model to 
examine the inflammatory control of CA125 may be less reliable due to the variable 
influence of potentially stimulatory agents (of unknown concentration) in the system. 
This may partly explain the contrasting results observed in the literature regarding CA125 
regulation by inflammatory stimuli.
In conclusion, this study clearly indicates the regulation of CA125 by inflammation. 
More specifically we have demonstrated that IL-1J3 increases the expression/turnover of 
CA125 at the cell surface while IL-6/sIL-6R induces CA125 release from the cell surface. 
The ability of IL-ip to increase CA125 surface expression and subsequent temporal 
increase in the amount of CA125 secreted from the cell surface by IL-6/sIL-6R poses an 
important question with regard to future work in this area as well as highlighting potential 
areas of future analysis regarding CA125’s regulation by other cytokines known to be 
involved in the inflammatory response, such as IL-8, TNF-a [Topley et al, 1993] and 
IFN-y {Robson et al, 2001]. Furthermore, we have also gained valuable insight into the 
possible mechanisms responsible for CA125’s regulation by inflammatory cytokines. 
The lack of inducible transcriptional activity and the subsequent changes in expression 
and secretion observed at the cell surface suggest that CA125 expression and production 
is primarily regulated at a level other than transcription. Although we can only speculate 
at the role of CA125 during inflammation, its apparent regulation at the cell surface, its 
size, location and the negligible amount of CA125 released from the cell suggest that 
CA125’s normal function resides predominantly on the mesothelial cell surface. 
Considering this, the function of CA125 is further investigated in chapter 5 where the role 
of CA125 in HPMC migration and wound healing is examined using our HPMC in vitro 
model.
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Chapter 5
The potential role of CA125 in 
regulating mesothelial cell repair
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5.1 INTRODUCTION
Denudation and injury of the peritoneal mesothelium is a frequent finding in biopsies 
obtained from the peritoneal cavity of PD patients 1 Williams et al, 20021. Comparison of 
the mesothelium in peritoneal biopsy samples taken from normal patients and those 
receiving PD (Figure 5.1) show the separation of the mesothelial cell layer from the 
underlying stroma, as a result of PD, as well as the loss of mesothelial cell interactions 
and alterations in m orphology [W illiams et al, 2003]. In addition to exposure to 
unphysiological dialysis solutions, episodes of peritonitis are also thought to be a major 
cause of damage and injury to the mesothelium during peritoneal dialysis [Davies et al, 
1996[. Such injury to the peritoneal mesothelium is thought to disrupt its protective and 
homeostatic properties and thereby predispose the membrane to fibrotic alterations and its 
subsequent loss of function as a dialysing organ. The repair or preservation of the 
mesothelium therefore represents a critical process in the restoration of the integrity of 
the peritoneal membrane [Yung and Davies, 1998][Yung et al, 2000].
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Figure 5.1 The effect of PD on the peritoneal mesothelium. (A) Parietal 
peritoneum from a normal patient. (B) Parietal peritoneum from a patient treated 
with peritoneal dialysis (Taken from [Williams et al, 2003]).
Prior to the present study the understanding of the wound healing process had been 
significantly aided by the developm ent of in vitro wound healing models that allow the 
“real time” analysis of the healing process in many cell types, such as epithelial cells of
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the nasal passage [Zahm et al, 1997] and the small intestine [McCormack et al, 1992], In 
order to specifically study the process o f re-mesothelialization an in vitro w ounding 
model was established [Yung and Davies, 1998] in which mechanical (scratch) wounding 
of HPMC monolayers was performed, allowing the temporal analysis of the progression 
of the wound closure by tim e-lapse photography |Yung and Davies, 1998]lYung et al, 
200011Morgan et al, 2003]. Using this model it was established that HPMC migration 
was the key process in promoting re-mesothelialization, with cells moving centripetally 
from the leading edge of the wound to re-cover the denuded area (Figure 5.2). This 
process was accom panied by an overall increase in HPMC proliferation shown by the 
evenly distributed proliferating cells throughout the wounded monolayer [Yung and 
Davies, 1998](Yung et al, 2000]. Despite this evidence, the mechanisms involved in 
healing of the m esothelium  follow ing injury remain controversial. O ther studies 
examining mesothelial wound healing in vivo have shown that wound healing may occur 
through different mechanisms involving the detachment, re-attachment and proliferation 
of m esothelial cells w ith in  the w ounded surface as opposed to subserosal cell 
differentiation [M utsaers et al, 2000][Foley-C om er et al, 2002]. The different 
mechanisms observed in the two systems may be explained by the lack of mesothelial cell 
precursors, fibroblasts and m acrophages, known to be involved in wound healing and 
tissue remodelling, within the in vitro system [Ryan et al, 1973].
Figure 5.2 Time dependant closure of an in vitro wounded human peritoneal 
mesothelial cell monolayer after a) 0 hours b) 8 hours c) 16 hours and d) 24 hours.
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Further analysis of HPMC migration in the in vitro model has shown that wounded 
HPMC monolayers have the ability to repair themselves in the absence of exogenous 
growth factors suggesting the repair process is a direct response of HPMC to injury. The 
absence of other cell types, such as macrophages and fibroblasts, within the system also 
indicates that the wound healing process observed in this system is a direct result of the 
HPMC response to injury. During this response HPMC have been shown to carry out a 
number of events such as deposition of their own extracellular matrix components 
(including laminin and fibronectin) in the wounded area, re-organization of their stress 
fibres and focal contacts [Yung and Davies, 1998], and the release of signalling 
molecules such as prostaglandin E2, PDGF, FGF, EFG and HGF/SF that play important 
roles in re-mesothelialization [Leavesley et al, 1999][Faull et al, 2001][Warn et al, 2001]. 
HPMC production of hyaluronan (HA) was also found to be important to this process 
(especially at the leading edge of the wound) as it is believed to increase cell mobility 
although its precise function in the wound healing process is not known [Yung et al, 
2001][Horiuchi et al, 2003]. The release of growth factors from disrupted cells or the 
loss of inhibitory signals through mechanical wounding is thought to be responsible for 
these cellular responses seen during the repair process. The addition of serum (FCS) to 
the system induces a significant increase in the rate of wound closure probably due to the 
action of stimulatory agents, such as EGF and PDGF for example, known to increase the 
HPMC migration [Yung and Davies, 1998].
The use of bio-incompatible dialysis fluids are believed to be the major cause by which 
denudation of the mesothelium occurs in patients receiving PD [Williams et al, 2002], 
More recent studies using the in vitro HPMC wound healing model described above have 
examined the effect of the glucose degradation products (GDP) present within PDFs on 
the rate of mesothelial wound closure [Morgan et al, 2003]. These studies identified that 
GDPs retard re-mesothelialization of the wounded monolayer suggesting that peritoneal 
dialysis fluids with improved biocompatibility (i.e. reduced GDPs) may be important in 
the protection of the mesothelium during PD. As discussed in section 1.7.3, use of these 
improved PDFs also coincides with an increase in CA125 effluent levels [Rippe et al, 
2001] [Jones et al, 2001] [Williams et al, 2004] thus highlighting a potential association
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between CA125 and the process of re-mesothlialization. In this chapter we attempt to 
analyse CA125’s role in this process by examining the effect of exogenous CA125 on our 
wound healing system. We will also attempt to link our findings to the clinical situation 
as we further investigate the apparent relationship between the rate of wound healing, 
CA125 concentration and GDP levels.
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5.2 METHODS
5.2.1 The effect of exogenous CA125 on mesothelial wound healing
The effect of adding exogenous CA125 on the rate of mesothelial wound healing was 
determined by adding M199 containing physiologically relevant concentrations of CA125 
antigen (Fuji-Rebio Diagnostic Inc) to the HPMC wound healing model as described in 
section 2.11.1. All HPMC were growth arrested for 48 hours (section 2.2.8) prior to 
scratching. M onolayers were incubated and monitored until wound closure. Rate of 
wound closure (pixels/hour) was determined as shown in Figure 5.3 and discussed in 
section 2.11.2.
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Figure 5.3 Analysis of HPMC rate of wound closure. (A) Image analysis of 
scratch size in wounded HPMC monolayers, (B) Determination of the rate of wound 
closure for the first 12 hours of HPMC wound closure. The rate of wound closure is 
represented by the gradient of the linear portion of the graph. The gradient is shown 
in pixels/hour.
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5.2.2 The effect of CA125 blocking on mesothelial wound healing
The effect that blocking endogenous CA125 activity produced by resident HPMC has on 
the rate of mesothelial wound healing was determined by the addition of M199 
containing defined concentrations (0.04, 0.4 and 4pg/ml) of OC125 antibody to the 
HPMC wound healing model as described in 2.11.1. All HPMC were growth arrested for 
48 hours (section 2.2.8) prior to scratching. Monolayers were incubated and monitored 
until wound closure. Rate of wound closure (pixels/hour) was determined as shown in 
Figure 5.3 and discussed in section 2.11.2.
5.2.3 Examination of CA125 shedding in response to high and low levels of glucose
degradation products (GDP) present in peritoneal dialysis fluid (PDF)
%
Commercially available solutions were either conventional lactate-buffered, heat 
sterilized fluids (Gambrosol®, Gambro, Lund, Sweden) containing 1.5 % or 4.0% glucose 
or those manufactured in a triple-chambered bags (Gambrosol-trio®, Gambro, Lund, 
Sweden) containing 1.5 % or 4.0% glucose. Growth arrested HPMC monolayers were 
incubated with Gambrosol® (containing 1.5% or 4.0% D-glucose) or Gambrosol-trio® 
(containing 1.5% or 4.0% D-glucose). Previous viability assessments on HPMC 
monolayer cultures (data not shown) indicate that HPMC remain viable in dialysis 
solution:M199 dilutions of 4:1 (25% v/v). Therefore, to ensure cell viability, all dialysis 
fluids were applied in a 25% v/v mixture with M199 (containing 2 mmol/L N-2- 
hydroxyethylpiperazine-N’-2ethanesulfonic acid (HEPES) to ensure that the pH was 
maintained at 7.4 throughout the experiment). HPMC stimulated with M199 were used as 
a control. After 48 hours the supernatant samples were collected and centrifuged at 
5000g for 3.5 minutes in order to remove any detached cells or cell debris. The 
supernatants were then assayed for CA125 concentration as described in section 2.9.
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5.2.4 Statistical analysis
All wounding experiments were performed in a 24 well plate with random assignment of 
wells to different treatments. All CA125 supernatant assays were performed in 6 well 
plates. All data are present as mean [±standard error of the mean (SEM)] from the stated 
number of independent experiments (n) performed on averaged quadruplicate (wounding) 
or duplicate (CA125 assay) samples with HPMC isolated from different omental donors. 
All data were analysed using Student’s t-test in Excel for Windows. Differences were 
considered significant when p<0.05.
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5.3 RESULTS
5.3.1 The effect of exogenous CA125 on mesothelial wound healing
The observed CA125 concentrations, seen in patient samples, can vary considerably; 
dependant on factors such as age [Breborowicz et al, 2005] and disease phenotypes such 
as ovarian cancer [Bast et al, 1983]. Additionally, as illustrated in Appendix I, peritoneal 
dialysis has been shown to alter the levels of CA125 seen in the peritoneal cavity 
dependant on the type of the PD solution used [Rippe et al, 2001] [Jones et al, 
2001][Williams et al, 2004]. The effect of the CA125 during HPMC wound healing 
under the observed physiologically relevant CA125 concentrations (i.e. those measured 
during peritoneal dialysis (12 U/ml to 180 U/ml) based on published data) was examined 
by the addition of exogenous CA125 antigen to the previously described in vitro wound 
healing model as seen in Figure 5.4. Serum free conditions were used to represent the 
endogenous rate of HPMC wound closure. Incubation with M l99 containing 2% FCS 
was used as a positive control to ensure the responsiveness of the system to potential rate 
enhancing stimulations.
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Figure 5.4 The effect of exogenous CA125 on the rate of HPMC re- 
mesothelialization. (A) Confluent monolayers of HPMC were mechanically 
scratched and incubated with either serum free M199 (negative control), M199 
containing CA125 antigen (25, 50 or lOOU/ml) or M199 containing 2% FCS (positive 
control (blue)). *p<0.05 compared to un-stimulated control, ‘n ’ refers to the 
number of independent experiments. (B) Representative images of re- 
mesothelialization following scratch wounding in HPMC from above experiment.
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As seen in Figure 5.4, the presence of FCS (blue bar) significantly increased (p=0.014) 
the rate of HPMC wound closure, when compared to the serum free control, thus 
indicating the fidelity of HPMC in this wound healing system and corroborating existing 
data regarding the effect of FCS on this wounding system [Yung and Davies, 1998]. 
Furthermore, a statistically significant increase in the rate of re-mesothelialization was 
observed for HPMC incubated with 50U/ml CA125 antigen (p=0.036) when compared to 
the serum free M l99 control. In untreated HPMC, the process of wound closure was 
complete by approximately 20 hours as seen in another study using an identical system 
[Morgan et al, 2003]
5.3.2 The effect of CA125 blocking on mesothelial wound healing
To date, the role of endogenous CA125 in wound healing is not known. To further 
investigate the involvement of CA125 in this process defined concentrations of the 
CA125 specific mouse anti-human monoclonal antibody, OC125, were used in an attempt 
to block the activity of the endogenous HPMC produced CA125 present within the 
previously described in vitro HPMC wound healing model. To eliminate the possibility 
of non-specific CA 125-antibody interactions, an irrelevant antibody (anti-sIL-6R) not 
specific to CA125, or expressed on the mesothelial cell surface [McLoughlin et al, 2004], 
was used as a control. Serum free conditions were used to represent the endogenous rate 
of HPMC wound closure. Incubation with M l99 containing 2% FCS was used to ensure 
the responsiveness of the system to potential rate enhancing stimulations.
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Figure 5.5 The effect of exogenous OC125 on the rate of HPMC re- 
mesothelialization. Confluent monolayers of HPMC were mechanically scratched 
and incubated with either serum free M199 (negative control), M199 containing 
OC125 (0.004, 0.04 or 4pg/ml), M199 containing 2% FCS (positive control (Blue)) or 
M199 containing 0.4pg/ml anti-sIL-6R antibody (green). *p<0.05 compared to un­
stimulated M199 control, ‘n ’ refers to the number of independent experiments.
As seen in Figure 5.5, the presence of 2% FCS induced a statistically significant increase 
in the rate of wound closure when compared to serum free control, thus corroborating 
existing data regarding the effect of FCS on this wounding system [Yung and Davies, 
19981- The addition of the CA125 specific monoclonal antibody, OC125, did not result 
in any significant change in the rate of wound closure when compared to the un­
stimulated control. No significant change in the rate of closure was observed for HPMC 
incubated with the anti-sIL-6R antibody.
5.3.3 Examination of CA125 shedding in response to high and low levels of glucose 
degradation products (GDP) present in peritoneal dialysis fluid (PDF)
Heat sterilization o f  conventional PDFs has been shown to promote the formation o f high 
levels o f glucose degradation products from the breakdown o f glucose [Kjellstrand et al, 
1995], Improved methods o f  sterilization using a multi-chamber bag system allow the
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separate sterilization o f  glucose and electrolytes, therefore reducing the amount of GDPs 
formed [W ieslander et a l, 1995]. Previous work has identified that CA125 levels are 
regulated in vivo in response to different dialysis solutions and that solutions designed to 
reduce glucose degradation show the greatest increase in CA125 effluent levels [Rippe et 
al, 2001] [Jones et a l, 2001] [W illiams et al, 2004]. Furthermore, high GDP containing 
solutions (Gambrosol®) have been shown to retard HPMC wound healing when compared 
to low GDP solutions (Gambrosol-trio®) as seen Appendix II. In order to examine the 
specific effect o f  GDPs on CA125 regulation, wounded HPMC monolayers were treated 
with high GDP dialysis fluids (Gambrosol® containing 1.5% or 4% glucose) or low GDP 
dialysis fluids (Gambrosol-trio® containing 1.5% or 4% glucose). HPMC stimulated with 
serum free M l99 were used as a control.
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Figure 5.6 The effect of GDPs on HPMC CA125 shedding. Gambrosol® (1.5% or 
4% glucose), Gambrosol-trio® (1.5% or 4% glucose) or serum free M199 was 
applied to confluent HPMC monolayers as a 25% v/v solution in M199. Samples 
were collected 48 hours after wounding and assayed for CA125 concentration. Cells 
treated with serum free M199 were used as a control. *p<0.05 compared to M199
control, Tp<0.05 compared to low GDP solutions, ‘n ’ refers to the number of
independent experiments.
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Exposure to PDFs containing high GDP concentrations significantly reduces HPMC 
CA125 secretion, independently of glucose concentration, when compared to the control. 
In contrast, PDFs containing low GDP concentrations induce a statistically significant 
increase in CA125 secretion independantly of glucose concentration when compared to 
the control. A significant change in CA125 supemantant concentration is also observed 
between low and high GDP solutions. This data appears to imply a relationship between 
GDP levels and HPMC CA125 secretion/shedding during the wounding process.
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5.4 DISCUSSION
To date, all of the studies that have examined the biocompatibility of peritoneal dialysis 
fluids in patients have demonstrated variable increases in CA125 concentrations (up to a 
maximal 4 fold increase) in the effluent of patients being treated with ‘improved’ PDFs, 
containing less glucose degradation products (GDP) and a neutral pH, when compared to 
more conventional bio-incompatible PDFs [Rippe et al, 2001] [Jones et al, 
2001][Williams et at, 2003]. Within these studies, the increased CA125 effluent levels 
are generally interpreted as a reflection of the improved integrity of the mesothelium as a 
result of reduced damage by more biocompatible dialysis fluids. Although this 
interpretation is consistent with an increase in the health of the mesothelium [Williams et 
al, 2004] it remains plausible that the changes observed in CA125 effluent levels are a 
result of altered expression and secretion as a consequence of specific components of the 
PDF. Therefore, the possibility of an up-regulation of CA125 shedding in response to 
inflammatory mediators (as demonstrated in chapter 4) induced by the new dialysis fluids 
remains, although this seems unlikely as levels of inflammatory markers, such as 
hyaluronic acid [Yung et al, 1996][Yamagata et al, 1999], have been shown to be 
reduced in response to the improved dialysis fluids indicative of a reduced inflammatory 
environment [Williams et al, 2004].
In this chapter the ability of the mesothelium to undergo self-repair following injury in 
response to the increased levels of CA125 observed during the use of biocompatible 
dialysis fluids was examined. Additionally, examination of CA125 production/shedding 
by HPMC in response to commercially available dialysis solutions containing low and 
high concentrations of glucose degradation products will allow understanding of how 
CA125 may be involved in the wound healing process.
As damage of the mesothelial cell layer of the peritoneal membrane commonly occurs 
during PD [Williams et al, 2003], the effect that physiologically relevant levels of CA125 
had on the rate of HPMC wound healing was examined (as seen in section 5.3.1). CA125 
concentrations of 25U/ml, 50U/ml and lOOU/ml were chosen as these mimicked the
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physiologically relevant levels seen in PD patients receiving conventional or more 
biocompatible formulations (Appendix I). Exogenous CA125 appears to have the effect 
of increasing the rate of HPMC wound closure when compared to the serum free control. 
Although the mechanisms by which this observed increase in rate of wound closure are 
not understood, these data suggest a potential role of CA125 in the process of HPMC 
migration. It would therefore seem possible that the improved physiology and 
functionality of the peritoneal membrane observed in vivo as a result of the use of 
improved biocompatible PDFs [Rippe et al, 2001] [Jones et al, 2001] [Williams et al, 
2004] may in part be due to the increased ability of the mesothelium to repair itself in 
response to normalised CA125 turnover. These observations are consistent with the 
potential role of other mucins in wound repair as previously reported in other in vitro cell 
models, such as injured bronchial epithelial cells, through their interactions with trefoil 
factors. The association of mucin molecules with trefoil factors, such as intestinal trefoil 
factor (ITF), is thought to activate specific cellular pathways (i.e. MAPK) resulting in 
alterations in cell-cell adhesions that in turn promote cell migration [Kinoshita et al,
2000]. The examination of similar signalling pathways in our system may represent a 
promising area of future work in HPMC research.
As previously discussed, the use of dialysis solutions containing reduced GDP levels is 
associated with the increase of CA125 peritoneal effluent levels [Rippe et al,
2001][Williams et al, 2004][Witowski et al, 2004]. Prior to this study no work had 
directly examined CA125’s regulation by GDPs although the available in vivo data 
suggested that GDPs may be the PDF component responsible for the observed increase in 
CA125 effluent levels. As seen in Figure 5.6, the GDP concentration of dialysis fluid has 
the effect of decreasing the amount of CA125 shed by HPMC suggesting that the changes 
seen in CA125 peritoneal effluent levels may be the result of repression of CA125 
shedding by high GDP concentrations as opposed to CA125 induction by other 
components present in the fluid. The level of CA125 modulation observed for HPMC 
treated with Gambrosol-trio® compared to that observed for Gambrosol® (approximately 
2 fold increase) in our in vitro system is comparable to the increase seen in the in vivo 
situation [Rippe et al, 2001] therefore substantiating our finding in a clinical context. In
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addition to this, the re-mesothelialization process has previously been shown to be 
accelerated by the reduction of GDPs present in PDFs [Morgan et al, 2003]. This 
apparent GDP induced retardation of wound healing and CA125 expression, together 
with CA125’s apparent ability to promote HPMC migration (Figure 5.4) provides further 
evidence of a potential relationship between CA125 induced re-mesothelialization and the 
GDP concentrations present during peritoneal dialysis.
To further examine CA125’s involvement in the re-mesothelialization process, OC125 
was employed to block the effect of endogenous CA125 activity in the HPMC wound- 
healing model. As seen in Figure 5.5, the addition of the OC125 had no significant effect 
on the rate of wound closure when compared to the serum free M l99 control suggesting 
that endogenous CA125 has no function in the wound healing process. To date, nothing is 
known regarding how OC125 binding might effect CA125’s ability to function, and 
considering no other studies have shown the successful blocking of CA125 activity using 
OC125 in any system it seems likely that inadequacies within this experimental model 
may provide a possible explanation for our findings. However, this experiment does 
serve to highlight the necessity for an improved or new system to study endogenous 
CA125 function. The blocking of endogenous CA125 using OC125 in a FCS treated 
model may provide a more meaningful future experiment. Nevertheless, further 
investigation into CA125’s role in cell migration is clearly dependant on the development 
of a HPMC in vitro wound healing model with reduced CA125 expression possibly via 
the application of siRNA technology.
In conclusion, this chapter demonstrates a role for CA125 in the HPMC wound healing 
process for the first time although the underlaying mechanisms by which CA125 
functions remains unclear. Additionally, we have shown that CA125’s apparent ability to 
increase the rate of re-mesothelialization may be directly related to the observed increase 
in CA125 peritoneal effluent levels seen in response to improved dialysis solutions, 
shown via the demonstration of CA125’s regulation by GDPs in our in vitro system. The 
mechanisms by which GDPs regulates CA125 production/shedding requires further 
investigation. Furthermore, due to CA125’s apparent involvement in the process of
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wound healing, the model used in this chapter represents an ideal system for future work 
in the elucidation of the function of CA125.
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APPENDIX I
CA125 effluent levels in response to low GDP dialysis solutions
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Box plots of effluent CA125 levels (U/ml) for patients treated with a high GDP 
solution (SPDF) for 12 weeks before treatment with a low GDP solution (Balance) 
for 12 weeks. CA125 levels were measured at the end of each treatment period. For 
each box plot median values are represented by the line within the box. The box 
presents 50% of the values (the 25th and 75th centiles), with the bars representing the 
highest and lowest values, excluding outliers (p ). n=36. (Taken from [Williams et al, 
2004]).
158
APPENDIX II
HPMC wound closure in response to Gambrosol® and Gambrosol-trio®
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Time course of remesothelialization following scatch wounding in HPMC exposed to 
Gambrosol® (G) (1.5% and 4.0% glucose), Gambrosol-trio® (Trio) (1.5% and 4.0% 
glucose) or to control medium (M199). (Taken from [Morgan et al, 2003]).
159
Chapter 6 
General Discussion
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For the past 25 years the measurment of CA125 has been used as a diagnostic tool for the 
detection of ovarian cancer [Bast et al, 1981][Bast et al, 1983]. More recently however, 
the measurment of aberrant CA125 levels within the peritoneal effluent of patients 
undergoing PD diverted much attention on to CA125’s apparent ability to act as a marker 
of mesothelial mass/integrity in the peritoneal cavity [Visser et al, 1995][Ho-Dac- 
Pannekeet et al, 1997]. The ability to culture HPMC in vitro has allowed further analysis 
of CA125 regulation by these cells and has resulted in a variety of contrasting hypotheses 
on how CA125 might be regulated in the normal and inflamed peritoneum [Zeillemarker 
et al, 1994][Visser et al, 1995][Ziemet et al, 1996]. To date, despite CA125’s diagnostic 
value in the monitoring of ovarian cancer and mesothelial cell mass/integrity, the 
regulation and expression of the CA125 gene, as well as its physiological function, have 
remained elusive. The aims of this thesis were to investigate the mechanisms controlling 
transcription of the CA125 gene, to re-evaluate how CA125 expression might be 
regulated during the inflammatory response and to define a biological function.
Completion of the Human Genome Project generated a large amount of sequence data 
and allowed the identification and comparison of specific gene sequences, but more 
importantly, it allowed identification of promoter sequences therefore leading to a better 
understanding of the transcriptional mechanisms controlling gene expression. At the 
beginning of this project little work had been carried out on the human CA125 gene. 
Initial attempts to clone the CA125 gene proved difficult [Yin et al, 2001] but the CA125 
gene structure was eventually elucidated by O’Brien and his colleges in 2002 [O’Brien et 
al, 2001][O’Brien et al, 2002]. The availability of the CA125 genomic sequence (cosmid 
sequences AC008734 and AC016584) and the complete mRNA sequence (AF414442.2) 
allowed the in silico reconstruction of the CA125 gene. In this thesis an extra 9bp of 
expressed sequence were found at the 5’ end of the CA125 message and subsequent 
experiments provided clear evidence that the beginning of the gene and the CA125 
promoter region had been located. However, the lack of typical consensus sequence 
motifs in the immediate up stream sequence, although not uncommon, may pose 
questions about whether the full gene sequence has been elucidated. Nevertheless, the 
subsequent analysis of the CA125 promoter region, under resting conditions and in
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response to retinoic acid and oestrogen (in primary HPMC) showed that the promoter 
region was active in vitro indicating the successful identification of the CA125 promoter 
region. These data also substantiated previous studies characterising CA125 as a mucin­
like molecule [Yin et al, 2001] [Yin et al, 2002] as our CA125 (or MUC16) promoter 
constructs displayed a similar magnitude of endogenous promoter activity similar to other 
surface expressed mucin genes, such as MU Cl [Thathiah et al, 2004], therefore providing 
further clues to the potential function of CA125 (i.e. as a lubricating molecule).
Although the promoter constructs described in this thesis represent the novel analysis of 
the CA125 promoter region, many difficulties and problems were presented by this 
model. Such problems included the transfection of primary cells that express CA125 in 
order to be certain that the cell type used possessed the transcriptional machinery required 
to express the antigen, and also allowed comparison with the clinical situation. The use of 
wild-type cells (HPMC) resulted in low transfection efficiencies in cells that typically 
express high levels of endogenous CA125 and therefore possibly reducing the sensitivity 
of the system. Nevertheless, as the use of primary cells in these experiments (i.e. 
mesothelial cells) allows our observation to be directly relevant to the clinical situation, it 
would seem that improvement of the transfection efficiencies in this system represents an 
area of future focus in the analysis of the CA125 promoter region.
Considering the importance of CA125 in the monitoring of ovarian cancer and its more 
recent adoption as a marker of the viability of the peritoneal mesothelium it seems 
somewhat surprising that the transcriptional mechanisms regulating CA125’s expression 
remain largely uninvestigated. The controversy that has been ever present in the 
understanding of CA125 may be attributed to the lack of a basic understanding of how 
this massive antigen in regulated. Identification of the CA125 promoter region represents 
a significant step forward in the understanding of this process and will open a gateway to 
a rapid and better understanding of CA125’s function. The immediate impact that the 
identification of the CA125 promoter region has on understanding the mechanisms 
involved in CA125’s regulation is evident in chapter 4 of this thesis which examines 
CA125’s regulation during inflammation. Analysis of the CA125 promoter constructs, as
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well as RT-PCR appears to eliminate transcriptional regulation as a major mechanism 
regulating CA125’s expression during inflammation. The subsequent analysis of 
CA125’s surface expression and shedding in response to inflammatory mediators 
indicated that the increased turnover of CA125 in response to (the pro inflammatory 
cytokine) IL-ip and increased shedding of CA125 in response to IL-6/sIL-6R trans­
signalling appears to be a process regulated at the cell surface. Using a growth arrested 
mesothelial cell culture system [Floege et al, 1990] in the absence of interfering growth 
factors and cytokines has allowed this work to clarify some of the existing discrepancies 
regarding CA125’s regulation by inflammatory cytokines [Zeillemarker et al, 
1994][Visser et al, 1995][Ziemet et al, 1996]. It also suggests that the regulation and 
function of CA125 occurs predominantly on the surface of mesothelial cells and that, as 
discussed by O’Brien and his colleges [O’Brien et al, 1998], cleavage enzymes 
potentially play a major role in this regulation. It has been suggested that CA125 may 
function as a lubricant in the peritoneal cavity due to both its anatomical location 
[Hardardottir et al, 1990] and characterisation as a member of the mucin molecule family 
[Yin et al, 2001] [Gum, 2002]. We can therefore speculate that increased CA125 
production during inflammation may be an attempt to maintain the lubricative layer 
formed by the mesothelium to preserve gut homeostasis and motility.
Despite CA125’s apparent regulation during inflammation (as shown in this study), from 
a clinical perspective, the argument for the use of CA125 as a marker of mesothelial 
mass/integrity remains [Ho-Dac-Pannekeet et al, 1997][Visser et al, 1995]. Although this 
thesis has to some extent, through the use of a growth arrested and synchronized cell 
model, partly clarified the existing discrepancies related to CA125 regulation, questions 
regarding in vitro and in vivo equivalency of CA125 expression data will ensure this topic 
remains contentious. Since few studies have investigated changes in CA125 levels seen 
during peritonitis in patient samples [Ho-Dac-Pannakeet et al, 1995], it remains unclear 
as to whether the changes induced by inflammatory stimuli in our in vitro model are 
comparable with that which is seen in a clinical context. Currently, comparison of in vitro 
and in vivo measured CA125 levels in many other studies show that the CA125 
appearance rates seen from in vivo studies can be 10-30 times lower than those measured
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from in vitro studies (when one compares data based on defined cell numbers in vitro and 
presumed mesothelial density in vivo). These data suggest the in vitro environment may 
not accurately represent the uremic and glucose rich peritoneal cavity where CA125 
expression may be supressed [Topley et al, 2005]. Despite this, the observed changes of 
CA125 modulation seen in chapter 4 (in response to IL-6/sIL-6R trans-signalling), 
correlate well with the observed magnitude of regulation seen in other in vitro and in vivo 
CA125 studies [Zeillemarker et al, 1994J[Zeimet et al, 1997][Jones etal, 2001][Williams 
et al, 2004] suggesting that our observations may indeed be relevant to the clinical 
situation.
The relationship between in vivo and in vitro CA125 data is further highlighted in chapter 
5 of this thesis. As seen in Figure 6.1, previous in vivo studies have shown an increase 
(maximally 3 to 4 fold) in the CA125 effluent levels of patients undergoing dialysis with 
more biocompatible dialysis solutions, compared to those receiving more conventional 
solutions. This increase is thought to be in response to lower GDP concentrations present 
within the newer solutions and is thought to be accompanied by the improved health of 
the mesothelium [Rippe et al, 2001][Jones et al, 2001][Williams et al, 2004][Witowski et 
al, 2004]. Within these studies we have shown that physiological concentrations of 
CA125 (i.e. those measurable in patients using new solutions) promote wound healing in 
our system. Using a similar system we have demonstrated the retardation of CA125 
secretion/shedding by high levels of GDPs. Coupled with existing in vitro data showing 
the retardation of HPMC wound healing by solutions containing high levels of GDP 
[Morgan et al, 2003], these data suggest that the improved health of the mesothelium 
observed in the in vivo biocompatibility studies [Rippe et al, 2001] [Jones et al,
2001] [Williams et al, 2004] [Witowski et al, 2004] may be as a direct result of peritoneal 
CA125 levels. It may still be conceivable that adding CA125 to peritoneal dialysis fluids 
in order to preserve the health of the mesothelium during treatment or inducing its 
expression may have potential clinical advantage in terms of membrane preservation.
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Figure 6.1 The potential role of CA125 in re-mesothelialization as a response to GDP levels in the dialysed peritoneum.
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Figure 6.2 Potential involvement of CA125 in re-mesothelialization in response to peritonitis induced injury.
Interestingly, CA125’s apparent ability to enhance the rate of re-mesothelialization may 
also be evident in the host’s response to bacterial infection during peritoneal dialysis. As 
seen in Figure 6.2, increased CA125 turnover and shedding by HPMC in response to IL- 
ip  and IL-6/sIL-6R trans-signalling (Chapter 4) may serve to enhance the repair process 
of the mesothelium in order to combat the damage and injury that commonly occurs as a 
result of peritonitis [Davies et al, 1996]. Although at this stage nothing is known about 
the mechanisms involved in how CA125 may increase the rate of HPMC wound healing, 
we can speculate that, due to the nature of CA125 and its implication in cell lubrication 
[Hardardottir et al, 1990][Hori et al, 2004], as well as existing evidence showing the 
facilitation of re-mesothelialisation by the deposition of ECM and other high molecular 
weight molecules (i.e. HA) at the wound edge [Yung et al, 2000][Horiuchi et al, 2003], 
deposition of CA125 in the wounded area may facilitate the improved migration of 
mesothelial cells into the disrupted area.
In summary, this thesis has used both in silico and experimental techniques to 
characterise the CA125 gene and its proximal promoter region. Further analysis of the 
CA125 proximal promoter region showed that the endogenous activity of the CA125 
promoter is typical of that observed for other mucin gene promoters. This study has also 
demonstrated, using a synchronised cell culture system, the transcriptionally-independent 
regulation of CA125’s surface expression and its shedding in response to IL-ip and IL-6 
signalling clarifying existing ideas regarding CA125’s regulation by inflammatory 
cytokines. Using a HPMC wound healing model we propose that a potential function for 
CA125 is in promoting re-mesothelialization. Finally, we have substantiated a 
relationship between CA125 expression and the GDP content of dialysis solutions and 
related this to the clinical situation where low GDP solutions are associated with 
increased in vivo CA125 concentrations.
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Future work
This works provides a preliminary insight into the regulation and function of CA125. 
The regulation of CA125 shedding by cleavage enzymes is currently not understood and 
represents an important area of future work for the understanding the regulation of 
CA125 expression. Examination of CA125’s potential as a signalling molecule (as has 
been seen for other mucin-like molecules) also provides an interesting avenue for future 
research. For the immediate progression of our understanding of CA125 in peritoneal 
dialysis further examination of CA125’s regulation by GDPs, utilising the CA125 
promoter constructs described in this thesis, and CA125’s function in HPMC wound 
healing remains the most likely area of research.
As mentioned throughout this thesis the development of a system displaying “knocked 
down” or “knocked out” CA125 expression remains a desirable and integral tool for 
progressing our understanding of CA125 biology. Development of a CA125 full or 
conditional knockout mouse (non-fatal) would allow for much needed further 
examination of CA125’s function while the development of an in vitro system, utilising 
siRNA technology in order to reduce CA125 expression, may provide a more realistic 
short term target. As seen in Appendix I, optimization of the knockdown of GAPDH 
expression in HPMC using this technology was successful, yet, our attempted reduction 
of CA125 expression in the same system using siRNA oligonucleotides specific for 
CA125 was unsuccessful due to the lethality of the transfection to HPMC. Should such a 
system be developed it would facilitate the analysis of CA125’s function in HPMC 
migration through the knockdown of CA125 expression in our in vitro wound healing 
model.
In 1998, O’Brien and his co-authors identified a series of key questions that required 
addressing including “the secretory or membrane bound nature o f CA125, the function of 
the CA125 molecule and the elusive CA125 gene” [O’Brien et al, 1998]. Considering 
these questions it would seem that this thesis has made some advances in the considerable 
volume of work required to answer these questions. Nevertheless, until the regulation of
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CA125 at a molecular level, how and what controls its secretion/shedding and most 
importantly its biological significance/role are fully defined we will continue to be 
somewhat in the dark as to CA125’s usefulness as a marker of mesothelial integrity.
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APPENDIX I
siRNA knockdown of HPMC GAPDH expression
In order to determine the most efficient mode of oligonucleotide transfection a defined 
number of detached HPMC were transfected with GAPDH siRNA oligonucloetide 
(Ambion Europe Ltd) or Scrambled (negative control) siRNA oligonucleotide (Ambion 
Europe Ltd) using FuGene-6 transfection reagent (Roche Diagnostics Ltd, Lewes, UK), 
NeoFX transfection reagent (Ambion Europe Ltd) or siPORT Amine transfection reagent 
(Ambion Europe Ltd) as recommended by the manufacturer’s protocols (and as discussed 
in section 2.3.6). RT-PCR (sections 2.3.1-4 and 2.4.1) using primers specific for 
GAPDH and P-actin (Table 6.1) was then performed to analyse the extent of GAPDH 
knockdown (Figure 6.3A).
Table 6.1 Oligonucleotide primers used in siRNA (RT-PCR) analysis
Primer pair Sense strand sequence Anti-sense strand sequence Cycle No
P-Actin GGAGCAATGATCTTGATCTT CCTTCCTGGGCATGGAGTCCT 30
GAPDH ATCCACAGTCTTCTGGGTGG CGAGATCCCTCCAAAATCAA 30
All primers are in 5’ - 3’ orientation
Semi-quanatitative analysis of GAPDH transcription was achieved using a ratio of each 
product to the p-actin house keeping gene via densiometric anaysis (Figure 6.3B).
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Figure 6.3 Optimisation of GAPDH knockdown in HPMC. (A) Representative 
gel showing HPMC expression of GAPDH and P-Actin 48 hours after siRNA 
transfection. HPMC were transfected with either lOOnM GAPDH siRNA 
oligonucleotide1, lOOnM Scram ble siRNA oligonucleotide2 or no siRNA 
olignoucleotide3 using either 2pl/ml FuGene-6 transfection reagent (FuGene-6), 
3pl/ml NeoFX transfection reagent (NeoFX) or 5pl/ml siPORT Amine transfection 
reagent (Amine). -RT=Negative control for reverse transcriptase, -PCR=Negative 
control for PCR. (B) Densiomteric analysis of GAPDH expression (as a ratio of p- 
Actin expression) 48 hours after siRNA transfection.
Amine
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As can be seen in Figure 6.3B, transfection with siPORT Amine transfection reagent 
resulted in the largest GAPDH knockdown («80% knockdown in expression when 
compared to its negative control). These data suggest that the siPORT Amine 
transfection reagent is optimal for the siRNA oligonucleotide transfection in HPMC. To 
further optimize the GAPDH knockdown using siPORT Amine transfection reagent 
(Ambion Europe Ltd), HPMC were transfected with defined concentrations of GAPDH 
siRNA oligonucleotide (Figure 6.4). RT-PCR (sections 2.3.1-4 and 2.4.1) using primers 
specific for GAPDH and P-actin (Table 6.1) was then performed in order to analyse the 
extent of GAPDH knockdown (Figure 6.4A). Semi-quantitative analysis of GAPDH 
transcription was achieved using a ratio of each product to the P-actin house keeping 
gene via densiometric anaysis (Figure 6.4B).
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Figure 6.4 Optimisation of GAPDH siRNA concentration in HPMC. (A) Agarose 
gel showing HPMC expression of GAPDH and p-actin 48 hours after siRNA 
transfection. HPMC were transfected with either GAPDH siRNA oligonucleotide 
(25nM, 50nM, 75nM or lOOnM), lOOnM Scramble siRNA oligonucleotide or no 
siRNA oligonucleotide (negative control) using 5pl/ml siPORT Amine transfection 
reagent. -RT = Negative control for reverse transcriptase, -PCR = Negative control 
for PCR. (B) Densiomteric analysis of GAPDH expression (as a ratio of P-actin 
expression) 48 hours after GAPDH siRNA transfection.
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As can be seen in Figure 6.4(B), all transfected concentrations of GAPDH siRNA 
oligonucleotide used resulted in an approxim ate 35% -  40% knockdown of HPMC 
GAPDH expression . To fully  quantify  the percentage knockdown of GAPDH 
expression, quantitative PCR (Figure 6.5) was used on the same extracted RNA (used in 
Figure 6.4) as described in section 2.4.2.
a.x<D<U
>
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Control Scramble 25nM 50nM 75nM lOOnM 
Oligo v. ____________________ ,
GAPDH siRNA concentration
Figure 6.5 Analysis of GAPDH expression 48 hours after siRNA transfection 
using quantitative PCR. HPMC were transfected with GAPDH siRNA 
oligonucleotide (25nM, 50nM, 75nM or lOOnM), lOOnM Scramble siRNA 
oligonucleotide or no siRNA oligonucleotide (negative control) using 5pl/ml siPORT 
Amine transfection reagent.
Figure 6.5 shows that transfection of 25nM GAPDH siRNA oligonucleotide resulted in 
the largest GAPDH knockdown (95% decrease in expression) in HPMC, though all other 
concentrations tested also induced a high degree of knockdown. These data indicate the 
successful knockdown of GAPDH expression in primary HPMC.
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